Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,10757417,half-life of plasma disappearance,The half-life of plasma disappearance of valproate was 25% reduced by lithium pretreatment (0.428 +/- 0.031 h with repeated lithium pretreatment vs 0.578 +/- 0.062 h for controls).,Effects of lithium on the pharmacokinetics of valproate in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10757417/),h,0.428,1578,DB01356,Lithium
,10757417,half-life of plasma disappearance,The half-life of plasma disappearance of valproate was 25% reduced by lithium pretreatment (0.428 +/- 0.031 h with repeated lithium pretreatment vs 0.578 +/- 0.062 h for controls).,Effects of lithium on the pharmacokinetics of valproate in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10757417/),h,0.578,1579,DB01356,Lithium
,3009841,half-life (t1/2),"The mean plasma lithium half-life (t1/2) following the single intravenous dose was 21.6 h, and the mean apparent specific volume of distribution of the central compartment (V'c) was 0.189 l/kg.",Pharmacokinetics of lithium in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3009841/),h,21.6,2221,DB01356,Lithium
,3009841,apparent specific volume of distribution of the central compartment (V'c),"The mean plasma lithium half-life (t1/2) following the single intravenous dose was 21.6 h, and the mean apparent specific volume of distribution of the central compartment (V'c) was 0.189 l/kg.",Pharmacokinetics of lithium in the dog. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3009841/),[l] / [kg],0.189,2222,DB01356,Lithium
,3009841,bioavailability,Mean bioavailability was 78.8% following oral administration.,Pharmacokinetics of lithium in the dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3009841/),%,78.8,2223,DB01356,Lithium
,29214648,areas under the plasma concentration-time curve,"When lithium chloride at 1.25 mg/kg, 2.5 mg/kg and 25 mg/kg was intravenously injected as a bolus, the areas under the plasma concentration-time curve of lithium until 60 minutes were calculated to be 6.23 mEq·min/l, 8.77 mEq·min/l and 64.6 mEq·min/l, respectively.",Nonlinear disposition of lithium in rats and saturation of its tubular reabsorption by the sodium-phosphate cotransporter as a cause. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29214648/),[meq·min] / [l],6.23,5132,DB01356,Lithium
,29214648,areas under the plasma concentration-time curve,"When lithium chloride at 1.25 mg/kg, 2.5 mg/kg and 25 mg/kg was intravenously injected as a bolus, the areas under the plasma concentration-time curve of lithium until 60 minutes were calculated to be 6.23 mEq·min/l, 8.77 mEq·min/l and 64.6 mEq·min/l, respectively.",Nonlinear disposition of lithium in rats and saturation of its tubular reabsorption by the sodium-phosphate cotransporter as a cause. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29214648/),[meq·min] / [l],8.77,5133,DB01356,Lithium
,29214648,areas under the plasma concentration-time curve,"When lithium chloride at 1.25 mg/kg, 2.5 mg/kg and 25 mg/kg was intravenously injected as a bolus, the areas under the plasma concentration-time curve of lithium until 60 minutes were calculated to be 6.23 mEq·min/l, 8.77 mEq·min/l and 64.6 mEq·min/l, respectively.",Nonlinear disposition of lithium in rats and saturation of its tubular reabsorption by the sodium-phosphate cotransporter as a cause. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29214648/),[meq·min] / [l],64.6,5134,DB01356,Lithium
,10890582,Cmax,"Higher Cmax (mg/l) were obtained when the tablet was administered with any kind of meal: 2.09 +/- 0.47 (fast), 2.95 +/- 1.04 (normal diet), 2.64 +/- 0.54 (high fat diet) and 2.87 +/- 0.67 (high fat/high protein diet).",Effect of three different diets on the bioavailability of a sustained release lithium carbonate matrix tablet. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10890582/),[mg] / [l],2.09,8330,DB01356,Lithium
,10890582,Cmax,"Higher Cmax (mg/l) were obtained when the tablet was administered with any kind of meal: 2.09 +/- 0.47 (fast), 2.95 +/- 1.04 (normal diet), 2.64 +/- 0.54 (high fat diet) and 2.87 +/- 0.67 (high fat/high protein diet).",Effect of three different diets on the bioavailability of a sustained release lithium carbonate matrix tablet. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10890582/),[mg] / [l],2.95,8331,DB01356,Lithium
,10890582,Cmax,"Higher Cmax (mg/l) were obtained when the tablet was administered with any kind of meal: 2.09 +/- 0.47 (fast), 2.95 +/- 1.04 (normal diet), 2.64 +/- 0.54 (high fat diet) and 2.87 +/- 0.67 (high fat/high protein diet).",Effect of three different diets on the bioavailability of a sustained release lithium carbonate matrix tablet. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10890582/),[mg] / [l],2.64,8332,DB01356,Lithium
,10890582,Cmax,"Higher Cmax (mg/l) were obtained when the tablet was administered with any kind of meal: 2.09 +/- 0.47 (fast), 2.95 +/- 1.04 (normal diet), 2.64 +/- 0.54 (high fat diet) and 2.87 +/- 0.67 (high fat/high protein diet).",Effect of three different diets on the bioavailability of a sustained release lithium carbonate matrix tablet. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10890582/),[mg] / [l],2.87,8333,DB01356,Lithium
,1706107,CLi,The mean baseline CLi was 23.1 +/- 1.64 ml/min/1.73 m2.,"Tubular function by lithium clearance, plasma amino acids and hormones following a meat meal in childhood. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1706107/),[ml] / [1.73·m2·min],23.1,8942,DB01356,Lithium
,1706107,CLi,"At peak GFR response (60 min from starting the meal), CLi averaged 27.6 +/- 2.4 ml/min/1.73 m2 (p less than 0.025 vs. baseline) and it was further increased (32.2 +/- 5.04 ml/min/1.73 m2, p less than 0.01 vs. baseline) 120 min after starting the meal, while GFR returned to baseline values.","Tubular function by lithium clearance, plasma amino acids and hormones following a meat meal in childhood. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1706107/),[ml] / [1.73·m2·min],27.6,8943,DB01356,Lithium
,1706107,CLi,"At peak GFR response (60 min from starting the meal), CLi averaged 27.6 +/- 2.4 ml/min/1.73 m2 (p less than 0.025 vs. baseline) and it was further increased (32.2 +/- 5.04 ml/min/1.73 m2, p less than 0.01 vs. baseline) 120 min after starting the meal, while GFR returned to baseline values.","Tubular function by lithium clearance, plasma amino acids and hormones following a meat meal in childhood. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1706107/),[ml] / [1.73·m2·min],32.2,8944,DB01356,Lithium
,1706107,Fractional lithium excretion,"Fractional lithium excretion averaged 0.23 +/- 0.04 at baseline and increased continuously after the meat meal and, at completion of the study, it averaged 0.38 +/- 0.07 (p less than 0.025 vs. baseline).","Tubular function by lithium clearance, plasma amino acids and hormones following a meat meal in childhood. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1706107/),,0.23,8945,DB01356,Lithium
,1706107,Fractional lithium excretion,"Fractional lithium excretion averaged 0.23 +/- 0.04 at baseline and increased continuously after the meat meal and, at completion of the study, it averaged 0.38 +/- 0.07 (p less than 0.025 vs. baseline).","Tubular function by lithium clearance, plasma amino acids and hormones following a meat meal in childhood. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1706107/),,0.38,8946,DB01356,Lithium
,11590973,serum,"Daily lithium doses ranged from 1050 mg to 1950 mg (mean 1569 mg, standard deviation [SD] 291 mg), The mean serum lithium concentrations for weeks 1, 2 and 3 were 0.74 mmol/L (SD 0.19 mmol/L), 0.67 mmol/L (SD 0.22 mmol/L) and 0.69 mmol/L (SD 0.13 mmol/L), respectively.",Accuracy of the Pepin method to determine appropriate lithium dosages in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11590973/),[mM] / [l],0.74,12221,DB01356,Lithium
,11590973,serum,"Daily lithium doses ranged from 1050 mg to 1950 mg (mean 1569 mg, standard deviation [SD] 291 mg), The mean serum lithium concentrations for weeks 1, 2 and 3 were 0.74 mmol/L (SD 0.19 mmol/L), 0.67 mmol/L (SD 0.22 mmol/L) and 0.69 mmol/L (SD 0.13 mmol/L), respectively.",Accuracy of the Pepin method to determine appropriate lithium dosages in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11590973/),[mM] / [l],0.69,12222,DB01356,Lithium
,11590973,concentrations,"Daily lithium doses ranged from 1050 mg to 1950 mg (mean 1569 mg, standard deviation [SD] 291 mg), The mean serum lithium concentrations for weeks 1, 2 and 3 were 0.74 mmol/L (SD 0.19 mmol/L), 0.67 mmol/L (SD 0.22 mmol/L) and 0.69 mmol/L (SD 0.13 mmol/L), respectively.",Accuracy of the Pepin method to determine appropriate lithium dosages in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11590973/),[mM] / [l],0.74,12223,DB01356,Lithium
,11590973,concentrations,"Daily lithium doses ranged from 1050 mg to 1950 mg (mean 1569 mg, standard deviation [SD] 291 mg), The mean serum lithium concentrations for weeks 1, 2 and 3 were 0.74 mmol/L (SD 0.19 mmol/L), 0.67 mmol/L (SD 0.22 mmol/L) and 0.69 mmol/L (SD 0.13 mmol/L), respectively.",Accuracy of the Pepin method to determine appropriate lithium dosages in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11590973/),[mM] / [l],0.67,12224,DB01356,Lithium
,11590973,concentrations,"Daily lithium doses ranged from 1050 mg to 1950 mg (mean 1569 mg, standard deviation [SD] 291 mg), The mean serum lithium concentrations for weeks 1, 2 and 3 were 0.74 mmol/L (SD 0.19 mmol/L), 0.67 mmol/L (SD 0.22 mmol/L) and 0.69 mmol/L (SD 0.13 mmol/L), respectively.",Accuracy of the Pepin method to determine appropriate lithium dosages in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11590973/),[mM] / [l],0.69,12225,DB01356,Lithium
,11560265,peak serum concentration,"Mean peak serum concentration was 0.561 mmol/L (range, 0.529 to 0.613 mmol/L), with actual measured mean serum value of 0.575 mmol/L (range, 0.52 to 0.67 mmol/L) at 2.5 minutes after administration of the last bolus.",Pharmacokinetics and toxic effects of lithium chloride after intravenous adminstration in conscious horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11560265/),[mM] / [l],0.561,13065,DB01356,Lithium
,11560265,serum value,"Mean peak serum concentration was 0.561 mmol/L (range, 0.529 to 0.613 mmol/L), with actual measured mean serum value of 0.575 mmol/L (range, 0.52 to 0.67 mmol/L) at 2.5 minutes after administration of the last bolus.",Pharmacokinetics and toxic effects of lithium chloride after intravenous adminstration in conscious horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11560265/),[mM] / [l],0.575,13066,DB01356,Lithium
,11560265,Half-life,"Half-life was 43.5 hours (range, 32 to 84 hours), and after 24 hours, mean serum lithium concentration was 0.13+/-0.05 mmol/L (range, 0.07 to 0.21 mmol/L).",Pharmacokinetics and toxic effects of lithium chloride after intravenous adminstration in conscious horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11560265/),h,43.5,13067,DB01356,Lithium
,9342502,oral bioavailability,Nefazodone undergoes significant first-pass metabolism resulting in an oral bioavailability of approximately 20%.,Clinical pharmacokinetics of nefazodone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9342502/),%,20,16638,DB01356,Lithium
,8378489,spin-lattice relaxation time,"A birdcage radiofrequency coil for 7Li was constructed and used to measure the 7Li spin-lattice relaxation time of 4.6 seconds in vivo in human head, and to acquire preliminary spectroscopic images of a phantom and human brain.",In vivo 7Li nuclear magnetic resonance study of lithium pharmacokinetics and chemical shift imaging in psychiatric patients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8378489/),seconds,4.6,18444,DB01356,Lithium
,3089949,slow,"Lithium carbonate confers upon the body the distinct characteristics of a two-compartment open model with a mean slow disposition rate constant (beta) of 0.0435 h-1 +/- 0.0086 SD, corresponding to a mean biological half-life of 16.49 h +/- 2.95 SD.",Absorption and disposition kinetics of lithium carbonate following administration of conventional and controlled release formulations. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3089949/),1/[h],0.0435,18980,DB01356,Lithium
,3089949,disposition rate constant (beta),"Lithium carbonate confers upon the body the distinct characteristics of a two-compartment open model with a mean slow disposition rate constant (beta) of 0.0435 h-1 +/- 0.0086 SD, corresponding to a mean biological half-life of 16.49 h +/- 2.95 SD.",Absorption and disposition kinetics of lithium carbonate following administration of conventional and controlled release formulations. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3089949/),1/[h],0.0435,18981,DB01356,Lithium
,3089949,biological half-life,"Lithium carbonate confers upon the body the distinct characteristics of a two-compartment open model with a mean slow disposition rate constant (beta) of 0.0435 h-1 +/- 0.0086 SD, corresponding to a mean biological half-life of 16.49 h +/- 2.95 SD.",Absorption and disposition kinetics of lithium carbonate following administration of conventional and controlled release formulations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3089949/),h,16.49,18982,DB01356,Lithium
,3089949,half-life,The mean half-life of the distributory alpha-phase was 1.40 h +/- 0.27 SD.,Absorption and disposition kinetics of lithium carbonate following administration of conventional and controlled release formulations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3089949/),h,1.40,18983,DB01356,Lithium
,3089949,apparent volume of distribution (Vdarea),"The apparent volume of distribution (Vdarea) was 0.539 l kg-1 +/- 0.130 SD and the volume of the central compartment (Vl) was 0.224 l/kg-1 +/- 0.066 SD, about one half that of the volume at steady state (Vdss) which was 0.445 l/kg-1 +/- 0.106 SD.",Absorption and disposition kinetics of lithium carbonate following administration of conventional and controlled release formulations. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3089949/),[l] / [kg],0.539,18984,DB01356,Lithium
,3089949,volume of the central compartment (Vl),"The apparent volume of distribution (Vdarea) was 0.539 l kg-1 +/- 0.130 SD and the volume of the central compartment (Vl) was 0.224 l/kg-1 +/- 0.066 SD, about one half that of the volume at steady state (Vdss) which was 0.445 l/kg-1 +/- 0.106 SD.",Absorption and disposition kinetics of lithium carbonate following administration of conventional and controlled release formulations. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3089949/),[l] / [kg],0.224,18985,DB01356,Lithium
,3089949,volume at steady state (Vdss),"The apparent volume of distribution (Vdarea) was 0.539 l kg-1 +/- 0.130 SD and the volume of the central compartment (Vl) was 0.224 l/kg-1 +/- 0.066 SD, about one half that of the volume at steady state (Vdss) which was 0.445 l/kg-1 +/- 0.106 SD.",Absorption and disposition kinetics of lithium carbonate following administration of conventional and controlled release formulations. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3089949/),[l] / [kg],0.445,18986,DB01356,Lithium
,3089949,Total body clearance (ClB),Total body clearance (ClB) was 0.0241 l/kg-1 h +/- 0.0102 SD.,Absorption and disposition kinetics of lithium carbonate following administration of conventional and controlled release formulations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3089949/),[l] / [kg],0.0241,18987,DB01356,Lithium
,3089949,time at which this concentration was attained (tpeak),Maximum serum concentration (Cmax) was 22% lower and the time at which this concentration was attained (tpeak) was delayed from 1.44 h to 4.25 h when compared with the conventional tablet.,Absorption and disposition kinetics of lithium carbonate following administration of conventional and controlled release formulations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3089949/),h,1.44,18988,DB01356,Lithium
,3089949,time at which this concentration was attained (tpeak),Maximum serum concentration (Cmax) was 22% lower and the time at which this concentration was attained (tpeak) was delayed from 1.44 h to 4.25 h when compared with the conventional tablet.,Absorption and disposition kinetics of lithium carbonate following administration of conventional and controlled release formulations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3089949/),h,4.25,18989,DB01356,Lithium
,3089949,Bioavailability,"Bioavailability, estimated as the total amount of lithium excreted in the urine, was 90.2 for the controlled release preparation and 94.5 for the immediate release tablet.",Absorption and disposition kinetics of lithium carbonate following administration of conventional and controlled release formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3089949/),,90.2,18990,DB01356,Lithium
,3089949,Bioavailability,"Bioavailability, estimated as the total amount of lithium excreted in the urine, was 90.2 for the controlled release preparation and 94.5 for the immediate release tablet.",Absorption and disposition kinetics of lithium carbonate following administration of conventional and controlled release formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3089949/),,94.5,18991,DB01356,Lithium
,8385174,Hill slope,"Hill plots derived from in vivo activation curves for erythrocytic Na(+)-Li+ countertransport showed that the normotensive participants had a Hill slope of 1 (SD 0.1), whereas the hypertensives had a Hill slope of 3.2 (SD 1.0).",Evidence for an altered mode of action of the sodium-lithium countertransporter in vivo in patients with untreated essential hypertension. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8385174/),,1,21469,DB01356,Lithium
,8385174,Hill slope,"Hill plots derived from in vivo activation curves for erythrocytic Na(+)-Li+ countertransport showed that the normotensive participants had a Hill slope of 1 (SD 0.1), whereas the hypertensives had a Hill slope of 3.2 (SD 1.0).",Evidence for an altered mode of action of the sodium-lithium countertransporter in vivo in patients with untreated essential hypertension. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8385174/),,3.2,21470,DB01356,Lithium
,8048569,Late proximal (TF/P)Li,"Late proximal (TF/P)Li was 1.01 after oral Li+, 1.16 after intravenous Li+ (P < 0.01), and 1.00 during osmotic diuresis.",Active lithium transport by rat renal proximal tubule: a micropuncture study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8048569/),,1.01,26632,DB01356,Lithium
,8048569,Late proximal (TF/P)Li,"Late proximal (TF/P)Li was 1.01 after oral Li+, 1.16 after intravenous Li+ (P < 0.01), and 1.00 during osmotic diuresis.",Active lithium transport by rat renal proximal tubule: a micropuncture study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8048569/),,1.16,26633,DB01356,Lithium
,8048569,Late proximal (TF/P)Li,"Late proximal (TF/P)Li was 1.01 after oral Li+, 1.16 after intravenous Li+ (P < 0.01), and 1.00 during osmotic diuresis.",Active lithium transport by rat renal proximal tubule: a micropuncture study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8048569/),,1.00,26634,DB01356,Lithium
,26579476,flow rate,Chromatographic separation was performed on a Phenomenex Gemini C18 column (50 mm×2.0 mm; 5 μm) using stepwise gradient elution with acetonitrile-water and 0.2 mmol/L lithium carbonate at a flow rate of 0.5 mL/min.,Determination of ginsenoside compound K in human plasma by liquid chromatography-tandem mass spectrometry of lithium adducts. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26579476/),[ml] / [min],0.5,29677,DB01356,Lithium
,3941708,rate of red-cell countertransport,"As a group, the hypertensive patients had a higher average (+/- SEM) rate of red-cell countertransport (0.378 +/- 0.030 mmol of lithium per liter of cells per hour, P less than 0.01) and a lower renal fractional lithium clearance (13.96 +/- 0.69 percent, P less than 0.01) than normotensive subjects (0.317 +/- 0.015 mmol of lithium per liter of cells per hour and 17.75 +/- 0.81 percent, respectively).",Red-cell lithium-sodium countertransport and renal lithium clearance in hypertension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3941708/),[lithium·mM] / [cells·h·l],0.378,32922,DB01356,Lithium
,3941708,renal fractional lithium clearance,"As a group, the hypertensive patients had a higher average (+/- SEM) rate of red-cell countertransport (0.378 +/- 0.030 mmol of lithium per liter of cells per hour, P less than 0.01) and a lower renal fractional lithium clearance (13.96 +/- 0.69 percent, P less than 0.01) than normotensive subjects (0.317 +/- 0.015 mmol of lithium per liter of cells per hour and 17.75 +/- 0.81 percent, respectively).",Red-cell lithium-sodium countertransport and renal lithium clearance in hypertension. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3941708/),%,13.96,32923,DB01356,Lithium
,3941708,renal fractional lithium clearance,"As a group, the hypertensive patients had a higher average (+/- SEM) rate of red-cell countertransport (0.378 +/- 0.030 mmol of lithium per liter of cells per hour, P less than 0.01) and a lower renal fractional lithium clearance (13.96 +/- 0.69 percent, P less than 0.01) than normotensive subjects (0.317 +/- 0.015 mmol of lithium per liter of cells per hour and 17.75 +/- 0.81 percent, respectively).",Red-cell lithium-sodium countertransport and renal lithium clearance in hypertension. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3941708/),[lithium·mM] / [cells·h·l],0.317,32924,DB01356,Lithium
,3941708,renal fractional lithium clearance,"As a group, the hypertensive patients had a higher average (+/- SEM) rate of red-cell countertransport (0.378 +/- 0.030 mmol of lithium per liter of cells per hour, P less than 0.01) and a lower renal fractional lithium clearance (13.96 +/- 0.69 percent, P less than 0.01) than normotensive subjects (0.317 +/- 0.015 mmol of lithium per liter of cells per hour and 17.75 +/- 0.81 percent, respectively).",Red-cell lithium-sodium countertransport and renal lithium clearance in hypertension. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3941708/),%,17.75,32925,DB01356,Lithium
,3941708,fractional,"Within the normotensive group, subjects with hypertension in at least one first-degree relative had significantly lower fractional lithium clearances than subjects with no hypertensive relatives (15.37 +/- 0.84 percent vs. 19.06 +/- 1.07 percent, P less than 0.05).",Red-cell lithium-sodium countertransport and renal lithium clearance in hypertension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3941708/),%,15.37,32926,DB01356,Lithium
,26433169,flow rate,"Plasma samples were pretreated by liquid-liquid extraction with n-butanol and chromatographed on a C18 column (2.1×50 mm i.d., 2.6 μm) using a gradient elution program consisting of acetonitrile and water (containing 0.03% formic acid and 0.1 mM lithium acetate) at a flow rate of 0.4 mL/min.",Simultaneous determination of four furostanol glycosides in rat plasma by UPLC-MS/MS and its application to PK study after oral administration of Dioscorea nipponica extracts. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26433169/),[ml] / [min],0.4,33715,DB01356,Lithium
more,26433169,recoveries,The recoveries of the whole analytes were more than 80.3% and exhibited no severe matrix effect.,Simultaneous determination of four furostanol glycosides in rat plasma by UPLC-MS/MS and its application to PK study after oral administration of Dioscorea nipponica extracts. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26433169/),%,80.3,33716,DB01356,Lithium
,8355319,peak concentrations,Serum lithium peak concentrations ranged between 1.4 and 9.6 mmol/L.,When should dialysis be performed in lithium poisoning? A kinetic study in 14 cases of lithium poisoning. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8355319/),[mM] / [l],1.4 and 9.6,34607,DB01356,Lithium
,8355319,apparent mean serum half-life,"The apparent mean serum half-life was 23.16 +/- 9 h, the mean total clearance was 26.5 +/- 13.3 mL/min and the mean renal clearance was 17.2 +/- 5.4 mL/min.",When should dialysis be performed in lithium poisoning? A kinetic study in 14 cases of lithium poisoning. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8355319/),h,23.16,34608,DB01356,Lithium
,8355319,total clearance,"The apparent mean serum half-life was 23.16 +/- 9 h, the mean total clearance was 26.5 +/- 13.3 mL/min and the mean renal clearance was 17.2 +/- 5.4 mL/min.",When should dialysis be performed in lithium poisoning? A kinetic study in 14 cases of lithium poisoning. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8355319/),[ml] / [min],26.5,34609,DB01356,Lithium
,8355319,renal clearance,"The apparent mean serum half-life was 23.16 +/- 9 h, the mean total clearance was 26.5 +/- 13.3 mL/min and the mean renal clearance was 17.2 +/- 5.4 mL/min.",When should dialysis be performed in lithium poisoning? A kinetic study in 14 cases of lithium poisoning. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8355319/),[ml] / [min],17.2,34610,DB01356,Lithium
,8355319,serum half-life,The serum half-life during hemodialysis ranged from 3.6 to 5.7 h and hemodialysis clearance was 63.2 to 114.4 mL/min.,When should dialysis be performed in lithium poisoning? A kinetic study in 14 cases of lithium poisoning. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8355319/),h,3.6 to 5.7,34611,DB01356,Lithium
,8355319,clearance,The serum half-life during hemodialysis ranged from 3.6 to 5.7 h and hemodialysis clearance was 63.2 to 114.4 mL/min.,When should dialysis be performed in lithium poisoning? A kinetic study in 14 cases of lithium poisoning. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8355319/),[ml] / [min],63.2 to 114.4,34612,DB01356,Lithium
,8355319,volume of distribution,The mean volume of distribution calculated in six cases was 0.63 +/- 0.09 L/kg.,When should dialysis be performed in lithium poisoning? A kinetic study in 14 cases of lithium poisoning. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8355319/),[l] / [kg],0.63,34613,DB01356,Lithium
,2813280,availability,"The mean estimates of availability were 1.035 +/- 0.109 (N = 7) and 0.984 +/- 0.052 (N = 11) for the traditional and the alternative method, respectively.",Estimation of bioavailability on a single occasion after semisimultaneous drug administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2813280/),,1.035,35173,DB01356,Lithium
,2813280,availability,"The mean estimates of availability were 1.035 +/- 0.109 (N = 7) and 0.984 +/- 0.052 (N = 11) for the traditional and the alternative method, respectively.",Estimation of bioavailability on a single occasion after semisimultaneous drug administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2813280/),,0.984,35174,DB01356,Lithium
,2813280,plasma clearance,"The plasma clearance of lithium was 169 +/- 15 ml/hr/kg, with a terminal half-life of 5.0 +/- 0.5 hr (N = 5).",Estimation of bioavailability on a single occasion after semisimultaneous drug administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2813280/),[ml] / [h·kg],169,35175,DB01356,Lithium
,2813280,terminal half-life,"The plasma clearance of lithium was 169 +/- 15 ml/hr/kg, with a terminal half-life of 5.0 +/- 0.5 hr (N = 5).",Estimation of bioavailability on a single occasion after semisimultaneous drug administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2813280/),h,5.0,35176,DB01356,Lithium
,6286526,half-lives,"Those on their initial course of lithium had the lowest half-lives (in days): 1.12 (urine), 1.28 (plasma), and 1.22 (red blood cells); those with less than 1 year of lithium had intermediate values: 1.85, 1.65, and 1.75, and those with more than 1 year of continuous lithium administration had the highest mean half-lives: 2.40, 2.43, and 2.24.","Lithium pharmacokinetics, duration of therapy, and the adenylate cyclase system. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6286526/),d,1.12,35902,DB01356,Lithium
,6286526,half-lives,"Those on their initial course of lithium had the lowest half-lives (in days): 1.12 (urine), 1.28 (plasma), and 1.22 (red blood cells); those with less than 1 year of lithium had intermediate values: 1.85, 1.65, and 1.75, and those with more than 1 year of continuous lithium administration had the highest mean half-lives: 2.40, 2.43, and 2.24.","Lithium pharmacokinetics, duration of therapy, and the adenylate cyclase system. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6286526/),d,1.28,35903,DB01356,Lithium
,6286526,half-lives,"Those on their initial course of lithium had the lowest half-lives (in days): 1.12 (urine), 1.28 (plasma), and 1.22 (red blood cells); those with less than 1 year of lithium had intermediate values: 1.85, 1.65, and 1.75, and those with more than 1 year of continuous lithium administration had the highest mean half-lives: 2.40, 2.43, and 2.24.","Lithium pharmacokinetics, duration of therapy, and the adenylate cyclase system. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6286526/),d,1.22,35904,DB01356,Lithium
,6286526,half-lives,"Those on their initial course of lithium had the lowest half-lives (in days): 1.12 (urine), 1.28 (plasma), and 1.22 (red blood cells); those with less than 1 year of lithium had intermediate values: 1.85, 1.65, and 1.75, and those with more than 1 year of continuous lithium administration had the highest mean half-lives: 2.40, 2.43, and 2.24.","Lithium pharmacokinetics, duration of therapy, and the adenylate cyclase system. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6286526/),d,1.85,35905,DB01356,Lithium
,6286526,half-lives,"Those on their initial course of lithium had the lowest half-lives (in days): 1.12 (urine), 1.28 (plasma), and 1.22 (red blood cells); those with less than 1 year of lithium had intermediate values: 1.85, 1.65, and 1.75, and those with more than 1 year of continuous lithium administration had the highest mean half-lives: 2.40, 2.43, and 2.24.","Lithium pharmacokinetics, duration of therapy, and the adenylate cyclase system. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6286526/),d,1.65,35906,DB01356,Lithium
,6286526,half-lives,"Those on their initial course of lithium had the lowest half-lives (in days): 1.12 (urine), 1.28 (plasma), and 1.22 (red blood cells); those with less than 1 year of lithium had intermediate values: 1.85, 1.65, and 1.75, and those with more than 1 year of continuous lithium administration had the highest mean half-lives: 2.40, 2.43, and 2.24.","Lithium pharmacokinetics, duration of therapy, and the adenylate cyclase system. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6286526/),d,1.75,35907,DB01356,Lithium
,6286526,half-lives,"Those on their initial course of lithium had the lowest half-lives (in days): 1.12 (urine), 1.28 (plasma), and 1.22 (red blood cells); those with less than 1 year of lithium had intermediate values: 1.85, 1.65, and 1.75, and those with more than 1 year of continuous lithium administration had the highest mean half-lives: 2.40, 2.43, and 2.24.","Lithium pharmacokinetics, duration of therapy, and the adenylate cyclase system. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6286526/),,2.40,35908,DB01356,Lithium
,6286526,half-lives,"Those on their initial course of lithium had the lowest half-lives (in days): 1.12 (urine), 1.28 (plasma), and 1.22 (red blood cells); those with less than 1 year of lithium had intermediate values: 1.85, 1.65, and 1.75, and those with more than 1 year of continuous lithium administration had the highest mean half-lives: 2.40, 2.43, and 2.24.","Lithium pharmacokinetics, duration of therapy, and the adenylate cyclase system. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6286526/),,2.43,35909,DB01356,Lithium
,6286526,half-lives,"Those on their initial course of lithium had the lowest half-lives (in days): 1.12 (urine), 1.28 (plasma), and 1.22 (red blood cells); those with less than 1 year of lithium had intermediate values: 1.85, 1.65, and 1.75, and those with more than 1 year of continuous lithium administration had the highest mean half-lives: 2.40, 2.43, and 2.24.","Lithium pharmacokinetics, duration of therapy, and the adenylate cyclase system. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6286526/),,2.24,35910,DB01356,Lithium
,26012509,flow rate,The mobile phase was comprised of acetonitrile and 0.1mmolL(-1) aqueous lithium acetate mixed with 0.03% formic acid at the flow rate of 0.2mLmin(-1).,Determination of pseudoprotodioscin in rat plasma by UPLC-MS/MS: Assay development and application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26012509/),1/[mlmin],0.2,36470,DB01356,Lithium
,26012509,bioavailability,PPD showed rapid excretion and with bioavailability of simply about 5.7% in rats.,Determination of pseudoprotodioscin in rat plasma by UPLC-MS/MS: Assay development and application to pharmacokinetic study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26012509/),%,5.7,36471,DB01356,Lithium
,16702900,Half-life,"Half-life of lithium in serum was 3.5 +/- 0.8 hours during the first HD, and 29 +/- 14 and 29 +/- 6 hours during therapy with diuretics or supportive treatment, respectively.",Lithium poisoning: pharmacokinetics and clearance during different therapeutic measures. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16702900/),h,3.5,42337,DB01356,Lithium
,16702900,Half-life,"Half-life of lithium in serum was 3.5 +/- 0.8 hours during the first HD, and 29 +/- 14 and 29 +/- 6 hours during therapy with diuretics or supportive treatment, respectively.",Lithium poisoning: pharmacokinetics and clearance during different therapeutic measures. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16702900/),h,29,42338,DB01356,Lithium
,16702900,Half-life,"Half-life of lithium in serum was 3.5 +/- 0.8 hours during the first HD, and 29 +/- 14 and 29 +/- 6 hours during therapy with diuretics or supportive treatment, respectively.",Lithium poisoning: pharmacokinetics and clearance during different therapeutic measures. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16702900/),h,29,42339,DB01356,Lithium
,16702900,clearance,"Lithium clearance during HD was 160 +/- 15 mL/min, and renal clearance during HD or treatment with diuretics was approximately 20 and 15 +/- 9 mL/min, respectively.",Lithium poisoning: pharmacokinetics and clearance during different therapeutic measures. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16702900/),[ml] / [min],160,42340,DB01356,Lithium
,16702900,renal clearance,"Lithium clearance during HD was 160 +/- 15 mL/min, and renal clearance during HD or treatment with diuretics was approximately 20 and 15 +/- 9 mL/min, respectively.",Lithium poisoning: pharmacokinetics and clearance during different therapeutic measures. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16702900/),[ml] / [min],20,42341,DB01356,Lithium
,16702900,renal clearance,"Lithium clearance during HD was 160 +/- 15 mL/min, and renal clearance during HD or treatment with diuretics was approximately 20 and 15 +/- 9 mL/min, respectively.",Lithium poisoning: pharmacokinetics and clearance during different therapeutic measures. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16702900/),[ml] / [min],15,42342,DB01356,Lithium
,32097685,half-lives,"Pharmacokinetic profiles of DOPAC and 3-HPAA followed a two-compartment body model, with a fast distribution into peripheral tissues (half-lives of 3.27-5.26 min) and rapid elimination from the body (half-lives of 18.4-33.3 min).","Single dose pharmacokinetics of intravenous 3,4-dihydroxyphenylacetic acid and 3-hydroxyphenylacetic acid in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32097685/),min,3.27-5.26,42421,DB01356,Lithium
,32097685,half-lives,"Pharmacokinetic profiles of DOPAC and 3-HPAA followed a two-compartment body model, with a fast distribution into peripheral tissues (half-lives of 3.27-5.26 min) and rapid elimination from the body (half-lives of 18.4-33.3 min).","Single dose pharmacokinetics of intravenous 3,4-dihydroxyphenylacetic acid and 3-hydroxyphenylacetic acid in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32097685/),min,18.4-33.3,42422,DB01356,Lithium
,3176101,k,"The mean (+/- SD) values generated for k, ka, and V were 0.035 +/- 0.008 (h-1), 0.897 +/- 0.059 (h-1), and 40.97 +/- 5.27 (L), respectively.","Comparison of three lithium dosing methods in 950 ""subjects"" by computer simulation. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3176101/),1/[h],0.035,43236,DB01356,Lithium
,3176101,ka,"The mean (+/- SD) values generated for k, ka, and V were 0.035 +/- 0.008 (h-1), 0.897 +/- 0.059 (h-1), and 40.97 +/- 5.27 (L), respectively.","Comparison of three lithium dosing methods in 950 ""subjects"" by computer simulation. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3176101/),1/[h],0.897,43237,DB01356,Lithium
,3176101,ka,"The mean (+/- SD) values generated for k, ka, and V were 0.035 +/- 0.008 (h-1), 0.897 +/- 0.059 (h-1), and 40.97 +/- 5.27 (L), respectively.","Comparison of three lithium dosing methods in 950 ""subjects"" by computer simulation. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3176101/),l,40.97,43238,DB01356,Lithium
,3176101,V,"The mean (+/- SD) values generated for k, ka, and V were 0.035 +/- 0.008 (h-1), 0.897 +/- 0.059 (h-1), and 40.97 +/- 5.27 (L), respectively.","Comparison of three lithium dosing methods in 950 ""subjects"" by computer simulation. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3176101/),l,40.97,43239,DB01356,Lithium
,2499471,clearance,"In RVH captopril reduced 51-Cr-EDTA clearance (67.3 (median) to 47.5 ml min-1, P less than 0.01), proximal absolute reabsorption of fluid (53.9 to 41.5 ml min-1, P less than 0.01) and distal absolute reabsorption of sodium (2195 to 1402 mumol min-1, P less than 0.01), whereas proximal fractional reabsorption increased slightly (77.5 to 80.2%, P less than 0.02).",Abnormal glomerular and tubular function during angiotensin converting enzyme inhibition in renovascular hypertension evaluated by the lithium clearance method. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2499471/),[ml] / [min],67.3,44373,DB01356,Lithium
,2499471,clearance,"In RVH captopril reduced 51-Cr-EDTA clearance (67.3 (median) to 47.5 ml min-1, P less than 0.01), proximal absolute reabsorption of fluid (53.9 to 41.5 ml min-1, P less than 0.01) and distal absolute reabsorption of sodium (2195 to 1402 mumol min-1, P less than 0.01), whereas proximal fractional reabsorption increased slightly (77.5 to 80.2%, P less than 0.02).",Abnormal glomerular and tubular function during angiotensin converting enzyme inhibition in renovascular hypertension evaluated by the lithium clearance method. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2499471/),[ml] / [min],47.5,44374,DB01356,Lithium
,2499471,proximal absolute reabsorption of fluid,"In RVH captopril reduced 51-Cr-EDTA clearance (67.3 (median) to 47.5 ml min-1, P less than 0.01), proximal absolute reabsorption of fluid (53.9 to 41.5 ml min-1, P less than 0.01) and distal absolute reabsorption of sodium (2195 to 1402 mumol min-1, P less than 0.01), whereas proximal fractional reabsorption increased slightly (77.5 to 80.2%, P less than 0.02).",Abnormal glomerular and tubular function during angiotensin converting enzyme inhibition in renovascular hypertension evaluated by the lithium clearance method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2499471/),[ml] / [min],53.9 to 41.5,44375,DB01356,Lithium
,2499471,distal absolute reabsorption of sodium,"In RVH captopril reduced 51-Cr-EDTA clearance (67.3 (median) to 47.5 ml min-1, P less than 0.01), proximal absolute reabsorption of fluid (53.9 to 41.5 ml min-1, P less than 0.01) and distal absolute reabsorption of sodium (2195 to 1402 mumol min-1, P less than 0.01), whereas proximal fractional reabsorption increased slightly (77.5 to 80.2%, P less than 0.02).",Abnormal glomerular and tubular function during angiotensin converting enzyme inhibition in renovascular hypertension evaluated by the lithium clearance method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2499471/),[μM] / [min],2195 to 1402,44376,DB01356,Lithium
,3110219,peak steady state serum concentration,"Following the morning lithium dose (0.21 +/- 0.06 mmol/kg/day, mean +/- standard deviation), a peak steady state serum concentration of 0.83 +/- 0.25 mmol/liter was achieved at 2.2 +/- 1.2 hours.",Pharmacokinetics of lithium in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3110219/),[mM] / [l],0.83,45765,DB01356,Lithium
,3110219,distribution half-life (alpha-t1/2),"The mean distribution half-life (alpha-t1/2) was 2.7 +/- 1.2 hours, with distribution being complete at 10.6 +/- 3.0 hours.",Pharmacokinetics of lithium in the elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3110219/),h,2.7,45766,DB01356,Lithium
,3110219,terminal elimination half-life (beta-t1/2),"The mean terminal elimination half-life (beta-t1/2), the mean apparent oral clearance (Cl), and the mean apparent volume of distribution (Varea) were 26.9 +/- 5.5 hours, 15.6 +/- 4.0 ml/min, and 0.64 +/- 0.16 liter/kg, respectively.",Pharmacokinetics of lithium in the elderly. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3110219/),h,26.9,45767,DB01356,Lithium
,3110219,apparent oral clearance (Cl),"The mean terminal elimination half-life (beta-t1/2), the mean apparent oral clearance (Cl), and the mean apparent volume of distribution (Varea) were 26.9 +/- 5.5 hours, 15.6 +/- 4.0 ml/min, and 0.64 +/- 0.16 liter/kg, respectively.",Pharmacokinetics of lithium in the elderly. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3110219/),[ml] / [min],15.6,45768,DB01356,Lithium
,3110219,apparent volume of distribution (Varea),"The mean terminal elimination half-life (beta-t1/2), the mean apparent oral clearance (Cl), and the mean apparent volume of distribution (Varea) were 26.9 +/- 5.5 hours, 15.6 +/- 4.0 ml/min, and 0.64 +/- 0.16 liter/kg, respectively.",Pharmacokinetics of lithium in the elderly. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3110219/),[l] / [kg],0.64,45769,DB01356,Lithium
,28768341,distribution volume,"Serum lithium concentrations at the time of sampling were estimated by 1-compartment model with Li-CL, fixed distribution volume (0.79 L/kg), and absorption rate (1.5/hour) in the 30 subjects.",Prediction Model of Serum Lithium Concentrations. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28768341/),[l] / [kg],0.79,46367,DB01356,Lithium
,28768341,absorption rate,"Serum lithium concentrations at the time of sampling were estimated by 1-compartment model with Li-CL, fixed distribution volume (0.79 L/kg), and absorption rate (1.5/hour) in the 30 subjects.",Prediction Model of Serum Lithium Concentrations. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28768341/),1/[h],1.5,46368,DB01356,Lithium
,31025773,clearance,"The population estimates of lithium clearance, volume of distribution, and absorption rate constant of the final model were 1.43 L/hr, 54 L (fixed), and 0.426 hr-1 (fixed), respectively.",Factors influencing lithium pharmacokinetics in patients with acute mania: A population pharmacokinetic analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31025773/),[l] / [h],1.43,50422,DB01356,Lithium
,31025773,volume of distribution,"The population estimates of lithium clearance, volume of distribution, and absorption rate constant of the final model were 1.43 L/hr, 54 L (fixed), and 0.426 hr-1 (fixed), respectively.",Factors influencing lithium pharmacokinetics in patients with acute mania: A population pharmacokinetic analysis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31025773/),l,54,50423,DB01356,Lithium
,31025773,absorption rate constant,"The population estimates of lithium clearance, volume of distribution, and absorption rate constant of the final model were 1.43 L/hr, 54 L (fixed), and 0.426 hr-1 (fixed), respectively.",Factors influencing lithium pharmacokinetics in patients with acute mania: A population pharmacokinetic analysis. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31025773/),1/[h],0.426,50424,DB01356,Lithium
,15355124,oral clearance,"The pharmacokinetics of topiramate are characterised by linear pharmacokinetics over the dose range 100-800 mg, low oral clearance (22-36 mL/min), which, in monotherapy, is predominantly through renal excretion (renal clearance 10-20 mL/min), and a long half-life (19-25 hours), which is reduced when coadministered with inducing AEDs such as phenytoin, phenobarbital and carbamazepine.",Pharmacokinetic interactions of topiramate. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),[ml] / [min],22-36,55128,DB01356,Lithium
,15355124,renal clearance,"The pharmacokinetics of topiramate are characterised by linear pharmacokinetics over the dose range 100-800 mg, low oral clearance (22-36 mL/min), which, in monotherapy, is predominantly through renal excretion (renal clearance 10-20 mL/min), and a long half-life (19-25 hours), which is reduced when coadministered with inducing AEDs such as phenytoin, phenobarbital and carbamazepine.",Pharmacokinetic interactions of topiramate. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),[ml] / [min],10-20,55129,DB01356,Lithium
,15355124,half-life,"The pharmacokinetics of topiramate are characterised by linear pharmacokinetics over the dose range 100-800 mg, low oral clearance (22-36 mL/min), which, in monotherapy, is predominantly through renal excretion (renal clearance 10-20 mL/min), and a long half-life (19-25 hours), which is reduced when coadministered with inducing AEDs such as phenytoin, phenobarbital and carbamazepine.",Pharmacokinetic interactions of topiramate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),h,19-25,55130,DB01356,Lithium
,15355124,absolute bioavailability,"The absolute bioavailability, or oral availability, of topiramate is 81-95% and is not affected by food.",Pharmacokinetic interactions of topiramate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),%,81-95,55131,DB01356,Lithium
,15355124,oral availability,"The absolute bioavailability, or oral availability, of topiramate is 81-95% and is not affected by food.",Pharmacokinetic interactions of topiramate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),%,81-95,55132,DB01356,Lithium
,33935755,clearance,"The clearance, central volume, inter-compartmental clearance, and peripheral volume estimates from the final population PK model were 0.98 L/h, 13.1 L, 0.84 L/h, and 8.2 L for children with a body weight of 20 kg.",Population Pharmacokinetics of Lithium in Young Pediatric Patients With Intellectual Disability. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33935755/),[l] / [h],0.98,59213,DB01356,Lithium
,33935755,central volume,"The clearance, central volume, inter-compartmental clearance, and peripheral volume estimates from the final population PK model were 0.98 L/h, 13.1 L, 0.84 L/h, and 8.2 L for children with a body weight of 20 kg.",Population Pharmacokinetics of Lithium in Young Pediatric Patients With Intellectual Disability. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33935755/),l,13.1,59214,DB01356,Lithium
,33935755,central volume,"The clearance, central volume, inter-compartmental clearance, and peripheral volume estimates from the final population PK model were 0.98 L/h, 13.1 L, 0.84 L/h, and 8.2 L for children with a body weight of 20 kg.",Population Pharmacokinetics of Lithium in Young Pediatric Patients With Intellectual Disability. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33935755/),[l] / [h],0.84,59215,DB01356,Lithium
,33935755,inter-compartmental clearance,"The clearance, central volume, inter-compartmental clearance, and peripheral volume estimates from the final population PK model were 0.98 L/h, 13.1 L, 0.84 L/h, and 8.2 L for children with a body weight of 20 kg.",Population Pharmacokinetics of Lithium in Young Pediatric Patients With Intellectual Disability. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33935755/),l,13.1,59216,DB01356,Lithium
,33935755,inter-compartmental clearance,"The clearance, central volume, inter-compartmental clearance, and peripheral volume estimates from the final population PK model were 0.98 L/h, 13.1 L, 0.84 L/h, and 8.2 L for children with a body weight of 20 kg.",Population Pharmacokinetics of Lithium in Young Pediatric Patients With Intellectual Disability. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33935755/),[l] / [h],0.84,59217,DB01356,Lithium
,33935755,peripheral volume,"The clearance, central volume, inter-compartmental clearance, and peripheral volume estimates from the final population PK model were 0.98 L/h, 13.1 L, 0.84 L/h, and 8.2 L for children with a body weight of 20 kg.",Population Pharmacokinetics of Lithium in Young Pediatric Patients With Intellectual Disability. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33935755/),l,8.2,59218,DB01356,Lithium
,11794846,half-life,"The aim of this study is the evaluation of the pharmacokinetics of a new lithium compound to be administered ""once a day"", with a half-life of 32.4 hours.","Intensive treatment with lithium carbonate ""once a day"" in bipolar patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11794846/),h,32.4,63439,DB01356,Lithium
,11794846,dose,"The average dose of ""once a day"" lithium was 821 (+/- 250) mg/day, the corresponding plasma level was 0.45 (+/- 0.11) mEq/L, and the dose (g) to plasma level ratio was 1.96 (+/- 0.66).","Intensive treatment with lithium carbonate ""once a day"" in bipolar patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11794846/),,1.96,63440,DB01356,Lithium
,27865605,CL/F,"Lithium measurements were described using a two-compartment model (CL/F=0.41Lh-1, V1/F=15.3L, Q/F=0.61Lh-1, and V2/F = 15.8L) and the most significant covariate on lithium CL was found to be creatinine clearance (reference model).",Population pharmacokinetic model of lithium and drug compliance assessment. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27865605/),1/[lh],0.41,68258,DB01356,Lithium
,27865605,V1/F,"Lithium measurements were described using a two-compartment model (CL/F=0.41Lh-1, V1/F=15.3L, Q/F=0.61Lh-1, and V2/F = 15.8L) and the most significant covariate on lithium CL was found to be creatinine clearance (reference model).",Population pharmacokinetic model of lithium and drug compliance assessment. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27865605/),l,15.3,68259,DB01356,Lithium
,27865605,Q/F,"Lithium measurements were described using a two-compartment model (CL/F=0.41Lh-1, V1/F=15.3L, Q/F=0.61Lh-1, and V2/F = 15.8L) and the most significant covariate on lithium CL was found to be creatinine clearance (reference model).",Population pharmacokinetic model of lithium and drug compliance assessment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27865605/),1/[lh],0.61,68260,DB01356,Lithium
,27865605,V2/F,"Lithium measurements were described using a two-compartment model (CL/F=0.41Lh-1, V1/F=15.3L, Q/F=0.61Lh-1, and V2/F = 15.8L) and the most significant covariate on lithium CL was found to be creatinine clearance (reference model).",Population pharmacokinetic model of lithium and drug compliance assessment. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27865605/),l,15.8,68261,DB01356,Lithium
,3025767,half life,The half life of lithium in both rodents was shorter (3.5 h and 6 h) than that found during maintenance therapy in man.,The pharmacokinetic profile of lithium in rat and mouse; an important factor in psychopharmacological investigation of the drug. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3025767/),h,3.5,71436,DB01356,Lithium
,3025767,half life,The half life of lithium in both rodents was shorter (3.5 h and 6 h) than that found during maintenance therapy in man.,The pharmacokinetic profile of lithium in rat and mouse; an important factor in psychopharmacological investigation of the drug. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3025767/),h,6,71437,DB01356,Lithium
,19049695,CL,"The final population PK parameters estimates of lithium were: CL = 0.51 l/h with 12.7% BSV, V1 (Fixed) = 15.2 l, Q (Fixed) = 7.44 l/h, and V2 (Fixed) = 6.7 l.",Estimation of lithium clearance from routine clinical data in Egyptian bipolar patients. A population pharmacokinetic approach. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19049695/),[l] / [h],0.51,71517,DB01356,Lithium
,19049695,V1,"The final population PK parameters estimates of lithium were: CL = 0.51 l/h with 12.7% BSV, V1 (Fixed) = 15.2 l, Q (Fixed) = 7.44 l/h, and V2 (Fixed) = 6.7 l.",Estimation of lithium clearance from routine clinical data in Egyptian bipolar patients. A population pharmacokinetic approach. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19049695/),l,15.2,71518,DB01356,Lithium
,19049695,Q,"The final population PK parameters estimates of lithium were: CL = 0.51 l/h with 12.7% BSV, V1 (Fixed) = 15.2 l, Q (Fixed) = 7.44 l/h, and V2 (Fixed) = 6.7 l.",Estimation of lithium clearance from routine clinical data in Egyptian bipolar patients. A population pharmacokinetic approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19049695/),[l] / [h],7.44,71519,DB01356,Lithium
,19049695,V2,"The final population PK parameters estimates of lithium were: CL = 0.51 l/h with 12.7% BSV, V1 (Fixed) = 15.2 l, Q (Fixed) = 7.44 l/h, and V2 (Fixed) = 6.7 l.",Estimation of lithium clearance from routine clinical data in Egyptian bipolar patients. A population pharmacokinetic approach. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19049695/),l,6.7,71520,DB01356,Lithium
,9864078,AUC at 72 hours,"For patients receiving gabapentin, the mean Li AUC at 72 hours was 9.91+/-3.54 mmol x hr/mL and did not differ significantly from the mean Li AUC of 10.19+/-2.89 mmol x hr/mL for patients receiving placebo.",Gabapentin does not alter single-dose lithium pharmacokinetics. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9864078/),[h·mM] / [ml],9.91,72859,DB01356,Lithium
,9864078,AUC,"For patients receiving gabapentin, the mean Li AUC at 72 hours was 9.91+/-3.54 mmol x hr/mL and did not differ significantly from the mean Li AUC of 10.19+/-2.89 mmol x hr/mL for patients receiving placebo.",Gabapentin does not alter single-dose lithium pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9864078/),[h·mM] / [ml],10.19,72860,DB01356,Lithium
,9864078,Li Cmax,The mean Li Cmax was 0.69+/-0.13 mmol/L for gabapentin patients and did not differ from the mean Li Cmax of 0.72+/-0.15 mmol/L for placebo patients.,Gabapentin does not alter single-dose lithium pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9864078/),[mM] / [l],0.69,72861,DB01356,Lithium
,9864078,Li Cmax,The mean Li Cmax was 0.69+/-0.13 mmol/L for gabapentin patients and did not differ from the mean Li Cmax of 0.72+/-0.15 mmol/L for placebo patients.,Gabapentin does not alter single-dose lithium pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9864078/),[mM] / [l],0.72,72862,DB01356,Lithium
,8162655,elimination half-life,The elimination half-life varies between 30 and 70 hours.,Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8162655/),h,30 and 70,74980,DB01356,Lithium
,8162655,oral bioavailability,The oral bioavailability of tenoxicam is 100% and rectal bioavailability is 80%.,Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8162655/),%,100,74981,DB01356,Lithium
,8162655,bioavailability,The oral bioavailability of tenoxicam is 100% and rectal bioavailability is 80%.,Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8162655/),%,80,74982,DB01356,Lithium
,8162655,elimination half-life,The mean elimination half-life is 60 to 75 hours.,Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8162655/),h,60 to 75,74983,DB01356,Lithium
,8162655,elimination half-life,The mean elimination half-life is 30 hours and does not appear to be affected by the age of the patient.,Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8162655/),h,30,74984,DB01356,Lithium
,8162655,elimination half-life,Lornoxicam differs from other oxicam NSAIDs because it has a short elimination half-life of 3 to 4 hours.,Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8162655/),h,3 to 4,74985,DB01356,Lithium
,27124003,clearance (CL/F),"The population PK parameters, clearance (CL/F), apparent distribution volume of the central compartment (V2/F), inter-compartmental clearance (Q/F) and apparent distribution volume of the peripheral compartment (V3/F), were 9.39 L/h, 10.4 L, 22.1 L/h, and 216 L, respectively.",Population Pharmacokinetics of Lithium Carbonate in Young Male Healthy Chinese Volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27124003/),[l] / [h],9.39,76788,DB01356,Lithium
,27124003,apparent distribution volume of the central compartment (V2/F),"The population PK parameters, clearance (CL/F), apparent distribution volume of the central compartment (V2/F), inter-compartmental clearance (Q/F) and apparent distribution volume of the peripheral compartment (V3/F), were 9.39 L/h, 10.4 L, 22.1 L/h, and 216 L, respectively.",Population Pharmacokinetics of Lithium Carbonate in Young Male Healthy Chinese Volunteers. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27124003/),l,10.4,76789,DB01356,Lithium
,27124003,apparent distribution volume of the central compartment (V2/F),"The population PK parameters, clearance (CL/F), apparent distribution volume of the central compartment (V2/F), inter-compartmental clearance (Q/F) and apparent distribution volume of the peripheral compartment (V3/F), were 9.39 L/h, 10.4 L, 22.1 L/h, and 216 L, respectively.",Population Pharmacokinetics of Lithium Carbonate in Young Male Healthy Chinese Volunteers. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27124003/),[l] / [h],22.1,76790,DB01356,Lithium
,27124003,inter-compartmental clearance (Q/F),"The population PK parameters, clearance (CL/F), apparent distribution volume of the central compartment (V2/F), inter-compartmental clearance (Q/F) and apparent distribution volume of the peripheral compartment (V3/F), were 9.39 L/h, 10.4 L, 22.1 L/h, and 216 L, respectively.",Population Pharmacokinetics of Lithium Carbonate in Young Male Healthy Chinese Volunteers. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27124003/),l,10.4,76791,DB01356,Lithium
,27124003,inter-compartmental clearance (Q/F),"The population PK parameters, clearance (CL/F), apparent distribution volume of the central compartment (V2/F), inter-compartmental clearance (Q/F) and apparent distribution volume of the peripheral compartment (V3/F), were 9.39 L/h, 10.4 L, 22.1 L/h, and 216 L, respectively.",Population Pharmacokinetics of Lithium Carbonate in Young Male Healthy Chinese Volunteers. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27124003/),[l] / [h],22.1,76792,DB01356,Lithium
,27124003,apparent distribution volume of the peripheral compartment (V3/F),"The population PK parameters, clearance (CL/F), apparent distribution volume of the central compartment (V2/F), inter-compartmental clearance (Q/F) and apparent distribution volume of the peripheral compartment (V3/F), were 9.39 L/h, 10.4 L, 22.1 L/h, and 216 L, respectively.",Population Pharmacokinetics of Lithium Carbonate in Young Male Healthy Chinese Volunteers. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27124003/),l,216,76793,DB01356,Lithium
,9695722,apparent volume of distribution,"Kinetics were characterized by a high apparent volume of distribution (43.7 +/- 11.2 L), a high total body clearance (5383 +/- 581 ml/min), and a short plasma half-life (5.57 +/- 0.8 minutes).",Metabolism and action of urodilatin infusion in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9695722/),l,43.7,77615,DB01356,Lithium
,9695722,total body clearance,"Kinetics were characterized by a high apparent volume of distribution (43.7 +/- 11.2 L), a high total body clearance (5383 +/- 581 ml/min), and a short plasma half-life (5.57 +/- 0.8 minutes).",Metabolism and action of urodilatin infusion in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9695722/),[ml] / [min],5383,77616,DB01356,Lithium
,9695722,plasma half-life,"Kinetics were characterized by a high apparent volume of distribution (43.7 +/- 11.2 L), a high total body clearance (5383 +/- 581 ml/min), and a short plasma half-life (5.57 +/- 0.8 minutes).",Metabolism and action of urodilatin infusion in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9695722/),min,5.57,77617,DB01356,Lithium
,9695722,maximal plasma urodilatin level,The maximal plasma urodilatin level was 177.2 +/- 25.8 pmol/L. Less than 1% of total infused urodilatin was recovered in urine.,Metabolism and action of urodilatin infusion in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9695722/),[pM] / [l],177.2,77618,DB01356,Lithium
,550669,t1/2serum,The ability to excrete lithium is not fully developed in 5-day-old rats: t1/2serum (23 h) and especially t1/2urine (72 h) are much longer than in adult rats (t1/2serum = 12 h; t1/2urine = 6.4 h).,[Pharmacokinetics of lithium in rats of various ages]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/550669/),h,23,77932,DB01356,Lithium
,550669,t1/2,The ability to excrete lithium is not fully developed in 5-day-old rats: t1/2serum (23 h) and especially t1/2urine (72 h) are much longer than in adult rats (t1/2serum = 12 h; t1/2urine = 6.4 h).,[Pharmacokinetics of lithium in rats of various ages]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/550669/),h,72,77933,DB01356,Lithium
,550669,t1/2serum,The ability to excrete lithium is not fully developed in 5-day-old rats: t1/2serum (23 h) and especially t1/2urine (72 h) are much longer than in adult rats (t1/2serum = 12 h; t1/2urine = 6.4 h).,[Pharmacokinetics of lithium in rats of various ages]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/550669/),h,12,77934,DB01356,Lithium
,550669,t1/2,The ability to excrete lithium is not fully developed in 5-day-old rats: t1/2serum (23 h) and especially t1/2urine (72 h) are much longer than in adult rats (t1/2serum = 12 h; t1/2urine = 6.4 h).,[Pharmacokinetics of lithium in rats of various ages]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/550669/),h,6.4,77935,DB01356,Lithium
,7878598,peak concentration,"The plasma concentrations of lithium measured during the placebo period were about 1 microgram/L, the peak concentration was 99.4 +/- 22.2 micrograms/L in the single dose study and 49.6 +/- 5.4 micrograms/L in the multiple doses study.",[Pharmacokinetics of low-dose lithium in healthy volunteers]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7878598/),[μg] / [l],99.4,78888,DB01356,Lithium
,7878598,peak concentration,"The plasma concentrations of lithium measured during the placebo period were about 1 microgram/L, the peak concentration was 99.4 +/- 22.2 micrograms/L in the single dose study and 49.6 +/- 5.4 micrograms/L in the multiple doses study.",[Pharmacokinetics of low-dose lithium in healthy volunteers]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7878598/),[μg] / [l],49.6,78889,DB01356,Lithium
,7878598,residual plasma levels,"In this last one, the residual plasma levels of lithium were between 20 and 25 micrograms/L.",[Pharmacokinetics of low-dose lithium in healthy volunteers]. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7878598/),[μg] / [l],20 and 25,78890,DB01356,Lithium
,7878598,T1/2,The pharmacokinetics parameters measured were: T1/2 = 22.6 +/- 3.1 h; Vd/F = 0.70 +/- 0.09 L/kg and Cl/F = 1.53 +/- 0.12 L/h.,[Pharmacokinetics of low-dose lithium in healthy volunteers]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7878598/),h,22.6,78891,DB01356,Lithium
,7878598,Vd/F,The pharmacokinetics parameters measured were: T1/2 = 22.6 +/- 3.1 h; Vd/F = 0.70 +/- 0.09 L/kg and Cl/F = 1.53 +/- 0.12 L/h.,[Pharmacokinetics of low-dose lithium in healthy volunteers]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7878598/),[l] / [kg],0.70,78892,DB01356,Lithium
,7878598,Cl/F,The pharmacokinetics parameters measured were: T1/2 = 22.6 +/- 3.1 h; Vd/F = 0.70 +/- 0.09 L/kg and Cl/F = 1.53 +/- 0.12 L/h.,[Pharmacokinetics of low-dose lithium in healthy volunteers]. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7878598/),[l] / [h],1.53,78893,DB01356,Lithium
,22770782,half-life,A short half-life (4.30±0.14 min) and a relatively high clearance (3.83±1.46 L/h/kg) were found.,"Development and full validation of an UPLC-MS/MS method for the determination of an anti-allergic indolinone derivative in rat plasma, and application to a preliminary pharmacokinetic study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22770782/),min,4.30,84785,DB01356,Lithium
,22770782,clearance,A short half-life (4.30±0.14 min) and a relatively high clearance (3.83±1.46 L/h/kg) were found.,"Development and full validation of an UPLC-MS/MS method for the determination of an anti-allergic indolinone derivative in rat plasma, and application to a preliminary pharmacokinetic study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22770782/),[l] / [h·kg],3.83,84786,DB01356,Lithium
,21872414,flow-rate,"Tamoxifen, N-desmethyl-tamoxifen, 4-hydroxy-tamoxifen and endoxifen were chromatographically separated on an Acquity UPLC(®) BEH C18 1.7 μm 2.1 mm×100 mm column eluted at a flow-rate of 0.300 ml/min on a gradient of 0.2mM ammonium formate and acetonitrile, both acidified with 0.1% formic acid.",Quantification of tamoxifen and three of its phase-I metabolites in human plasma by liquid chromatography/triple-quadrupole mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21872414/),[ml] / [min],0.300,89948,DB01356,Lithium
,21872414,overall run time,"The overall run time of the method was 10 min, with elution times of 2.9, 3.0, 4.1 and 4.2 min for endoxifen, 4-hydroxy-tamoxifen, N-desmethyl-tamoxifen and tamoxifen, respectively.",Quantification of tamoxifen and three of its phase-I metabolites in human plasma by liquid chromatography/triple-quadrupole mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21872414/),min,10,89949,DB01356,Lithium
,21872414,elution times,"The overall run time of the method was 10 min, with elution times of 2.9, 3.0, 4.1 and 4.2 min for endoxifen, 4-hydroxy-tamoxifen, N-desmethyl-tamoxifen and tamoxifen, respectively.",Quantification of tamoxifen and three of its phase-I metabolites in human plasma by liquid chromatography/triple-quadrupole mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21872414/),min,2.9,89950,DB01356,Lithium
,21872414,elution times,"The overall run time of the method was 10 min, with elution times of 2.9, 3.0, 4.1 and 4.2 min for endoxifen, 4-hydroxy-tamoxifen, N-desmethyl-tamoxifen and tamoxifen, respectively.",Quantification of tamoxifen and three of its phase-I metabolites in human plasma by liquid chromatography/triple-quadrupole mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21872414/),min,3.0,89951,DB01356,Lithium
,21872414,elution times,"The overall run time of the method was 10 min, with elution times of 2.9, 3.0, 4.1 and 4.2 min for endoxifen, 4-hydroxy-tamoxifen, N-desmethyl-tamoxifen and tamoxifen, respectively.",Quantification of tamoxifen and three of its phase-I metabolites in human plasma by liquid chromatography/triple-quadrupole mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21872414/),min,4.1,89952,DB01356,Lithium
,21872414,elution times,"The overall run time of the method was 10 min, with elution times of 2.9, 3.0, 4.1 and 4.2 min for endoxifen, 4-hydroxy-tamoxifen, N-desmethyl-tamoxifen and tamoxifen, respectively.",Quantification of tamoxifen and three of its phase-I metabolites in human plasma by liquid chromatography/triple-quadrupole mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21872414/),min,4.2,89953,DB01356,Lithium
,11510628,time to reach maximum observed plasma concentration,"In pharmacokinetic studies in humans, quetiapine was rapidly absorbed after oral administration, with median time to reach maximum observed plasma concentration ranging from 1 to 2 hours.",Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11510628/),h,1 to 2,91263,DB01356,Lithium
,11510628,terminal half-life,The drug is eliminated with a mean terminal half-life of approximately 7 hours.,Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11510628/),h,7,91264,DB01356,Lithium
,28147361,renal clearance,Its renal clearance was calculated to be 1.62 mL/min/kg.,Enantioselective Effect of Flurbiprofen on Lithium Disposition in Rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28147361/),[ml] / [kg·min],1.62,93482,DB01356,Lithium
,8571068,clearance,"We did not demonstrate any statistically significant difference between the group of ADPKD and control group in lithium clearance and in fraction excretion of lithium (23.6 +/- 14.5 vs. 19.5 +/- 8.7 ml/min, resp. 15.3 +/- 8.8 vs 13.8 +/- 7.8%).",[Lithium clearance in polycystic kidney disease]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8571068/),[ml] / [min],23.6,101465,DB01356,Lithium
,8571068,fraction excretion,"We did not demonstrate any statistically significant difference between the group of ADPKD and control group in lithium clearance and in fraction excretion of lithium (23.6 +/- 14.5 vs. 19.5 +/- 8.7 ml/min, resp. 15.3 +/- 8.8 vs 13.8 +/- 7.8%).",[Lithium clearance in polycystic kidney disease]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8571068/),%,15.3,101466,DB01356,Lithium
,8571068,fraction excretion,"We did not demonstrate any statistically significant difference between the group of ADPKD and control group in lithium clearance and in fraction excretion of lithium (23.6 +/- 14.5 vs. 19.5 +/- 8.7 ml/min, resp. 15.3 +/- 8.8 vs 13.8 +/- 7.8%).",[Lithium clearance in polycystic kidney disease]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8571068/),%,13.8,101467,DB01356,Lithium
,8571068,distal tubular resorption of sodium,"Nor proximal tubular resorption of sodium, neither distal tubular resorption of sodium did differ between the group of ADPKD and control group (86.18 +/- 2.2 vs 84.7 +/- 1.80% resp. 94.7 +/- 2.6 vs. 94.5 +/- 3.6%).",[Lithium clearance in polycystic kidney disease]. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8571068/),%,94.7,101468,DB01356,Lithium
,8571068,distal tubular resorption of sodium,"Nor proximal tubular resorption of sodium, neither distal tubular resorption of sodium did differ between the group of ADPKD and control group (86.18 +/- 2.2 vs 84.7 +/- 1.80% resp. 94.7 +/- 2.6 vs. 94.5 +/- 3.6%).",[Lithium clearance in polycystic kidney disease]. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8571068/),%,94.5,101469,DB01356,Lithium
,956394,Plasma urate,Plasma urate was increased from 1.2 +/- 0.6 to 20.1 +/- 3.1 mg/100 ml (P less than 0.001).,A micropuncture study of the early phase of acute urate nephropathy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/956394/),[mg] / [100·ml],1.2,101957,DB01356,Lithium
,956394,Plasma urate,Plasma urate was increased from 1.2 +/- 0.6 to 20.1 +/- 3.1 mg/100 ml (P less than 0.001).,A micropuncture study of the early phase of acute urate nephropathy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/956394/),[mg] / [100·ml],20.1,101958,DB01356,Lithium
,956394,Urinary urate,Urinary urate rose from 24.3 +/- 5.1 to 142.2 +/- 21.0 mg/100 ml (P less than 0.001).,A micropuncture study of the early phase of acute urate nephropathy. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/956394/),[mg] / [100·ml],24.3,101959,DB01356,Lithium
,956394,Urinary urate,Urinary urate rose from 24.3 +/- 5.1 to 142.2 +/- 21.0 mg/100 ml (P less than 0.001).,A micropuncture study of the early phase of acute urate nephropathy. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/956394/),[mg] / [100·ml],142.2,101960,DB01356,Lithium
,956394,urine flow rate,"Renal plasma flow and glomerular filtration rate fell to 17 and 14% of control values, respectively, and urine flow rate decreased from 11.3 +/- 4.8 to 4.2 +/- 2.2 mul/min (all P less than 0.005) Superficial nephron filtration rate fell less than that of the whole kidney (70 vs. 86%).",A micropuncture study of the early phase of acute urate nephropathy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/956394/),[mul] / [min],11.3,101961,DB01356,Lithium
,956394,urine flow rate,"Renal plasma flow and glomerular filtration rate fell to 17 and 14% of control values, respectively, and urine flow rate decreased from 11.3 +/- 4.8 to 4.2 +/- 2.2 mul/min (all P less than 0.005) Superficial nephron filtration rate fell less than that of the whole kidney (70 vs. 86%).",A micropuncture study of the early phase of acute urate nephropathy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/956394/),[mul] / [min],4.2,101962,DB01356,Lithium
,956394,Vascular resistance,Vascular resistance beyond the peritubular capillaries increased from 4.8 X 10(9) to 21.6 X 10(9) dynes s/cm5.,A micropuncture study of the early phase of acute urate nephropathy. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/956394/),[dynes·s] / [cm5],4.8 X 10(9),101963,DB01356,Lithium
,956394,Vascular resistance,Vascular resistance beyond the peritubular capillaries increased from 4.8 X 10(9) to 21.6 X 10(9) dynes s/cm5.,A micropuncture study of the early phase of acute urate nephropathy. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/956394/),[dynes·s] / [cm5],21.6 X 10(9),101964,DB01356,Lithium
,21319957,urine volume,"The urine volume of STZ mice was approximately 26 mL/day, 22 times that of normal mice.",Changes in the pharmacokinetics of digoxin in polyuria in streptozotocin-induced diabetic mice and lithium carbonate-treated mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21319957/),[ml] / [d],26,102540,DB01356,Lithium
,1416324,observed peak serum lithium concentration,"Compared with control, sodium polystyrene sulfonate and sorbitol reduced the area under the lithium serum concentration-time curve by 11.33%, reduced the mean observed peak serum lithium concentration 0.07 +/- 0.08 mmol/L, and delayed the time to the mean observed peak serum lithium concentration by 2.04 +/- 2.40 hours.",Effect of sodium polystyrene sulfonate on lithium bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1416324/),[mM] / [l],0.07,105139,DB01356,Lithium
,1416324,time to the mean observed peak serum lithium concentration,"Compared with control, sodium polystyrene sulfonate and sorbitol reduced the area under the lithium serum concentration-time curve by 11.33%, reduced the mean observed peak serum lithium concentration 0.07 +/- 0.08 mmol/L, and delayed the time to the mean observed peak serum lithium concentration by 2.04 +/- 2.40 hours.",Effect of sodium polystyrene sulfonate on lithium bioavailability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1416324/),h,2.04,105140,DB01356,Lithium
,23494798,flow rate,"Chromatographic separation was performed on a Sepax GP-C18 column (50 × 2.1 mm, 5 μM) with a mobile phase consisting of ACN-water and 1.5 μM formic acid and 25 mM lithium acetate (90 : 10, v/v) at a flow rate of 0.4 ml/min for 3.0 min.",Lithium adduct as precursor ion for sensitive and rapid quantification of 20 (S)-protopanaxadiol in rat plasma by liquid chromatography/quadrupole linear ion trap mass spectrometry and application to rat pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23494798/),[ml] / [min],0.4,105754,DB01356,Lithium
,23494798,m/z,"Multiple-reaction-monitoring mode was performed using lithium adduct ion as precursor ion of m/z 467.5/449.4 and 455.6/407.4 for the drug and IS, respectively.",Lithium adduct as precursor ion for sensitive and rapid quantification of 20 (S)-protopanaxadiol in rat plasma by liquid chromatography/quadrupole linear ion trap mass spectrometry and application to rat pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23494798/),,467.5,105755,DB01356,Lithium
,23494798,m/z,"Multiple-reaction-monitoring mode was performed using lithium adduct ion as precursor ion of m/z 467.5/449.4 and 455.6/407.4 for the drug and IS, respectively.",Lithium adduct as precursor ion for sensitive and rapid quantification of 20 (S)-protopanaxadiol in rat plasma by liquid chromatography/quadrupole linear ion trap mass spectrometry and application to rat pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23494798/),,449.4,105756,DB01356,Lithium
,23494798,m/z,"Multiple-reaction-monitoring mode was performed using lithium adduct ion as precursor ion of m/z 467.5/449.4 and 455.6/407.4 for the drug and IS, respectively.",Lithium adduct as precursor ion for sensitive and rapid quantification of 20 (S)-protopanaxadiol in rat plasma by liquid chromatography/quadrupole linear ion trap mass spectrometry and application to rat pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23494798/),,455.6,105757,DB01356,Lithium
,23494798,m/z,"Multiple-reaction-monitoring mode was performed using lithium adduct ion as precursor ion of m/z 467.5/449.4 and 455.6/407.4 for the drug and IS, respectively.",Lithium adduct as precursor ion for sensitive and rapid quantification of 20 (S)-protopanaxadiol in rat plasma by liquid chromatography/quadrupole linear ion trap mass spectrometry and application to rat pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23494798/),,407.4,105758,DB01356,Lithium
,23494798,limit of detection,The limit of detection was 0.2 ng/ml in rat plasma for PPD.,Lithium adduct as precursor ion for sensitive and rapid quantification of 20 (S)-protopanaxadiol in rat plasma by liquid chromatography/quadrupole linear ion trap mass spectrometry and application to rat pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23494798/),[ng] / [ml],0.2,105759,DB01356,Lithium
,7582387,Terminal plasma half-life,Terminal plasma half-life ranged from 19.0-29.0 h and RBC/plasma ratio was 0.32 +/- 0.11.,Pharmacokinetics of lithium in plasma and red blood cells in acute and chronic intoxicated patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582387/),h,19.0-29.0,113500,DB01356,Lithium
,7582387,RBC/plasma ratio,Terminal plasma half-life ranged from 19.0-29.0 h and RBC/plasma ratio was 0.32 +/- 0.11.,Pharmacokinetics of lithium in plasma and red blood cells in acute and chronic intoxicated patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582387/),,0.32,113501,DB01356,Lithium
,7582387,"distribution volume of the terminal phase, Vz","The distribution volume of the terminal phase, Vz, was estimated at 0.84 +/- 0.32 l/kg and renal clearance was 0.38 +/- 0.11 ml/mn/kg.",Pharmacokinetics of lithium in plasma and red blood cells in acute and chronic intoxicated patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582387/),[l] / [kg],0.84,113502,DB01356,Lithium
,7582387,renal clearance,"The distribution volume of the terminal phase, Vz, was estimated at 0.84 +/- 0.32 l/kg and renal clearance was 0.38 +/- 0.11 ml/mn/kg.",Pharmacokinetics of lithium in plasma and red blood cells in acute and chronic intoxicated patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582387/),[ml] / [kg·mn],0.38,113503,DB01356,Lithium
,7582387,Terminal plasma half-life,Terminal plasma half-life ranged from 36.5-79.4 h and zero-order decline appeared in 8 of the 10 patients.,Pharmacokinetics of lithium in plasma and red blood cells in acute and chronic intoxicated patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582387/),h,36.5-79.4,113504,DB01356,Lithium
,7582387,RBC/plasma ratio,The RBC/plasma ratio was 0.87 +/- 0.22 on admission.,Pharmacokinetics of lithium in plasma and red blood cells in acute and chronic intoxicated patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582387/),,0.87,113505,DB01356,Lithium
,7582387,Vz,Vz was estimated at 0.71 +/- 0.27 l/kg and renal clearance was 0.16 +/- 0.07 ml/mn/kg.,Pharmacokinetics of lithium in plasma and red blood cells in acute and chronic intoxicated patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582387/),[l] / [kg],0.71,113506,DB01356,Lithium
,7582387,renal clearance,Vz was estimated at 0.71 +/- 0.27 l/kg and renal clearance was 0.16 +/- 0.07 ml/mn/kg.,Pharmacokinetics of lithium in plasma and red blood cells in acute and chronic intoxicated patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582387/),[ml] / [kg·mn],0.16,113507,DB01356,Lithium
,12507057,elimination half-life,The elimination half-life was calculated to be 5.14 hours.,A case of levetiracetam (Keppra) poisoning with clinical and toxicokinetic data. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12507057/),h,5.14,117772,DB01356,Lithium
,1806626,elimination half-life,The elimination half-life is about 32 h; metabolism is by demethylation to an inactive metabolite.,Clinical implications of the pharmacology of sertraline. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1806626/),h,32,117841,DB01356,Lithium
,3118402,plasma clearances,"Renal clearances of Li+ were lower during night time, plasma clearances were 22 to 43 ml/min when not corrected for urinary recovery and 21 to 28 ml/min when corrected.",The pharmacokinetics of lithium in normal humans: expected and unexpected observations in view of basic kinetic principles. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3118402/),[ml] / [min],22 to 43,120839,DB01356,Lithium
,3118402,plasma clearances,"Renal clearances of Li+ were lower during night time, plasma clearances were 22 to 43 ml/min when not corrected for urinary recovery and 21 to 28 ml/min when corrected.",The pharmacokinetics of lithium in normal humans: expected and unexpected observations in view of basic kinetic principles. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3118402/),[ml] / [min],21 to 28,120840,DB01356,Lithium
,3118402,Urinary recovery,Urinary recovery (measured on 96 hours) was 65.0 to 99.7% and was individually less stable than plasma clearance.,The pharmacokinetics of lithium in normal humans: expected and unexpected observations in view of basic kinetic principles. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3118402/),%,65.0 to 99.7,120841,DB01356,Lithium
,2049899,volume of distribution,"With the initial model, the mean lithium volume of distribution was 32.8 L and mean lithium clearance was 1.36 L/hr.",Population pharmacokinetics of lithium. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049899/),l,32.8,121843,DB01356,Lithium
,2049899,clearance,"With the initial model, the mean lithium volume of distribution was 32.8 L and mean lithium clearance was 1.36 L/hr.",Population pharmacokinetics of lithium. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049899/),[l] / [h],1.36,121844,DB01356,Lithium
,9550632,absolute sodium excretion,"Large decreases in absolute sodium excretion, from 79+/-10 to 34+/-5 micromol/min (P<0.01), and fractional sodium excretion, from 0.5+/-0.0 to 0.3+/-0.0% (P<0.01), were associated with significant reductions in fractional lithium excretion (P<0.05) and maximum urine flow (P<0.01).",Effects of a nitric oxide synthesis inhibitor on renal sodium handling and diluting capacity in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9550632/),[μM] / [min],79,121918,DB01356,Lithium
,9550632,absolute sodium excretion,"Large decreases in absolute sodium excretion, from 79+/-10 to 34+/-5 micromol/min (P<0.01), and fractional sodium excretion, from 0.5+/-0.0 to 0.3+/-0.0% (P<0.01), were associated with significant reductions in fractional lithium excretion (P<0.05) and maximum urine flow (P<0.01).",Effects of a nitric oxide synthesis inhibitor on renal sodium handling and diluting capacity in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9550632/),[μM] / [min],34,121919,DB01356,Lithium
,9550632,fractional sodium excretion,"Large decreases in absolute sodium excretion, from 79+/-10 to 34+/-5 micromol/min (P<0.01), and fractional sodium excretion, from 0.5+/-0.0 to 0.3+/-0.0% (P<0.01), were associated with significant reductions in fractional lithium excretion (P<0.05) and maximum urine flow (P<0.01).",Effects of a nitric oxide synthesis inhibitor on renal sodium handling and diluting capacity in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9550632/),%,0.5,121920,DB01356,Lithium
,9550632,fractional sodium excretion,"Large decreases in absolute sodium excretion, from 79+/-10 to 34+/-5 micromol/min (P<0.01), and fractional sodium excretion, from 0.5+/-0.0 to 0.3+/-0.0% (P<0.01), were associated with significant reductions in fractional lithium excretion (P<0.05) and maximum urine flow (P<0.01).",Effects of a nitric oxide synthesis inhibitor on renal sodium handling and diluting capacity in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9550632/),%,0.3,121921,DB01356,Lithium
,9550632,Minimal urine sodium concentration,Minimal urine sodium concentration decreased from 5.8+/-0.04 to 3.9+/-0.4 mmol/l (P<0.01) whereas minimal urine osmolality increased (P<0.05).,Effects of a nitric oxide synthesis inhibitor on renal sodium handling and diluting capacity in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9550632/),[mM] / [l],5.8,121922,DB01356,Lithium
,9550632,Minimal urine sodium concentration,Minimal urine sodium concentration decreased from 5.8+/-0.04 to 3.9+/-0.4 mmol/l (P<0.01) whereas minimal urine osmolality increased (P<0.05).,Effects of a nitric oxide synthesis inhibitor on renal sodium handling and diluting capacity in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9550632/),[mM] / [l],3.9,121923,DB01356,Lithium
,7884646,urine output,"Prospective epidemiologic studies demonstrate that lithium carbonate in therapeutic oral doses with the plasma level between 1.2 and 1.5 meq/L (225 to 676 mg of lithium) do not cause diabetes insipidus, urine output increases in men to 3 liters; GFR does not significantly increase; creatinine clearance remains stable in women but decreases in men; renal concentrating capacity is significantly reduced; calcium metabolism is altered by lowering urinary calcium excretion and increasing serum calcium concentrations, thereby increasing circulating PTH.","Lithium: a review of its pharmacokinetics, health effects, and toxicology. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7884646/),,3,123416,DB01356,Lithium
,1680992,K12,The pharmacokinetic parameters were as follows: K12 (microconstant) = 0.3455 +/- 0.5345 (mean +/- SD) h-1; K21 (microconstant) = 0.1691 +/- 0.1242 h-1; K10 (microconstant) = 0.1320 +/- 0.1112 h-1; Vl (volume of distribution of central compartment) = 16.9057 +/- 5.9384 1; Vss (volume of distribution at steady state) = 38.8917 +/- 11.4540 1; V-beta (volume of distribution of elimination phase) = 46.3809 +/- 13.8742 1; alpha (distribution rate constant) = 0.5932 +/- 0.7090; and beta (excretion rate constant) = 0.0361 +/- 0.0141.,Maintenance lithium levels could be lowered: based on Taiwanese and Danish studies. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680992/),1/[h],0.3455,123884,DB01356,Lithium
,1680992,K21,The pharmacokinetic parameters were as follows: K12 (microconstant) = 0.3455 +/- 0.5345 (mean +/- SD) h-1; K21 (microconstant) = 0.1691 +/- 0.1242 h-1; K10 (microconstant) = 0.1320 +/- 0.1112 h-1; Vl (volume of distribution of central compartment) = 16.9057 +/- 5.9384 1; Vss (volume of distribution at steady state) = 38.8917 +/- 11.4540 1; V-beta (volume of distribution of elimination phase) = 46.3809 +/- 13.8742 1; alpha (distribution rate constant) = 0.5932 +/- 0.7090; and beta (excretion rate constant) = 0.0361 +/- 0.0141.,Maintenance lithium levels could be lowered: based on Taiwanese and Danish studies. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680992/),1/[h],0.1691,123885,DB01356,Lithium
,1680992,K10,The pharmacokinetic parameters were as follows: K12 (microconstant) = 0.3455 +/- 0.5345 (mean +/- SD) h-1; K21 (microconstant) = 0.1691 +/- 0.1242 h-1; K10 (microconstant) = 0.1320 +/- 0.1112 h-1; Vl (volume of distribution of central compartment) = 16.9057 +/- 5.9384 1; Vss (volume of distribution at steady state) = 38.8917 +/- 11.4540 1; V-beta (volume of distribution of elimination phase) = 46.3809 +/- 13.8742 1; alpha (distribution rate constant) = 0.5932 +/- 0.7090; and beta (excretion rate constant) = 0.0361 +/- 0.0141.,Maintenance lithium levels could be lowered: based on Taiwanese and Danish studies. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680992/),1/[h],0.1320,123886,DB01356,Lithium
,1680992,Vl (volume of distribution of central compartment),The pharmacokinetic parameters were as follows: K12 (microconstant) = 0.3455 +/- 0.5345 (mean +/- SD) h-1; K21 (microconstant) = 0.1691 +/- 0.1242 h-1; K10 (microconstant) = 0.1320 +/- 0.1112 h-1; Vl (volume of distribution of central compartment) = 16.9057 +/- 5.9384 1; Vss (volume of distribution at steady state) = 38.8917 +/- 11.4540 1; V-beta (volume of distribution of elimination phase) = 46.3809 +/- 13.8742 1; alpha (distribution rate constant) = 0.5932 +/- 0.7090; and beta (excretion rate constant) = 0.0361 +/- 0.0141.,Maintenance lithium levels could be lowered: based on Taiwanese and Danish studies. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680992/),1,16.9057,123887,DB01356,Lithium
,1680992,Vss (volume of distribution at steady state),The pharmacokinetic parameters were as follows: K12 (microconstant) = 0.3455 +/- 0.5345 (mean +/- SD) h-1; K21 (microconstant) = 0.1691 +/- 0.1242 h-1; K10 (microconstant) = 0.1320 +/- 0.1112 h-1; Vl (volume of distribution of central compartment) = 16.9057 +/- 5.9384 1; Vss (volume of distribution at steady state) = 38.8917 +/- 11.4540 1; V-beta (volume of distribution of elimination phase) = 46.3809 +/- 13.8742 1; alpha (distribution rate constant) = 0.5932 +/- 0.7090; and beta (excretion rate constant) = 0.0361 +/- 0.0141.,Maintenance lithium levels could be lowered: based on Taiwanese and Danish studies. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680992/),1,38.8917,123888,DB01356,Lithium
,1680992,V-beta (volume of distribution of elimination phase),The pharmacokinetic parameters were as follows: K12 (microconstant) = 0.3455 +/- 0.5345 (mean +/- SD) h-1; K21 (microconstant) = 0.1691 +/- 0.1242 h-1; K10 (microconstant) = 0.1320 +/- 0.1112 h-1; Vl (volume of distribution of central compartment) = 16.9057 +/- 5.9384 1; Vss (volume of distribution at steady state) = 38.8917 +/- 11.4540 1; V-beta (volume of distribution of elimination phase) = 46.3809 +/- 13.8742 1; alpha (distribution rate constant) = 0.5932 +/- 0.7090; and beta (excretion rate constant) = 0.0361 +/- 0.0141.,Maintenance lithium levels could be lowered: based on Taiwanese and Danish studies. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680992/),1,46.3809,123889,DB01356,Lithium
,1680992,alpha (distribution rate constant),The pharmacokinetic parameters were as follows: K12 (microconstant) = 0.3455 +/- 0.5345 (mean +/- SD) h-1; K21 (microconstant) = 0.1691 +/- 0.1242 h-1; K10 (microconstant) = 0.1320 +/- 0.1112 h-1; Vl (volume of distribution of central compartment) = 16.9057 +/- 5.9384 1; Vss (volume of distribution at steady state) = 38.8917 +/- 11.4540 1; V-beta (volume of distribution of elimination phase) = 46.3809 +/- 13.8742 1; alpha (distribution rate constant) = 0.5932 +/- 0.7090; and beta (excretion rate constant) = 0.0361 +/- 0.0141.,Maintenance lithium levels could be lowered: based on Taiwanese and Danish studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680992/),,0.5932,123890,DB01356,Lithium
,1680992,beta (excretion rate constant),The pharmacokinetic parameters were as follows: K12 (microconstant) = 0.3455 +/- 0.5345 (mean +/- SD) h-1; K21 (microconstant) = 0.1691 +/- 0.1242 h-1; K10 (microconstant) = 0.1320 +/- 0.1112 h-1; Vl (volume of distribution of central compartment) = 16.9057 +/- 5.9384 1; Vss (volume of distribution at steady state) = 38.8917 +/- 11.4540 1; V-beta (volume of distribution of elimination phase) = 46.3809 +/- 13.8742 1; alpha (distribution rate constant) = 0.5932 +/- 0.7090; and beta (excretion rate constant) = 0.0361 +/- 0.0141.,Maintenance lithium levels could be lowered: based on Taiwanese and Danish studies. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680992/),,0.0361,123891,DB01356,Lithium
,1680992,elimination half-life,"The mean elimination half-life, AUC (the area under the curve) and clearance were 22.5 +/- 9.9 h (range from 9.6 to 50.4 h), 16.33 +/- 5.52 mmoll-1h (8.69 to 31.81 mmoll-1 h), and 1.65 +/- 0.53 1h-1 (0.76 to 2.28 1h-1) or 28.59 +/- 9.58 ml/kg-1 h-1, respectively.",Maintenance lithium levels could be lowered: based on Taiwanese and Danish studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680992/),h,22.5,123892,DB01356,Lithium
,1680992,AUC (the area under the curve),"The mean elimination half-life, AUC (the area under the curve) and clearance were 22.5 +/- 9.9 h (range from 9.6 to 50.4 h), 16.33 +/- 5.52 mmoll-1h (8.69 to 31.81 mmoll-1 h), and 1.65 +/- 0.53 1h-1 (0.76 to 2.28 1h-1) or 28.59 +/- 9.58 ml/kg-1 h-1, respectively.",Maintenance lithium levels could be lowered: based on Taiwanese and Danish studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680992/),1/[mmoll],16.33,123893,DB01356,Lithium
,1680992,clearance,"The mean elimination half-life, AUC (the area under the curve) and clearance were 22.5 +/- 9.9 h (range from 9.6 to 50.4 h), 16.33 +/- 5.52 mmoll-1h (8.69 to 31.81 mmoll-1 h), and 1.65 +/- 0.53 1h-1 (0.76 to 2.28 1h-1) or 28.59 +/- 9.58 ml/kg-1 h-1, respectively.",Maintenance lithium levels could be lowered: based on Taiwanese and Danish studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680992/),1/[1h],1.65,123894,DB01356,Lithium
,1680992,clearance,"The mean elimination half-life, AUC (the area under the curve) and clearance were 22.5 +/- 9.9 h (range from 9.6 to 50.4 h), 16.33 +/- 5.52 mmoll-1h (8.69 to 31.81 mmoll-1 h), and 1.65 +/- 0.53 1h-1 (0.76 to 2.28 1h-1) or 28.59 +/- 9.58 ml/kg-1 h-1, respectively.",Maintenance lithium levels could be lowered: based on Taiwanese and Danish studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680992/),[ml] / [kg],28.59,123895,DB01356,Lithium
,20101186,Response rates,Response rates were 72.6% in the lithium group and 79.5% in the valproate group.,"Efficacy of valproate versus lithium in mania or mixed mania: a randomized, open 12-week trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20101186/),%,72.6,124463,DB01356,Lithium
,20101186,Response rates,Response rates were 72.6% in the lithium group and 79.5% in the valproate group.,"Efficacy of valproate versus lithium in mania or mixed mania: a randomized, open 12-week trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20101186/),%,79.5,124464,DB01356,Lithium
,20101186,Remission rates,"Remission rates were 58.5 and 71.9%, respectively.","Efficacy of valproate versus lithium in mania or mixed mania: a randomized, open 12-week trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20101186/),%,58.5,124465,DB01356,Lithium
,20101186,Remission rates,"Remission rates were 58.5 and 71.9%, respectively.","Efficacy of valproate versus lithium in mania or mixed mania: a randomized, open 12-week trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20101186/),%,71.9,124466,DB01356,Lithium
,20101186,time to treatment response,No intergroup differences were observed in median time to treatment response (21 days) or change in Clinical Global Impression Bipolar Disorder instrument or Montgomery and Asberg Depression Rating Scale scores.,"Efficacy of valproate versus lithium in mania or mixed mania: a randomized, open 12-week trial. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20101186/),d,21,124467,DB01356,Lithium
,24997387,renal clearance,"The renal clearance of lithium was calculated to be 0.740 ml/min/kg in control rats, and this was 26.7% of creatinine clearance.",Sodium-phosphate cotransporter mediates reabsorption of lithium in rat kidney. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24997387/),[ml] / [kg·min],0.740,125664,DB01356,Lithium
,1660546,urinary,"The urinary amount of furosemide in the Li-treated rats was significantly lower than that in the control animals [Li group (n = 12): 514 +/- 75 (mean +/- S.E.) vs. control group (n = 12): 916 +/- 85 micrograms/kg/6 hr, P less than 0.01].",Influence of chronic lithium treatment on urinary amount of furosemide in rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1660546/),[μg] / [6·h·kg],51,127528,DB01356,Lithium
,1660546,urinary,"The urinary amount of furosemide in the Li-treated rats was significantly lower than that in the control animals [Li group (n = 12): 514 +/- 75 (mean +/- S.E.) vs. control group (n = 12): 916 +/- 85 micrograms/kg/6 hr, P less than 0.01].",Influence of chronic lithium treatment on urinary amount of furosemide in rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1660546/),[μg] / [6·h·kg],91,127529,DB01356,Lithium
,25354763,absorption,"Delayed absorption (4.03 vs 0.31 h), increased plasma elimination (0.65 vs 0.37 l/kg/h) and shorter half-life (1.75 vs 2.68 h) were observed in acute-on-chronically compared with acutely poisoned rats.",Study of blood and brain lithium pharmacokinetics in the rat according to three different modalities of poisoning. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25354763/),h,4.03,127806,DB01356,Lithium
,25354763,absorption,"Delayed absorption (4.03 vs 0.31 h), increased plasma elimination (0.65 vs 0.37 l/kg/h) and shorter half-life (1.75 vs 2.68 h) were observed in acute-on-chronically compared with acutely poisoned rats.",Study of blood and brain lithium pharmacokinetics in the rat according to three different modalities of poisoning. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25354763/),h,0.31,127807,DB01356,Lithium
,25354763,plasma elimination,"Delayed absorption (4.03 vs 0.31 h), increased plasma elimination (0.65 vs 0.37 l/kg/h) and shorter half-life (1.75 vs 2.68 h) were observed in acute-on-chronically compared with acutely poisoned rats.",Study of blood and brain lithium pharmacokinetics in the rat according to three different modalities of poisoning. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25354763/),[l] / [h·kg],0.65,127808,DB01356,Lithium
,25354763,plasma elimination,"Delayed absorption (4.03 vs 0.31 h), increased plasma elimination (0.65 vs 0.37 l/kg/h) and shorter half-life (1.75 vs 2.68 h) were observed in acute-on-chronically compared with acutely poisoned rats.",Study of blood and brain lithium pharmacokinetics in the rat according to three different modalities of poisoning. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25354763/),[l] / [h·kg],0.37,127809,DB01356,Lithium
,25354763,half-life,"Delayed absorption (4.03 vs 0.31 h), increased plasma elimination (0.65 vs 0.37 l/kg/h) and shorter half-life (1.75 vs 2.68 h) were observed in acute-on-chronically compared with acutely poisoned rats.",Study of blood and brain lithium pharmacokinetics in the rat according to three different modalities of poisoning. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25354763/),h,1.75,127810,DB01356,Lithium
,25354763,half-life,"Delayed absorption (4.03 vs 0.31 h), increased plasma elimination (0.65 vs 0.37 l/kg/h) and shorter half-life (1.75 vs 2.68 h) were observed in acute-on-chronically compared with acutely poisoned rats.",Study of blood and brain lithium pharmacokinetics in the rat according to three different modalities of poisoning. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25354763/),h,2.68,127811,DB01356,Lithium
,25354763,area-under-the-curve of brain concentrations,"However, brain lithium accumulation was more marked in acute-on-chronically than acutely poisoned rats [area-under-the-curve of brain concentrations (379 ± 41 vs 295 ± 26, P < .05) and brain-to-plasma ratio (45 ± 10 vs 8 ± 2, P < .0001) at 54 h].",Study of blood and brain lithium pharmacokinetics in the rat according to three different modalities of poisoning. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25354763/),,379,127812,DB01356,Lithium
,25354763,area-under-the-curve of brain concentrations,"However, brain lithium accumulation was more marked in acute-on-chronically than acutely poisoned rats [area-under-the-curve of brain concentrations (379 ± 41 vs 295 ± 26, P < .05) and brain-to-plasma ratio (45 ± 10 vs 8 ± 2, P < .0001) at 54 h].",Study of blood and brain lithium pharmacokinetics in the rat according to three different modalities of poisoning. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25354763/),,295,127813,DB01356,Lithium
,25354763,brain-to-plasma ratio,"However, brain lithium accumulation was more marked in acute-on-chronically than acutely poisoned rats [area-under-the-curve of brain concentrations (379 ± 41 vs 295 ± 26, P < .05) and brain-to-plasma ratio (45 ± 10 vs 8 ± 2, P < .0001) at 54 h].",Study of blood and brain lithium pharmacokinetics in the rat according to three different modalities of poisoning. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25354763/),,45,127814,DB01356,Lithium
,25354763,brain-to-plasma ratio,"However, brain lithium accumulation was more marked in acute-on-chronically than acutely poisoned rats [area-under-the-curve of brain concentrations (379 ± 41 vs 295 ± 26, P < .05) and brain-to-plasma ratio (45 ± 10 vs 8 ± 2, P < .0001) at 54 h].",Study of blood and brain lithium pharmacokinetics in the rat according to three different modalities of poisoning. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25354763/),,8,127815,DB01356,Lithium
,25354763,brain-to-plasma ratio,"Moreover, brain lithium distribution was increased in chronically compared with acute-on-chronically poisoned rats (brain-to-plasma ratio: 9 ± 1 vs 3 ± 0, P < .01).",Study of blood and brain lithium pharmacokinetics in the rat according to three different modalities of poisoning. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25354763/),,9,127816,DB01356,Lithium
,25354763,brain-to-plasma ratio,"Moreover, brain lithium distribution was increased in chronically compared with acute-on-chronically poisoned rats (brain-to-plasma ratio: 9 ± 1 vs 3 ± 0, P < .01).",Study of blood and brain lithium pharmacokinetics in the rat according to three different modalities of poisoning. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25354763/),,3,127817,DB01356,Lithium
,10511917,half-life,"Its mean half-life in healthy individuals was 33 hours, ranging from 21 to 54 hours.",Olanzapine. Pharmacokinetic and pharmacodynamic profile. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10511917/),h,33,129674,DB01356,Lithium
,10511917,apparent plasma clearance,"The mean apparent plasma clearance was 26 L/h, ranging from 12 to 47 L/h.",Olanzapine. Pharmacokinetic and pharmacodynamic profile. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10511917/),[l] / [h],26,129675,DB01356,Lithium
,12078335,AUC,"Mean AUC values were 3.01 mM-hours for standard Carbolithium vs. 3.53 mM-hrs for Carbolithium Once-A-Day, and respective mean levels across 96 hours were 0.214 +/- 0.107 vs. 0.252 +/- 0.097 mM.",A novel slow-release formulation of lithium carbonate (Carbolithium Once-A-Day) vs. standard Carbolithium: a comparative pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12078335/),mM-hours,3.01,129937,DB01356,Lithium
,12078335,AUC,"Mean AUC values were 3.01 mM-hours for standard Carbolithium vs. 3.53 mM-hrs for Carbolithium Once-A-Day, and respective mean levels across 96 hours were 0.214 +/- 0.107 vs. 0.252 +/- 0.097 mM.",A novel slow-release formulation of lithium carbonate (Carbolithium Once-A-Day) vs. standard Carbolithium: a comparative pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12078335/),mM-hrs,3.53,129938,DB01356,Lithium
,12078335,AUC,"Mean AUC values were 3.01 mM-hours for standard Carbolithium vs. 3.53 mM-hrs for Carbolithium Once-A-Day, and respective mean levels across 96 hours were 0.214 +/- 0.107 vs. 0.252 +/- 0.097 mM.",A novel slow-release formulation of lithium carbonate (Carbolithium Once-A-Day) vs. standard Carbolithium: a comparative pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12078335/),mM,0.214,129939,DB01356,Lithium
,12078335,AUC,"Mean AUC values were 3.01 mM-hours for standard Carbolithium vs. 3.53 mM-hrs for Carbolithium Once-A-Day, and respective mean levels across 96 hours were 0.214 +/- 0.107 vs. 0.252 +/- 0.097 mM.",A novel slow-release formulation of lithium carbonate (Carbolithium Once-A-Day) vs. standard Carbolithium: a comparative pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12078335/),mM,0.252,129940,DB01356,Lithium
,12078335,AUC,"For the first 24 hours, mean AUC values were 2.64 for Carbolithium vs. 3.03 mM-hours for Carbolithium Once-A-Day, and corresponding means were 0.264 vs. 0.303 mM.",A novel slow-release formulation of lithium carbonate (Carbolithium Once-A-Day) vs. standard Carbolithium: a comparative pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12078335/),mM-hours,2.64,129941,DB01356,Lithium
,12078335,AUC,"For the first 24 hours, mean AUC values were 2.64 for Carbolithium vs. 3.03 mM-hours for Carbolithium Once-A-Day, and corresponding means were 0.264 vs. 0.303 mM.",A novel slow-release formulation of lithium carbonate (Carbolithium Once-A-Day) vs. standard Carbolithium: a comparative pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12078335/),mM-hours,3.03,129942,DB01356,Lithium
,12078335,AUC,"For the first 24 hours, mean AUC values were 2.64 for Carbolithium vs. 3.03 mM-hours for Carbolithium Once-A-Day, and corresponding means were 0.264 vs. 0.303 mM.",A novel slow-release formulation of lithium carbonate (Carbolithium Once-A-Day) vs. standard Carbolithium: a comparative pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12078335/),mM,0.264,129943,DB01356,Lithium
,12078335,AUC,"For the first 24 hours, mean AUC values were 2.64 for Carbolithium vs. 3.03 mM-hours for Carbolithium Once-A-Day, and corresponding means were 0.264 vs. 0.303 mM.",A novel slow-release formulation of lithium carbonate (Carbolithium Once-A-Day) vs. standard Carbolithium: a comparative pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12078335/),mM,0.303,129944,DB01356,Lithium
,9350065,water reabsorption,"When plasma potassium concentration was raised from 2.6 +/- 0.2 to 7.9 +/- 0.2 mmol l-1, water reabsorption decreased from 23.9 +/- 2.9 to 19.8 +/- 2.2 ml min-1, whereas lithium reabsorption increased from 10.5 +/- 2.3 to 18.1 +/- 2.3 mumol min-1, at constant glomerular filtration rate.",Dissociation between water and lithium transport during acute changes in plasma potassium concentration in dog kidney. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350065/),[ml] / [min],23.9,139282,DB01356,Lithium
,9350065,water reabsorption,"When plasma potassium concentration was raised from 2.6 +/- 0.2 to 7.9 +/- 0.2 mmol l-1, water reabsorption decreased from 23.9 +/- 2.9 to 19.8 +/- 2.2 ml min-1, whereas lithium reabsorption increased from 10.5 +/- 2.3 to 18.1 +/- 2.3 mumol min-1, at constant glomerular filtration rate.",Dissociation between water and lithium transport during acute changes in plasma potassium concentration in dog kidney. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350065/),[ml] / [min],19.8,139283,DB01356,Lithium
,9350065,reabsorption,"When plasma potassium concentration was raised from 2.6 +/- 0.2 to 7.9 +/- 0.2 mmol l-1, water reabsorption decreased from 23.9 +/- 2.9 to 19.8 +/- 2.2 ml min-1, whereas lithium reabsorption increased from 10.5 +/- 2.3 to 18.1 +/- 2.3 mumol min-1, at constant glomerular filtration rate.",Dissociation between water and lithium transport during acute changes in plasma potassium concentration in dog kidney. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350065/),[μM] / [min],10.5,139284,DB01356,Lithium
,9350065,reabsorption,"When plasma potassium concentration was raised from 2.6 +/- 0.2 to 7.9 +/- 0.2 mmol l-1, water reabsorption decreased from 23.9 +/- 2.9 to 19.8 +/- 2.2 ml min-1, whereas lithium reabsorption increased from 10.5 +/- 2.3 to 18.1 +/- 2.3 mumol min-1, at constant glomerular filtration rate.",Dissociation between water and lithium transport during acute changes in plasma potassium concentration in dog kidney. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350065/),[μM] / [min],18.1,139285,DB01356,Lithium
,15217988,dissociation constants (KI),"In vitro, the dissociation constants (KI) for ABT as the P450 mechanism-based inactivator were determined to be 45.6 and 193 microM, and the maximal inactivation rate constants (kinact) were determined to be 0.089 and 0.075 min(-1) for the mouse and guinea pig liver microsomes, respectively.",Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in guinea pigs and mice using serial sampling. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217988/),μM,45.6,139333,DB01356,Lithium
,15217988,dissociation constants (KI),"In vitro, the dissociation constants (KI) for ABT as the P450 mechanism-based inactivator were determined to be 45.6 and 193 microM, and the maximal inactivation rate constants (kinact) were determined to be 0.089 and 0.075 min(-1) for the mouse and guinea pig liver microsomes, respectively.",Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in guinea pigs and mice using serial sampling. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217988/),μM,193,139334,DB01356,Lithium
,15217988,maximal inactivation rate constants (kinact),"In vitro, the dissociation constants (KI) for ABT as the P450 mechanism-based inactivator were determined to be 45.6 and 193 microM, and the maximal inactivation rate constants (kinact) were determined to be 0.089 and 0.075 min(-1) for the mouse and guinea pig liver microsomes, respectively.",Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in guinea pigs and mice using serial sampling. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217988/),1/[min],0.089,139335,DB01356,Lithium
,15217988,maximal inactivation rate constants (kinact),"In vitro, the dissociation constants (KI) for ABT as the P450 mechanism-based inactivator were determined to be 45.6 and 193 microM, and the maximal inactivation rate constants (kinact) were determined to be 0.089 and 0.075 min(-1) for the mouse and guinea pig liver microsomes, respectively.",Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in guinea pigs and mice using serial sampling. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15217988/),1/[min],0.075,139336,DB01356,Lithium
,19842945,Li T(1/2),"Median Li T(1/2) in the treated and control groups was 20.5 and 43.2 hours, respectively (p = 0.0006).",Successful treatment of lithium toxicity with sodium polystyrene sulfonate: a retrospective cohort study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19842945/),h,20.5,140611,DB01356,Lithium
,19842945,Li T(1/2),"Median Li T(1/2) in the treated and control groups was 20.5 and 43.2 hours, respectively (p = 0.0006).",Successful treatment of lithium toxicity with sodium polystyrene sulfonate: a retrospective cohort study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19842945/),h,43.2,140612,DB01356,Lithium
,10850840,peak plasma concentration,"Mean (+/- SD) peak plasma concentration of BDZ following IV administration (1,316 +/- 216 microg/L) was greater than that following IN administration (448 +/- 41 microg/L).",Comparison of plasma benzodiazepine concentrations following intranasal and intravenous administration of diazepam to dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850840/),[μg] / [l],"1,316",141201,DB01356,Lithium
,10850840,peak plasma concentration,"Mean (+/- SD) peak plasma concentration of BDZ following IV administration (1,316 +/- 216 microg/L) was greater than that following IN administration (448 +/- 41 microg/L).",Comparison of plasma benzodiazepine concentrations following intranasal and intravenous administration of diazepam to dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850840/),[μg] / [l],448,141202,DB01356,Lithium
< or =,10850840,Time to peak concentration,Time to peak concentration was < or = 3 minutes following IV administration and 4.5 +/- 1.5 minutes following IN administration.,Comparison of plasma benzodiazepine concentrations following intranasal and intravenous administration of diazepam to dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850840/),min,3,141203,DB01356,Lithium
,10850840,Time to peak concentration,Time to peak concentration was < or = 3 minutes following IV administration and 4.5 +/- 1.5 minutes following IN administration.,Comparison of plasma benzodiazepine concentrations following intranasal and intravenous administration of diazepam to dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850840/),min,4.5,141204,DB01356,Lithium
,10850840,bioavailability,Mean bioavailability of BDZ following IN administration was 80 +/- 9%.,Comparison of plasma benzodiazepine concentrations following intranasal and intravenous administration of diazepam to dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850840/),%,80,141205,DB01356,Lithium
,1320543,fractional lithium excretion,"Control levels of fractional lithium excretion (12.4 +/- 1.2%, mean +/- SEM) were not influenced by hydration, hydration plus arginine vasopressin administration or the lithium dosage.","Lithium clearance in dogs: effects of water loading, amiloride and lithium dosage. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1320543/),%,12.4,143914,DB01356,Lithium
,1320543,fractional,"The low fractional lithium excretion even during amiloride infusion (14.1-16.8%) may well be due to a high fractional reabsorption of lithium in the proximal tubules; however, a significant reabsorption of lithium distal to the proximal straight tubules by amiloride-insensitive pathways cannot be excluded.","Lithium clearance in dogs: effects of water loading, amiloride and lithium dosage. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1320543/),%,14.1-16.8,143915,DB01356,Lithium
,17163560,IC(50),"Asymmetric synthesis of the most potent compound 23 a gave rise to the (3R,4S)-enantiomer 30 and the (3S,4R)-enantiomer 31, which showed IC(50) values of 2.9 and 385.9 nM, respectively.","Synthesis and biological evaluation of 1,3,3,4-tetrasubstituted pyrrolidine CCR5 receptor antagonists. Discovery of a potent and orally bioavailable anti-HIV agent. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17163560/),nM,2.9,144331,DB01356,Lithium
,17163560,IC(50),"Asymmetric synthesis of the most potent compound 23 a gave rise to the (3R,4S)-enantiomer 30 and the (3S,4R)-enantiomer 31, which showed IC(50) values of 2.9 and 385.9 nM, respectively.","Synthesis and biological evaluation of 1,3,3,4-tetrasubstituted pyrrolidine CCR5 receptor antagonists. Discovery of a potent and orally bioavailable anti-HIV agent. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17163560/),nM,385.9,144332,DB01356,Lithium
,17163560,EC(50),"Compound 30 displayed excellent replication inhibition of seven genetically diverse R5 HIV-1 strains in the PBMC model, in a concentration-dependent manner with EC(50) values ranging from 0.3 nM to 30 nM.","Synthesis and biological evaluation of 1,3,3,4-tetrasubstituted pyrrolidine CCR5 receptor antagonists. Discovery of a potent and orally bioavailable anti-HIV agent. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17163560/),nM,0.3,144333,DB01356,Lithium
,17163560,EC(50),"Compound 30 displayed excellent replication inhibition of seven genetically diverse R5 HIV-1 strains in the PBMC model, in a concentration-dependent manner with EC(50) values ranging from 0.3 nM to 30 nM.","Synthesis and biological evaluation of 1,3,3,4-tetrasubstituted pyrrolidine CCR5 receptor antagonists. Discovery of a potent and orally bioavailable anti-HIV agent. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17163560/),nM,30,144334,DB01356,Lithium
,17163560,oral bioavailabilities,"This molecule showed oral bioavailabilities of 41.2 % and 21.6 % in rats and dogs, respectively.","Synthesis and biological evaluation of 1,3,3,4-tetrasubstituted pyrrolidine CCR5 receptor antagonists. Discovery of a potent and orally bioavailable anti-HIV agent. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17163560/),%,41.2,144335,DB01356,Lithium
,17163560,oral bioavailabilities,"This molecule showed oral bioavailabilities of 41.2 % and 21.6 % in rats and dogs, respectively.","Synthesis and biological evaluation of 1,3,3,4-tetrasubstituted pyrrolidine CCR5 receptor antagonists. Discovery of a potent and orally bioavailable anti-HIV agent. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17163560/),%,21.6,144336,DB01356,Lithium
,9169962,steady-state volume of distribution,"The steady-state volume of distribution and total plasma clearance were estimated to be 63.4 +/- 38.3 L and 1.47 +/- 0.49 L/hr, respectively, which were similar to those reported in studies of Caucasian subjects.",Lithium pharmacokinetics in Chinese manic-depressive patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9169962/),l,63.4,144942,DB01356,Lithium
,9169962,total plasma clearance,"The steady-state volume of distribution and total plasma clearance were estimated to be 63.4 +/- 38.3 L and 1.47 +/- 0.49 L/hr, respectively, which were similar to those reported in studies of Caucasian subjects.",Lithium pharmacokinetics in Chinese manic-depressive patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9169962/),[l] / [h],1.47,144943,DB01356,Lithium
,30419292,bioavailability,"After one week of dietary phosphate challenges, lithium bioavailability was ~30% lower on low versus high dietary phosphate, possibly the consequence of a smaller area under the curve after oral administration.",Contribution of NHE3 and dietary phosphate to lithium pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30419292/),%,30,145914,DB01356,Lithium
,3907374,Urinary sodium excretions,"Urinary sodium excretions were 22 +/- 4, 202 +/- 19, and 1,052 +/- 86 meq/day.","Renal sodium handling in normal humans subjected to low, normal, and extremely high sodium supplies. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3907374/),[meq] / [d],22,148476,DB01356,Lithium
,3907374,Urinary sodium excretions,"Urinary sodium excretions were 22 +/- 4, 202 +/- 19, and 1,052 +/- 86 meq/day.","Renal sodium handling in normal humans subjected to low, normal, and extremely high sodium supplies. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3907374/),[meq] / [d],202,148477,DB01356,Lithium
,3907374,Urinary sodium excretions,"Urinary sodium excretions were 22 +/- 4, 202 +/- 19, and 1,052 +/- 86 meq/day.","Renal sodium handling in normal humans subjected to low, normal, and extremely high sodium supplies. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3907374/),[meq] / [d],"1,052",148478,DB01356,Lithium
,3907374,inulin clearance,"From the lower to the upper sodium intake level, 24-h creatinine clearance rose from 111 +/- 7 to 136 +/- 11 ml/min and inulin clearance from 103 +/- 9 to 129 +/- 9 ml/min, whereas proximal and distal fractional sodium reabsorption (FSRprox and FSRdist, respectively) fell from 86.8 +/- 1.3 to 79.0 +/- 2.7% and from 96.5 +/- 0.5 to 76.0 +/- 1.9%, respectively.","Renal sodium handling in normal humans subjected to low, normal, and extremely high sodium supplies. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3907374/),[ml] / [min],103,148479,DB01356,Lithium
,3907374,inulin clearance,"From the lower to the upper sodium intake level, 24-h creatinine clearance rose from 111 +/- 7 to 136 +/- 11 ml/min and inulin clearance from 103 +/- 9 to 129 +/- 9 ml/min, whereas proximal and distal fractional sodium reabsorption (FSRprox and FSRdist, respectively) fell from 86.8 +/- 1.3 to 79.0 +/- 2.7% and from 96.5 +/- 0.5 to 76.0 +/- 1.9%, respectively.","Renal sodium handling in normal humans subjected to low, normal, and extremely high sodium supplies. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3907374/),[ml] / [min],129,148480,DB01356,Lithium
≥,27281580,Recoveries,Recoveries of indirubin and I.S. were consistent and ≥75.5%.,Development and full validation of an UPLC-MS/MS method for the quantification of the plant-derived alkaloid indirubin in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27281580/),%,75.5,150196,DB01356,Lithium
,27281580,half-life (t1/2),"Indirubin had a half-life (t1/2) of 35min, and a relatively high clearance (CL) of 2.71L/h/kg.",Development and full validation of an UPLC-MS/MS method for the quantification of the plant-derived alkaloid indirubin in rat plasma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27281580/),min,35,150197,DB01356,Lithium
,27281580,clearance (CL),"Indirubin had a half-life (t1/2) of 35min, and a relatively high clearance (CL) of 2.71L/h/kg.",Development and full validation of an UPLC-MS/MS method for the quantification of the plant-derived alkaloid indirubin in rat plasma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27281580/),[l] / [h·kg],2.71,150198,DB01356,Lithium
,2636654,Flow rate,Flow rate was maintained at 22 ml/hr.,Plasma alloisoleucine: analytical method and clearance in ketoacid-supplemented normals. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2636654/),[ml] / [h],22,153103,DB01356,Lithium
,2636654,Limit of quantitation,Limit of quantitation was estimated at 0.2 mumols/100 ml.,Plasma alloisoleucine: analytical method and clearance in ketoacid-supplemented normals. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2636654/),[mumols] / [100·ml],0.2,153104,DB01356,Lithium
,22943745,T(max),"Furthermore, the addition of aripiprazole did not change the median T(max) of lithium or valproate (4 h).",Lack of a pharmacokinetic drug-drug interaction between lithium and valproate when co-administered with aripiprazole. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22943745/),h,4,162135,DB01356,Lithium
,7912279,cell-to-medium concentration ratios,"The uptakes of cimetidine and nizatidine achieved equilibrium in 5 min with cell-to-medium concentration ratios of 12.0 and 3.5, respectively.","Carrier-mediated active transport of histamine H2 receptor antagonists, cimetidine and nizatidine, into isolated rat hepatocytes: contribution of type I system. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7912279/),,12.0,166574,DB01356,Lithium
,7912279,cell-to-medium concentration ratios,"The uptakes of cimetidine and nizatidine achieved equilibrium in 5 min with cell-to-medium concentration ratios of 12.0 and 3.5, respectively.","Carrier-mediated active transport of histamine H2 receptor antagonists, cimetidine and nizatidine, into isolated rat hepatocytes: contribution of type I system. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7912279/),,3.5,166575,DB01356,Lithium
,8852394,renal clearance,Lithium significantly reduced the renal clearance of venlafaxine from 0.053 to 0.027 L/h/kg.,Pharmacokinetic interaction between multiple-dose venlafaxine and single-dose lithium. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8852394/),[l] / [h·kg],0.053,167009,DB01356,Lithium
,8852394,renal clearance,Lithium significantly reduced the renal clearance of venlafaxine from 0.053 to 0.027 L/h/kg.,Pharmacokinetic interaction between multiple-dose venlafaxine and single-dose lithium. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8852394/),[l] / [h·kg],0.027,167010,DB01356,Lithium
,8852394,Total clearance,Total clearance (0.026 L/h/kg) and steady-state volume of distribution (0.71 L/kg) of lithium were not affected by administration of venlafaxine.,Pharmacokinetic interaction between multiple-dose venlafaxine and single-dose lithium. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8852394/),[l] / [h·kg],0.026,167011,DB01356,Lithium
,8852394,steady-state volume of distribution,Total clearance (0.026 L/h/kg) and steady-state volume of distribution (0.71 L/kg) of lithium were not affected by administration of venlafaxine.,Pharmacokinetic interaction between multiple-dose venlafaxine and single-dose lithium. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8852394/),[l] / [kg],0.71,167012,DB01356,Lithium
,4037295,biological half-life,The biological half-life of trace lithium was 16.9 +/- 2.8 h.,Matrix modifiers in graphite furnace atomic absorption analysis of trace lithium in biological fluids. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4037295/),h,16.9,170059,DB01356,Lithium
,6896645,fraction of dose absorbed,"The fraction of dose absorbed was 0.42 +/- 0.058 and 0.75 +/- 0.18 for p.o. solution and p.o. tablet, respectively.",Absolute and relative bioavailability of lithium dosage forms in the beagle dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6896645/),,0.42,172554,DB01356,Lithium
,6896645,fraction of dose absorbed,"The fraction of dose absorbed was 0.42 +/- 0.058 and 0.75 +/- 0.18 for p.o. solution and p.o. tablet, respectively.",Absolute and relative bioavailability of lithium dosage forms in the beagle dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6896645/),,0.75,172555,DB01356,Lithium
,17177646,Kel,At saliva we got constant of elimination Kel = 0.02(-1)h and elimination half life (t(1/2)) was t(1/2)=34.6 h.,Saliva and serum lithium monitoring in hospitalized patients and possibility to replace serum to saliva. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17177646/),h,0.02(,172865,DB01356,Lithium
,17177646,t(1/2),At saliva we got constant of elimination Kel = 0.02(-1)h and elimination half life (t(1/2)) was t(1/2)=34.6 h.,Saliva and serum lithium monitoring in hospitalized patients and possibility to replace serum to saliva. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17177646/),h,34.6,172866,DB01356,Lithium
,17177646,t(1/2),For serum was t(1/2)= 24 h what means that lithium ions elimination is slower from saliva then from serum.,Saliva and serum lithium monitoring in hospitalized patients and possibility to replace serum to saliva. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17177646/),h,24,172867,DB01356,Lithium
,3252023,clearance,"Within minutes after administration of cisplatin a significant increase in lithium clearance, fractional lithium clearance (CLi/Cin) and e-TT/OT was observed (from 270 +/- 32 to 387 +/- 60 microliters/min/g kidney weight, 0.202 +/- 0.03 to 0.340 +/- 0.06 and 0.415 +/- 0.02 to 0.497 +/- 0.02, respectively).",Effect of cisplatin on proximal convoluted and straight segments of the rat kidney. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3252023/),[μl] / [g·min],270,173389,DB01356,Lithium
,3252023,fractional lithium clearance (CLi/Cin),"Within minutes after administration of cisplatin a significant increase in lithium clearance, fractional lithium clearance (CLi/Cin) and e-TT/OT was observed (from 270 +/- 32 to 387 +/- 60 microliters/min/g kidney weight, 0.202 +/- 0.03 to 0.340 +/- 0.06 and 0.415 +/- 0.02 to 0.497 +/- 0.02, respectively).",Effect of cisplatin on proximal convoluted and straight segments of the rat kidney. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3252023/),[μl] / [g·min],387,173390,DB01356,Lithium
,3252023,fractional lithium clearance (CLi/Cin),"Within minutes after administration of cisplatin a significant increase in lithium clearance, fractional lithium clearance (CLi/Cin) and e-TT/OT was observed (from 270 +/- 32 to 387 +/- 60 microliters/min/g kidney weight, 0.202 +/- 0.03 to 0.340 +/- 0.06 and 0.415 +/- 0.02 to 0.497 +/- 0.02, respectively).",Effect of cisplatin on proximal convoluted and straight segments of the rat kidney. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3252023/),,0.202,173391,DB01356,Lithium
,3252023,fractional lithium clearance (CLi/Cin),"Within minutes after administration of cisplatin a significant increase in lithium clearance, fractional lithium clearance (CLi/Cin) and e-TT/OT was observed (from 270 +/- 32 to 387 +/- 60 microliters/min/g kidney weight, 0.202 +/- 0.03 to 0.340 +/- 0.06 and 0.415 +/- 0.02 to 0.497 +/- 0.02, respectively).",Effect of cisplatin on proximal convoluted and straight segments of the rat kidney. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3252023/),,0.340,173392,DB01356,Lithium
,3252023,fractional lithium clearance (CLi/Cin),"Within minutes after administration of cisplatin a significant increase in lithium clearance, fractional lithium clearance (CLi/Cin) and e-TT/OT was observed (from 270 +/- 32 to 387 +/- 60 microliters/min/g kidney weight, 0.202 +/- 0.03 to 0.340 +/- 0.06 and 0.415 +/- 0.02 to 0.497 +/- 0.02, respectively).",Effect of cisplatin on proximal convoluted and straight segments of the rat kidney. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3252023/),,0.415,173393,DB01356,Lithium
,3252023,fractional lithium clearance (CLi/Cin),"Within minutes after administration of cisplatin a significant increase in lithium clearance, fractional lithium clearance (CLi/Cin) and e-TT/OT was observed (from 270 +/- 32 to 387 +/- 60 microliters/min/g kidney weight, 0.202 +/- 0.03 to 0.340 +/- 0.06 and 0.415 +/- 0.02 to 0.497 +/- 0.02, respectively).",Effect of cisplatin on proximal convoluted and straight segments of the rat kidney. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3252023/),,0.497,173394,DB01356,Lithium
,3252023,e-TT/OT,"Within minutes after administration of cisplatin a significant increase in lithium clearance, fractional lithium clearance (CLi/Cin) and e-TT/OT was observed (from 270 +/- 32 to 387 +/- 60 microliters/min/g kidney weight, 0.202 +/- 0.03 to 0.340 +/- 0.06 and 0.415 +/- 0.02 to 0.497 +/- 0.02, respectively).",Effect of cisplatin on proximal convoluted and straight segments of the rat kidney. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3252023/),,0.340,173395,DB01356,Lithium
,3252023,e-TT/OT,"Within minutes after administration of cisplatin a significant increase in lithium clearance, fractional lithium clearance (CLi/Cin) and e-TT/OT was observed (from 270 +/- 32 to 387 +/- 60 microliters/min/g kidney weight, 0.202 +/- 0.03 to 0.340 +/- 0.06 and 0.415 +/- 0.02 to 0.497 +/- 0.02, respectively).",Effect of cisplatin on proximal convoluted and straight segments of the rat kidney. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3252023/),,0.415,173396,DB01356,Lithium
,3252023,e-TT/OT,"Within minutes after administration of cisplatin a significant increase in lithium clearance, fractional lithium clearance (CLi/Cin) and e-TT/OT was observed (from 270 +/- 32 to 387 +/- 60 microliters/min/g kidney weight, 0.202 +/- 0.03 to 0.340 +/- 0.06 and 0.415 +/- 0.02 to 0.497 +/- 0.02, respectively).",Effect of cisplatin on proximal convoluted and straight segments of the rat kidney. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3252023/),,0.497,173397,DB01356,Lithium
,4006376,peak serum lithium level,"Alcohol did, however, increase the peak serum lithium level in nine of 10 subjects, from a mean of 0.62 mEq/L in the placebo condition to 0.70 mEq/L in the alcohol condition.",Effect of acute alcohol consumption on lithium kinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4006376/),[meq] / [l],0.62,173523,DB01356,Lithium
,4006376,peak serum lithium level,"Alcohol did, however, increase the peak serum lithium level in nine of 10 subjects, from a mean of 0.62 mEq/L in the placebo condition to 0.70 mEq/L in the alcohol condition.",Effect of acute alcohol consumption on lithium kinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4006376/),[meq] / [l],0.70,173524,DB01356,Lithium
,10771456,renal clearance,Mean renal clearance of lithium decreased by 0.09 l h(-1) (5%) in the ziprasidone group and by 0.14 l h(-1) (9%) in the placebo group.,The effects of ziprasidone on steady-state lithium levels and renal clearance of lithium. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771456/),h(-·l,0,174992,DB01356,Lithium
,10771456,renal clearance,Mean renal clearance of lithium decreased by 0.09 l h(-1) (5%) in the ziprasidone group and by 0.14 l h(-1) (9%) in the placebo group.,The effects of ziprasidone on steady-state lithium levels and renal clearance of lithium. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771456/),,0,174993,DB01356,Lithium
,33078092,IC50,"The optimization efforts led to potent compounds 42 and 53‒55 with IC50 values of 41, 44, 32, and 42 nmol/L, respectively.","Design, synthesis, molecular modeling, and biological evaluation of acrylamide derivatives as potent inhibitors of human dihydroorotate dehydrogenase for the treatment of rheumatoid arthritis. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33078092/),[nM] / [l],41,177259,DB01356,Lithium
,33078092,IC50,"The optimization efforts led to potent compounds 42 and 53‒55 with IC50 values of 41, 44, 32, and 42 nmol/L, respectively.","Design, synthesis, molecular modeling, and biological evaluation of acrylamide derivatives as potent inhibitors of human dihydroorotate dehydrogenase for the treatment of rheumatoid arthritis. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33078092/),[nM] / [l],44,177260,DB01356,Lithium
,33078092,IC50,"The optimization efforts led to potent compounds 42 and 53‒55 with IC50 values of 41, 44, 32, and 42 nmol/L, respectively.","Design, synthesis, molecular modeling, and biological evaluation of acrylamide derivatives as potent inhibitors of human dihydroorotate dehydrogenase for the treatment of rheumatoid arthritis. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33078092/),[nM] / [l],32,177261,DB01356,Lithium
,33078092,IC50,"The optimization efforts led to potent compounds 42 and 53‒55 with IC50 values of 41, 44, 32, and 42 nmol/L, respectively.","Design, synthesis, molecular modeling, and biological evaluation of acrylamide derivatives as potent inhibitors of human dihydroorotate dehydrogenase for the treatment of rheumatoid arthritis. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33078092/),[nM] / [l],42,177262,DB01356,Lithium
less,4715579,maximum energy,"The residual excess radioactivity was about four orders of magnitude smaller than that published, yet was still statistically significant, consisting mainly of electrons having a maximum energy less than about 400 keV.",The excess radioactivity of trypsin mixtures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4715579/),kev,400,177607,DB01356,Lithium
,4715579,half-life,The excess radioactivity of a mixture of trypsin and LiCl had a probable half-life between 5 and 46 days.,The excess radioactivity of trypsin mixtures. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4715579/),d,5 and 46,177608,DB01356,Lithium
,1769139,renal plasma flow,"In the patients, there was on average a 35% decrease of glomerular filtration rates (109 +/- 64 [SD] ml/min) and renal plasma flow (490 +/- 275 ml/min) and a 25% decrease of lithium clearance (22 +/- 12 ml/min); the lithium clearance correlated closely with the glomerular filtration rates and renal plasma flow (r = 0.69; p less than 0.001).",Lithium clearance in patients with chronic renal diseases. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1769139/),[ml] / [min],490,179344,DB01356,Lithium
,1769139,clearance,"In the patients, there was on average a 35% decrease of glomerular filtration rates (109 +/- 64 [SD] ml/min) and renal plasma flow (490 +/- 275 ml/min) and a 25% decrease of lithium clearance (22 +/- 12 ml/min); the lithium clearance correlated closely with the glomerular filtration rates and renal plasma flow (r = 0.69; p less than 0.001).",Lithium clearance in patients with chronic renal diseases. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1769139/),[ml] / [min],22,179345,DB01356,Lithium
,1769139,absolute proximal reabsorption of fluid,The absolute proximal reabsorption of fluid was decreased by 38% (89 +/- 56 ml/min) while the distal absolute reabsorption of sodium (21 +/- 12 ml/min) was unchanged.,Lithium clearance in patients with chronic renal diseases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1769139/),[ml] / [min],89,179346,DB01356,Lithium
,1769139,distal absolute reabsorption of sodium,The absolute proximal reabsorption of fluid was decreased by 38% (89 +/- 56 ml/min) while the distal absolute reabsorption of sodium (21 +/- 12 ml/min) was unchanged.,Lithium clearance in patients with chronic renal diseases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1769139/),[ml] / [min],21,179347,DB01356,Lithium
,9870406,Migration times,"Migration times were: potassium, 2.98 min; calcium, 3.48 min; sodium, 3.60 min; barium (internal standard), 4.15 min and lithium, 4.26 min.",Capillary ion analysis of lithium concentrations in biological fluids and tissues of Poecilia (teleost). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9870406/),min,2.98,179699,DB01356,Lithium
,9870406,Migration times,"Migration times were: potassium, 2.98 min; calcium, 3.48 min; sodium, 3.60 min; barium (internal standard), 4.15 min and lithium, 4.26 min.",Capillary ion analysis of lithium concentrations in biological fluids and tissues of Poecilia (teleost). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9870406/),min,3.48,179700,DB01356,Lithium
,9870406,Migration times,"Migration times were: potassium, 2.98 min; calcium, 3.48 min; sodium, 3.60 min; barium (internal standard), 4.15 min and lithium, 4.26 min.",Capillary ion analysis of lithium concentrations in biological fluids and tissues of Poecilia (teleost). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9870406/),min,3.60,179701,DB01356,Lithium
,9870406,Migration times,"Migration times were: potassium, 2.98 min; calcium, 3.48 min; sodium, 3.60 min; barium (internal standard), 4.15 min and lithium, 4.26 min.",Capillary ion analysis of lithium concentrations in biological fluids and tissues of Poecilia (teleost). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9870406/),min,4.15,179702,DB01356,Lithium
,9870406,Migration times,"Migration times were: potassium, 2.98 min; calcium, 3.48 min; sodium, 3.60 min; barium (internal standard), 4.15 min and lithium, 4.26 min.",Capillary ion analysis of lithium concentrations in biological fluids and tissues of Poecilia (teleost). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9870406/),min,4.26,179703,DB01356,Lithium
,2224996,CLr,The mean values of CLr of the investigated group--26.4 ml/min are in agreement with the results published by other authors.,[Comparison of plasmatic and renal clearance of lithium]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2224996/),[ml] / [min],26.4,188368,DB01356,Lithium
,1815050,bioavailability,"The results obtained show that the bioavailability of the formulation is 75% of the immediate-release formulation used as control and that the release rate, although close to the desired value, lasts only 7 or 8 h; these results agree with those given by numerical deconvolution using the mean urinary excretion curves.",Design and evaluation of sustained-release tablets of lithium in a fat matrix and its bioavailability in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1815050/),%,75,190699,DB01356,Lithium
,1473613,sodium clearance,"Low- and high-dose insulin infusions were followed by a fall in sodium clearance from 1.6 +/- 0.1 ml/min to 1.2 +/- 0.1 and 1.0 +/- 0.1 ml/min, respectively.",Effects of insulin on renal haemodynamics and the proximal and distal tubular sodium handling in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1473613/),[ml] / [min],1.6,191657,DB01356,Lithium
,1473613,sodium clearance,"Low- and high-dose insulin infusions were followed by a fall in sodium clearance from 1.6 +/- 0.1 ml/min to 1.2 +/- 0.1 and 1.0 +/- 0.1 ml/min, respectively.",Effects of insulin on renal haemodynamics and the proximal and distal tubular sodium handling in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1473613/),[ml] / [min],1.2,191658,DB01356,Lithium
,1473613,sodium clearance,"Low- and high-dose insulin infusions were followed by a fall in sodium clearance from 1.6 +/- 0.1 ml/min to 1.2 +/- 0.1 and 1.0 +/- 0.1 ml/min, respectively.",Effects of insulin on renal haemodynamics and the proximal and distal tubular sodium handling in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1473613/),[ml] / [min],1.0,191659,DB01356,Lithium
,22003841,C(max),"The increase was significant when a single dose of levofloxacin was administered with steady-state level of lithium (C(max) of lithium: 2.54 ± 0.15 vs 2.79 ± 0.12 mm, P < 0.001 and AUC(0-α) of lithium: 24.36 ± 3.68 vs 31.88 ± 4.83 mmol/mL h, P < 0.001).",Effect of levofloxacin on lithium - a pharmacokinetic study in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22003841/),mm,2.54,192444,DB01356,Lithium
,22003841,C(max),"The increase was significant when a single dose of levofloxacin was administered with steady-state level of lithium (C(max) of lithium: 2.54 ± 0.15 vs 2.79 ± 0.12 mm, P < 0.001 and AUC(0-α) of lithium: 24.36 ± 3.68 vs 31.88 ± 4.83 mmol/mL h, P < 0.001).",Effect of levofloxacin on lithium - a pharmacokinetic study in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22003841/),mm,2.79,192445,DB01356,Lithium
,22003841,AUC(0-α),"The increase was significant when a single dose of levofloxacin was administered with steady-state level of lithium (C(max) of lithium: 2.54 ± 0.15 vs 2.79 ± 0.12 mm, P < 0.001 and AUC(0-α) of lithium: 24.36 ± 3.68 vs 31.88 ± 4.83 mmol/mL h, P < 0.001).",Effect of levofloxacin on lithium - a pharmacokinetic study in rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22003841/),[mM] / [h·ml],24.36,192446,DB01356,Lithium
,22003841,AUC(0-α),"The increase was significant when a single dose of levofloxacin was administered with steady-state level of lithium (C(max) of lithium: 2.54 ± 0.15 vs 2.79 ± 0.12 mm, P < 0.001 and AUC(0-α) of lithium: 24.36 ± 3.68 vs 31.88 ± 4.83 mmol/mL h, P < 0.001).",Effect of levofloxacin on lithium - a pharmacokinetic study in rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22003841/),[mM] / [h·ml],31.88,192447,DB01356,Lithium
,22003841,C(max),"The increase in lithium levels was also significant when levofloxacin was coprescribed for 3 days after lithium steady-state levels were achieved (C(max) increased from 2.72 ± 0.29 to 3.96 ± 0.29 mm, P < 0.001 and AUC(0-α) increased from 27.1 ± 4.96 to 42.64 ± 4.94 mmol/mL h).",Effect of levofloxacin on lithium - a pharmacokinetic study in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22003841/),mm,2.72,192448,DB01356,Lithium
,22003841,C(max),"The increase in lithium levels was also significant when levofloxacin was coprescribed for 3 days after lithium steady-state levels were achieved (C(max) increased from 2.72 ± 0.29 to 3.96 ± 0.29 mm, P < 0.001 and AUC(0-α) increased from 27.1 ± 4.96 to 42.64 ± 4.94 mmol/mL h).",Effect of levofloxacin on lithium - a pharmacokinetic study in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22003841/),mm,3.96,192449,DB01356,Lithium
,22003841,AUC(0-α),"The increase in lithium levels was also significant when levofloxacin was coprescribed for 3 days after lithium steady-state levels were achieved (C(max) increased from 2.72 ± 0.29 to 3.96 ± 0.29 mm, P < 0.001 and AUC(0-α) increased from 27.1 ± 4.96 to 42.64 ± 4.94 mmol/mL h).",Effect of levofloxacin on lithium - a pharmacokinetic study in rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22003841/),[mM] / [h·ml],27.1,192450,DB01356,Lithium
,22003841,AUC(0-α),"The increase in lithium levels was also significant when levofloxacin was coprescribed for 3 days after lithium steady-state levels were achieved (C(max) increased from 2.72 ± 0.29 to 3.96 ± 0.29 mm, P < 0.001 and AUC(0-α) increased from 27.1 ± 4.96 to 42.64 ± 4.94 mmol/mL h).",Effect of levofloxacin on lithium - a pharmacokinetic study in rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22003841/),[mM] / [h·ml],42.64,192451,DB01356,Lithium
,2079355,peak serum Li concentration,The values (mean +/- SD) obtained were peak serum Li concentration 0.81 +/- 0.18 mEq/l; time to peak 2.57 +/- 0.87 h; total Li clearance 33.2 +/- 15.5 ml/min; volume of distribution 0.62 +/- 0.26 l/kg; elimination rate constant 0.0514 +/- 0.02 h; area under serum concentration-time curve 16.41 +/- 11.41 mEq/1 h; serum half life 15.34 +/- 6.06 h.,Single dose pharmacokinetics of lithium and prediction of maintenance dose in manic depressive patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2079355/),[meq] / [l],0.81,192476,DB01356,Lithium
,2079355,time to peak,The values (mean +/- SD) obtained were peak serum Li concentration 0.81 +/- 0.18 mEq/l; time to peak 2.57 +/- 0.87 h; total Li clearance 33.2 +/- 15.5 ml/min; volume of distribution 0.62 +/- 0.26 l/kg; elimination rate constant 0.0514 +/- 0.02 h; area under serum concentration-time curve 16.41 +/- 11.41 mEq/1 h; serum half life 15.34 +/- 6.06 h.,Single dose pharmacokinetics of lithium and prediction of maintenance dose in manic depressive patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2079355/),h,2.57,192477,DB01356,Lithium
,2079355,total Li clearance,The values (mean +/- SD) obtained were peak serum Li concentration 0.81 +/- 0.18 mEq/l; time to peak 2.57 +/- 0.87 h; total Li clearance 33.2 +/- 15.5 ml/min; volume of distribution 0.62 +/- 0.26 l/kg; elimination rate constant 0.0514 +/- 0.02 h; area under serum concentration-time curve 16.41 +/- 11.41 mEq/1 h; serum half life 15.34 +/- 6.06 h.,Single dose pharmacokinetics of lithium and prediction of maintenance dose in manic depressive patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2079355/),[ml] / [min],33.2,192478,DB01356,Lithium
,2079355,volume of distribution,The values (mean +/- SD) obtained were peak serum Li concentration 0.81 +/- 0.18 mEq/l; time to peak 2.57 +/- 0.87 h; total Li clearance 33.2 +/- 15.5 ml/min; volume of distribution 0.62 +/- 0.26 l/kg; elimination rate constant 0.0514 +/- 0.02 h; area under serum concentration-time curve 16.41 +/- 11.41 mEq/1 h; serum half life 15.34 +/- 6.06 h.,Single dose pharmacokinetics of lithium and prediction of maintenance dose in manic depressive patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2079355/),[l] / [kg],0.62,192479,DB01356,Lithium
,2079355,elimination rate constant,The values (mean +/- SD) obtained were peak serum Li concentration 0.81 +/- 0.18 mEq/l; time to peak 2.57 +/- 0.87 h; total Li clearance 33.2 +/- 15.5 ml/min; volume of distribution 0.62 +/- 0.26 l/kg; elimination rate constant 0.0514 +/- 0.02 h; area under serum concentration-time curve 16.41 +/- 11.41 mEq/1 h; serum half life 15.34 +/- 6.06 h.,Single dose pharmacokinetics of lithium and prediction of maintenance dose in manic depressive patients. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2079355/),h,0.0514,192480,DB01356,Lithium
,2079355,area under serum concentration-time curve,The values (mean +/- SD) obtained were peak serum Li concentration 0.81 +/- 0.18 mEq/l; time to peak 2.57 +/- 0.87 h; total Li clearance 33.2 +/- 15.5 ml/min; volume of distribution 0.62 +/- 0.26 l/kg; elimination rate constant 0.0514 +/- 0.02 h; area under serum concentration-time curve 16.41 +/- 11.41 mEq/1 h; serum half life 15.34 +/- 6.06 h.,Single dose pharmacokinetics of lithium and prediction of maintenance dose in manic depressive patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2079355/),[meq] / [1·h],16.41,192481,DB01356,Lithium
,2079355,serum half life,The values (mean +/- SD) obtained were peak serum Li concentration 0.81 +/- 0.18 mEq/l; time to peak 2.57 +/- 0.87 h; total Li clearance 33.2 +/- 15.5 ml/min; volume of distribution 0.62 +/- 0.26 l/kg; elimination rate constant 0.0514 +/- 0.02 h; area under serum concentration-time curve 16.41 +/- 11.41 mEq/1 h; serum half life 15.34 +/- 6.06 h.,Single dose pharmacokinetics of lithium and prediction of maintenance dose in manic depressive patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2079355/),h,15.34,192482,DB01356,Lithium
,2079355,steady state serum lithium concentration,"Thereafter, the applicability of various dose prediction methods was evaluated vis-a-vis the actual doses needed to attain steady state serum lithium concentration of 0.6-1.2 mEq/l in 46 patients.",Single dose pharmacokinetics of lithium and prediction of maintenance dose in manic depressive patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2079355/),[meq] / [l],0.6-1.2,192483,DB01356,Lithium
,6440774,renal clearance,The daily dosage (1.5 to 6 250 mg tablets in two or three daily intakes) is deduced from the according lithium renal clearance (0.4 to over 2 l/h) by means of a nomogram established in previous studies on about 50 patients.,[Renal clearance technic for individualizing lithium dosage in routine hospital care]. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6440774/),[l] / [h],0.4 to over 2,193158,DB01356,Lithium
,2847983,effective renal plasma flow,"Nifedipine did not cause any change in subjects with no family history of hypertension, but in those with one hypertensive parent there was a marked increase in effective renal plasma flow (from 644 +/- 39 to 847 +/- 42 [SEM] ml/min x 1.73 m2; p less than 0.001) and a decrease in filtration fraction (from 17.6 +/- 1.0 to 12.6 +/- 0.4%; p less than 0.001), while the glomerular filtration rate was unchanged, thus suggesting a prevailing efferent vasodilation.",Abnormal renal responses to calcium entry blockade in normotensive offspring of hypertensive parents. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2847983/),[ml] / [1.73·m2·min],644,194443,DB01356,Lithium
,2847983,effective renal plasma flow,"Nifedipine did not cause any change in subjects with no family history of hypertension, but in those with one hypertensive parent there was a marked increase in effective renal plasma flow (from 644 +/- 39 to 847 +/- 42 [SEM] ml/min x 1.73 m2; p less than 0.001) and a decrease in filtration fraction (from 17.6 +/- 1.0 to 12.6 +/- 0.4%; p less than 0.001), while the glomerular filtration rate was unchanged, thus suggesting a prevailing efferent vasodilation.",Abnormal renal responses to calcium entry blockade in normotensive offspring of hypertensive parents. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2847983/),[ml] / [1.73·m2·min],847,194444,DB01356,Lithium
,2847983,clearance,"Lithium clearance also rose (from 29.0 +/- 2.0 to 32.8 +/- 1.9 ml/min, p less than 0.001), and the derived value of fractional proximal reabsorption diminished (from 75.8 +/- 1.0 to 71.3 +/- 1.2%, p less than 0.001).",Abnormal renal responses to calcium entry blockade in normotensive offspring of hypertensive parents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2847983/),[ml] / [min],29.0,194445,DB01356,Lithium
,2847983,clearance,"Lithium clearance also rose (from 29.0 +/- 2.0 to 32.8 +/- 1.9 ml/min, p less than 0.001), and the derived value of fractional proximal reabsorption diminished (from 75.8 +/- 1.0 to 71.3 +/- 1.2%, p less than 0.001).",Abnormal renal responses to calcium entry blockade in normotensive offspring of hypertensive parents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2847983/),[ml] / [min],32.8,194446,DB01356,Lithium
,3669496,clearance,Inulin clearance rose from 110 +/- 14 to 135 +/- 23 ml/min and lithium clearance from 30.9 +/- 7.6 to 48.9 +/- 15.1 ml/min.,Lithium clearance during the paradoxical natriuresis of hypotonic expansion in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3669496/),[ml] / [min],110,194621,DB01356,Lithium
,3669496,clearance,Inulin clearance rose from 110 +/- 14 to 135 +/- 23 ml/min and lithium clearance from 30.9 +/- 7.6 to 48.9 +/- 15.1 ml/min.,Lithium clearance during the paradoxical natriuresis of hypotonic expansion in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3669496/),[ml] / [min],135,194622,DB01356,Lithium
,3669496,clearance,Inulin clearance rose from 110 +/- 14 to 135 +/- 23 ml/min and lithium clearance from 30.9 +/- 7.6 to 48.9 +/- 15.1 ml/min.,Lithium clearance during the paradoxical natriuresis of hypotonic expansion in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3669496/),[ml] / [min],30.9,194623,DB01356,Lithium
,3669496,clearance,Inulin clearance rose from 110 +/- 14 to 135 +/- 23 ml/min and lithium clearance from 30.9 +/- 7.6 to 48.9 +/- 15.1 ml/min.,Lithium clearance during the paradoxical natriuresis of hypotonic expansion in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3669496/),[ml] / [min],48.9,194624,DB01356,Lithium
,1836548,Para-aminohippurate clearance (CPAH),"Para-aminohippurate clearance (CPAH) increased from 256.4 +/- 21.5 to 291.5 +/- 26.3 ml/min (P less than 0.05), renal vascular resistance was reduced by 21.5% (P less than 0.01) and inulin clearance (CIn) was unchanged.",Effects of isradipine on renal function in cyclosporin-treated renal transplanted patients. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1836548/),[ml] / [min],256.4,200248,DB01356,Lithium
,1836548,Para-aminohippurate clearance (CPAH),"Para-aminohippurate clearance (CPAH) increased from 256.4 +/- 21.5 to 291.5 +/- 26.3 ml/min (P less than 0.05), renal vascular resistance was reduced by 21.5% (P less than 0.01) and inulin clearance (CIn) was unchanged.",Effects of isradipine on renal function in cyclosporin-treated renal transplanted patients. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1836548/),[ml] / [min],291.5,200249,DB01356,Lithium
,27393139,clearance,The population mean (inter-individual variability) clearance was 1.64 L/h/53 kg LBW0.75 (19 %) and central volume of distribution 23.6 L/53 kg LBW (6.8 %).,Lithium in Paediatric Patients with Bipolar Disorder: Implications for Selection of Dosage Regimens via Population Pharmacokinetics/Pharmacodynamics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27393139/),[l] / [53·h·kg],1.64,200434,DB01356,Lithium
,27393139,central volume of distribution,The population mean (inter-individual variability) clearance was 1.64 L/h/53 kg LBW0.75 (19 %) and central volume of distribution 23.6 L/53 kg LBW (6.8 %).,Lithium in Paediatric Patients with Bipolar Disorder: Implications for Selection of Dosage Regimens via Population Pharmacokinetics/Pharmacodynamics. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27393139/),[l] / [53·kg],23.6,200435,DB01356,Lithium
above,27393139,trough concentrations,"A maintenance dose of 25 mg/kg TBW/day lithium carbonate in two daily doses was predicted to achieve a ≥50 % reduction in YMRS in 74 % of patients, while ~8 % of patients would be expected to have trough concentrations above the nominal safety threshold of 1.4 mEq/L.",Lithium in Paediatric Patients with Bipolar Disorder: Implications for Selection of Dosage Regimens via Population Pharmacokinetics/Pharmacodynamics. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27393139/),[meq] / [l],1.4,200436,DB01356,Lithium
,11284442,renal,"Ramipril decreased renal lithium clearance (90+/-8 vs. 142+/-10 microl/min/100 g, P<0.001, n=24) and increased the fractional lithium reabsorption (74.3+/-1.9 vs. 66.7+/-1.7%, P<0.05) and plasma lithium concentration (0.108+/-0.006 vs. 0.085+/-0.004 mM, P<0.01).",Effects of icatibant on the ramipril-induced decreased in renal lithium clearance in the rat. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11284442/),[μl] / [100·g·min],90,202267,DB01356,Lithium
,11284442,renal,"Ramipril decreased renal lithium clearance (90+/-8 vs. 142+/-10 microl/min/100 g, P<0.001, n=24) and increased the fractional lithium reabsorption (74.3+/-1.9 vs. 66.7+/-1.7%, P<0.05) and plasma lithium concentration (0.108+/-0.006 vs. 0.085+/-0.004 mM, P<0.01).",Effects of icatibant on the ramipril-induced decreased in renal lithium clearance in the rat. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11284442/),[μl] / [100·g·min],142,202268,DB01356,Lithium
,11284442,clearance,"Icatibant had no effect per se on renal function but attenuated the ramipril-induced decrease in renal lithium clearance (118+/-16 vs. 90+/-8 microl/min/100 g, n=12 and 24 respectively, P<0.05 one-tailed test) and systolic blood pressure.",Effects of icatibant on the ramipril-induced decreased in renal lithium clearance in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11284442/),[μl] / [100·g·min],118,202269,DB01356,Lithium
,11284442,clearance,"Icatibant had no effect per se on renal function but attenuated the ramipril-induced decrease in renal lithium clearance (118+/-16 vs. 90+/-8 microl/min/100 g, n=12 and 24 respectively, P<0.05 one-tailed test) and systolic blood pressure.",Effects of icatibant on the ramipril-induced decreased in renal lithium clearance in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11284442/),[μl] / [100·g·min],90,202270,DB01356,Lithium
,32055590,m,"Mass spectrometric detection and quantitation were conducted by selected reaction-monitoring on a negative electrospray ionization mode with the following transitions: m/z 521.11 → 361.10, 477.03 → 361.10, and 269.00 → 169.60 for ticagrelor, AR-C124910XX, and tolbutamide, respectively.","Simultaneous quantification of ticagrelor and its active metabolite, AR-C124910XX, in human plasma by liquid chromatography-tandem mass spectrometry: Applications in steady-state pharmacokinetics in patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32055590/),,521.11,203077,DB01356,Lithium
,32055590,m,"Mass spectrometric detection and quantitation were conducted by selected reaction-monitoring on a negative electrospray ionization mode with the following transitions: m/z 521.11 → 361.10, 477.03 → 361.10, and 269.00 → 169.60 for ticagrelor, AR-C124910XX, and tolbutamide, respectively.","Simultaneous quantification of ticagrelor and its active metabolite, AR-C124910XX, in human plasma by liquid chromatography-tandem mass spectrometry: Applications in steady-state pharmacokinetics in patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32055590/),,477.03,203078,DB01356,Lithium
,32055590,m,"Mass spectrometric detection and quantitation were conducted by selected reaction-monitoring on a negative electrospray ionization mode with the following transitions: m/z 521.11 → 361.10, 477.03 → 361.10, and 269.00 → 169.60 for ticagrelor, AR-C124910XX, and tolbutamide, respectively.","Simultaneous quantification of ticagrelor and its active metabolite, AR-C124910XX, in human plasma by liquid chromatography-tandem mass spectrometry: Applications in steady-state pharmacokinetics in patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32055590/),,269.00,203079,DB01356,Lithium
,3176100,half life (t1/2),Pharmacokinetic parameters (mean +/- SD) from plasma and saliva were respectively: half life (t1/2) 17 +/- 6 vs. 21.8 +/- 14 h; mean residence time 23.7 +/- 7.4 vs.,Lack of correlation between lithium pharmacokinetic parameters obtained from plasma and saliva. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3176100/),h,17,204519,DB01356,Lithium
,3176100,half life (t1/2),Pharmacokinetic parameters (mean +/- SD) from plasma and saliva were respectively: half life (t1/2) 17 +/- 6 vs. 21.8 +/- 14 h; mean residence time 23.7 +/- 7.4 vs.,Lack of correlation between lithium pharmacokinetic parameters obtained from plasma and saliva. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3176100/),h,21.8,204520,DB01356,Lithium
,3176100,mean residence time,Pharmacokinetic parameters (mean +/- SD) from plasma and saliva were respectively: half life (t1/2) 17 +/- 6 vs. 21.8 +/- 14 h; mean residence time 23.7 +/- 7.4 vs.,Lack of correlation between lithium pharmacokinetic parameters obtained from plasma and saliva. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3176100/),,23.7,204521,DB01356,Lithium
,3176100,total clearance,24.4 +/- 15.3 h; total clearance 30.6 +/- 9.3 vs.,Lack of correlation between lithium pharmacokinetic parameters obtained from plasma and saliva. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3176100/),,30.6,204522,DB01356,Lithium
,3176100,apparent volume of distribution,28.6 +/- 6.2 ml/h/kg; and apparent volume of distribution 0.71 +/- 0.20 vs. 0.84 +/- 0.37 L/kg.,Lack of correlation between lithium pharmacokinetic parameters obtained from plasma and saliva. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3176100/),[l] / [kg],0.71,204523,DB01356,Lithium
,3176100,apparent volume of distribution,28.6 +/- 6.2 ml/h/kg; and apparent volume of distribution 0.71 +/- 0.20 vs. 0.84 +/- 0.37 L/kg.,Lack of correlation between lithium pharmacokinetic parameters obtained from plasma and saliva. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3176100/),[l] / [kg],0.84,204524,DB01356,Lithium
,29112289,plasma Li+ concentration at time zero,"Geometric mean values of noncompartmental parameters were plasma Li+ concentration at time zero, 2.19 mmol/L; terminal elimination half-life, 25.68 h; area under the plasma concentration-time curve from time zero to the limit of quantification, 550 mmol/L min; clearance, 0.273 mL/min/kg; mean residence time, 31.22 h; and volume of distribution at steady state, 511 mL/kg.",Pharmacokinetics of intravenous lithium chloride and assessment of agreement between two methods of lithium concentration measurement in the horse. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29112289/),[mM] / [l],2.19,204769,DB01356,Lithium
,29112289,terminal elimination half-life,"Geometric mean values of noncompartmental parameters were plasma Li+ concentration at time zero, 2.19 mmol/L; terminal elimination half-life, 25.68 h; area under the plasma concentration-time curve from time zero to the limit of quantification, 550 mmol/L min; clearance, 0.273 mL/min/kg; mean residence time, 31.22 h; and volume of distribution at steady state, 511 mL/kg.",Pharmacokinetics of intravenous lithium chloride and assessment of agreement between two methods of lithium concentration measurement in the horse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29112289/),h,25.68,204770,DB01356,Lithium
,29112289,area under the plasma concentration-time curve from time zero,"Geometric mean values of noncompartmental parameters were plasma Li+ concentration at time zero, 2.19 mmol/L; terminal elimination half-life, 25.68 h; area under the plasma concentration-time curve from time zero to the limit of quantification, 550 mmol/L min; clearance, 0.273 mL/min/kg; mean residence time, 31.22 h; and volume of distribution at steady state, 511 mL/kg.",Pharmacokinetics of intravenous lithium chloride and assessment of agreement between two methods of lithium concentration measurement in the horse. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29112289/),[mM] / [l·min],550,204771,DB01356,Lithium
,29112289,clearance,"Geometric mean values of noncompartmental parameters were plasma Li+ concentration at time zero, 2.19 mmol/L; terminal elimination half-life, 25.68 h; area under the plasma concentration-time curve from time zero to the limit of quantification, 550 mmol/L min; clearance, 0.273 mL/min/kg; mean residence time, 31.22 h; and volume of distribution at steady state, 511 mL/kg.",Pharmacokinetics of intravenous lithium chloride and assessment of agreement between two methods of lithium concentration measurement in the horse. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29112289/),[ml] / [kg·min],0.273,204772,DB01356,Lithium
,29112289,mean residence time,"Geometric mean values of noncompartmental parameters were plasma Li+ concentration at time zero, 2.19 mmol/L; terminal elimination half-life, 25.68 h; area under the plasma concentration-time curve from time zero to the limit of quantification, 550 mmol/L min; clearance, 0.273 mL/min/kg; mean residence time, 31.22 h; and volume of distribution at steady state, 511 mL/kg.",Pharmacokinetics of intravenous lithium chloride and assessment of agreement between two methods of lithium concentration measurement in the horse. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29112289/),h,31.22,204773,DB01356,Lithium
,29112289,volume of distribution at steady state,"Geometric mean values of noncompartmental parameters were plasma Li+ concentration at time zero, 2.19 mmol/L; terminal elimination half-life, 25.68 h; area under the plasma concentration-time curve from time zero to the limit of quantification, 550 mmol/L min; clearance, 0.273 mL/min/kg; mean residence time, 31.22 h; and volume of distribution at steady state, 511 mL/kg.",Pharmacokinetics of intravenous lithium chloride and assessment of agreement between two methods of lithium concentration measurement in the horse. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29112289/),[ml] / [kg],511,204774,DB01356,Lithium
,3826382,CLi,"The changes in CLi were surprisingly large, from 40.6 +/- 7.6 to 75.8 +/- 18.4 ml/min.",Lithium clearance in mineralocorticoid escape in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3826382/),[ml] / [min],40.6,204826,DB01356,Lithium
,3826382,CLi,"The changes in CLi were surprisingly large, from 40.6 +/- 7.6 to 75.8 +/- 18.4 ml/min.",Lithium clearance in mineralocorticoid escape in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3826382/),[ml] / [min],75.8,204827,DB01356,Lithium
,30554270,VS,"Using a population approach, we built a PK population model of srLi including one S compartment (VS = 23.0 L, ClS = 1.21 L h-1), one E compartment (VE = 64.7 L, ClSE = 3.63 L h-1, ClES = 9.46 L h-1), and one U compartment (F = 0.62) and estimate the ratio of concentrations to Li in E over S at 0.38 with 27% between-subject variability.","Population pharmacokinetic modeling of sustained release lithium in the serum, erythrocytes and urine of patients with bipolar disorder. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30554270/),l,23.0,205000,DB01356,Lithium
,30554270,ClS,"Using a population approach, we built a PK population model of srLi including one S compartment (VS = 23.0 L, ClS = 1.21 L h-1), one E compartment (VE = 64.7 L, ClSE = 3.63 L h-1, ClES = 9.46 L h-1), and one U compartment (F = 0.62) and estimate the ratio of concentrations to Li in E over S at 0.38 with 27% between-subject variability.","Population pharmacokinetic modeling of sustained release lithium in the serum, erythrocytes and urine of patients with bipolar disorder. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30554270/),[l] / [h],1.21,205001,DB01356,Lithium
,30554270,VE,"Using a population approach, we built a PK population model of srLi including one S compartment (VS = 23.0 L, ClS = 1.21 L h-1), one E compartment (VE = 64.7 L, ClSE = 3.63 L h-1, ClES = 9.46 L h-1), and one U compartment (F = 0.62) and estimate the ratio of concentrations to Li in E over S at 0.38 with 27% between-subject variability.","Population pharmacokinetic modeling of sustained release lithium in the serum, erythrocytes and urine of patients with bipolar disorder. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30554270/),l,64.7,205002,DB01356,Lithium
,30554270,ClSE,"Using a population approach, we built a PK population model of srLi including one S compartment (VS = 23.0 L, ClS = 1.21 L h-1), one E compartment (VE = 64.7 L, ClSE = 3.63 L h-1, ClES = 9.46 L h-1), and one U compartment (F = 0.62) and estimate the ratio of concentrations to Li in E over S at 0.38 with 27% between-subject variability.","Population pharmacokinetic modeling of sustained release lithium in the serum, erythrocytes and urine of patients with bipolar disorder. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30554270/),[l] / [h],3.63,205003,DB01356,Lithium
,30554270,ClES,"Using a population approach, we built a PK population model of srLi including one S compartment (VS = 23.0 L, ClS = 1.21 L h-1), one E compartment (VE = 64.7 L, ClSE = 3.63 L h-1, ClES = 9.46 L h-1), and one U compartment (F = 0.62) and estimate the ratio of concentrations to Li in E over S at 0.38 with 27% between-subject variability.","Population pharmacokinetic modeling of sustained release lithium in the serum, erythrocytes and urine of patients with bipolar disorder. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30554270/),[l] / [h],9.46,205004,DB01356,Lithium
,1835288,SNA,"Muscle SNA was greatly increased in the ascitic nonresponder patients compared with the normal subjects (64 +/- 4 versus 27 +/- 7 bursts/minute, p less than 0.001), moderately increased in ascitic responders (47 +/- 6 bursts/minute, p less than 0.05), but not significantly increased in nonascitic patients with cirrhosis (34 +/- 5 bursts/minute).",Muscle sympathetic nerve activity and renal responsiveness to atrial natriuretic factor during the development of hepatic ascites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1835288/),[bursts] / [min],64,207462,DB01356,Lithium
,1835288,SNA,"Muscle SNA was greatly increased in the ascitic nonresponder patients compared with the normal subjects (64 +/- 4 versus 27 +/- 7 bursts/minute, p less than 0.001), moderately increased in ascitic responders (47 +/- 6 bursts/minute, p less than 0.05), but not significantly increased in nonascitic patients with cirrhosis (34 +/- 5 bursts/minute).",Muscle sympathetic nerve activity and renal responsiveness to atrial natriuretic factor during the development of hepatic ascites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1835288/),[bursts] / [min],27,207463,DB01356,Lithium
,1835288,SNA,"Muscle SNA was greatly increased in the ascitic nonresponder patients compared with the normal subjects (64 +/- 4 versus 27 +/- 7 bursts/minute, p less than 0.001), moderately increased in ascitic responders (47 +/- 6 bursts/minute, p less than 0.05), but not significantly increased in nonascitic patients with cirrhosis (34 +/- 5 bursts/minute).",Muscle sympathetic nerve activity and renal responsiveness to atrial natriuretic factor during the development of hepatic ascites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1835288/),[bursts] / [min],47,207464,DB01356,Lithium
,1835288,SNA,"Muscle SNA was greatly increased in the ascitic nonresponder patients compared with the normal subjects (64 +/- 4 versus 27 +/- 7 bursts/minute, p less than 0.001), moderately increased in ascitic responders (47 +/- 6 bursts/minute, p less than 0.05), but not significantly increased in nonascitic patients with cirrhosis (34 +/- 5 bursts/minute).",Muscle sympathetic nerve activity and renal responsiveness to atrial natriuretic factor during the development of hepatic ascites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1835288/),[bursts] / [min],34,207465,DB01356,Lithium
,6411413,minimum steady-state serum concentration,"Based on these determinations, the patients were then given individualized lithium doses to reach a minimum steady-state serum concentration of 1.0 meq/liter.",Prediction of lithium carbonate dosage in psychiatric inpatients using the repeated one-point method. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6411413/),[meq] / [l],1.0,210356,DB01356,Lithium
,6411413,minimum steady-state serum concentrations,"The mean +/- S.D. measured and predicted minimum steady-state serum concentrations for all patients were 1.03 +/- 0.06 meq/liter and 0.97 +/- 0.08 meq/liter, respectively.",Prediction of lithium carbonate dosage in psychiatric inpatients using the repeated one-point method. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6411413/),[meq] / [l],0.97,210357,DB01356,Lithium
,7082707,half-life,For the slow component 6Li had an average half-life of 12.9 and 7Li 15.9 hr.,Stable isotopes of lithium: in vivo differential distribution between plasma and cerebrospinal fluid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7082707/),h,12.9,214700,DB01356,Lithium
,7082707,half-life,For the slow component 6Li had an average half-life of 12.9 and 7Li 15.9 hr.,Stable isotopes of lithium: in vivo differential distribution between plasma and cerebrospinal fluid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7082707/),h,15.9,214701,DB01356,Lithium
,7827213,half-life,"The median half-life for lithium was 28 hr in the brain, and 16 hr in serum.",24-hour lithium concentration in human brain studied by Li-7 magnetic resonance spectroscopy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7827213/),h,28,218314,DB01356,Lithium
,7827213,half-life,"The median half-life for lithium was 28 hr in the brain, and 16 hr in serum.",24-hour lithium concentration in human brain studied by Li-7 magnetic resonance spectroscopy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7827213/),h,16,218315,DB01356,Lithium
,2961879,half-life,ANP had a short half-life (12.4 min) and a renal clearance 6-fold greater than the creatinine clearance.,Kinetics and pharmacodynamics of atrial natriuretic peptide and lithium clearance in the isolated perfused rat kidney. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2961879/),min,12.4,218614,DB01356,Lithium
,8194283,elimination half-life,"The elimination half-life of fluoxetine is about 1 to 4 days, while that of its metabolite norfluoxetine ranges from 7 to 15 days.",Clinical pharmacokinetics of fluoxetine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8194283/),d,1 to 4,219943,DB01356,Lithium
,8194283,elimination half-life,"The elimination half-life of fluoxetine is about 1 to 4 days, while that of its metabolite norfluoxetine ranges from 7 to 15 days.",Clinical pharmacokinetics of fluoxetine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8194283/),d,7 to 15,219944,DB01356,Lithium
,365541,Maximum mean serum levels,Maximum mean serum levels of 1.13 mmol/l and 0.78 mmol/l were achieved at 6 h and 12 h respectively with the ordinary and sustained-release forms.,Pharmacokinetics of ordinary and sustained-release lithium carbonate in manic patients after acute dosage. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/365541/),[mM] / [l],1.13,221507,DB01356,Lithium
,365541,Maximum mean serum levels,Maximum mean serum levels of 1.13 mmol/l and 0.78 mmol/l were achieved at 6 h and 12 h respectively with the ordinary and sustained-release forms.,Pharmacokinetics of ordinary and sustained-release lithium carbonate in manic patients after acute dosage. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/365541/),[mM] / [l],0.78,221508,DB01356,Lithium
,365541,half-lives of absorption,"The mean half-lives of absorption, redistribution and elimination were 0.78 h +/- 0.05 (SE), 5.06 h +/- 0.23, 26.8 h +/- 4.5 and 3.73 h +/- 0.37 (SE), 4.42 h +/- 0.28 and 25.6 h +/- 5.5 for the ordinary and sustained-release forms respectively.",Pharmacokinetics of ordinary and sustained-release lithium carbonate in manic patients after acute dosage. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/365541/),h,0.78,221509,DB01356,Lithium
,365541,elimination,"The mean half-lives of absorption, redistribution and elimination were 0.78 h +/- 0.05 (SE), 5.06 h +/- 0.23, 26.8 h +/- 4.5 and 3.73 h +/- 0.37 (SE), 4.42 h +/- 0.28 and 25.6 h +/- 5.5 for the ordinary and sustained-release forms respectively.",Pharmacokinetics of ordinary and sustained-release lithium carbonate in manic patients after acute dosage. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/365541/),h,3.73,221510,DB01356,Lithium
,365541,elimination,"The mean half-lives of absorption, redistribution and elimination were 0.78 h +/- 0.05 (SE), 5.06 h +/- 0.23, 26.8 h +/- 4.5 and 3.73 h +/- 0.37 (SE), 4.42 h +/- 0.28 and 25.6 h +/- 5.5 for the ordinary and sustained-release forms respectively.",Pharmacokinetics of ordinary and sustained-release lithium carbonate in manic patients after acute dosage. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/365541/),h,4.42,221511,DB01356,Lithium
,365541,elimination,"The mean half-lives of absorption, redistribution and elimination were 0.78 h +/- 0.05 (SE), 5.06 h +/- 0.23, 26.8 h +/- 4.5 and 3.73 h +/- 0.37 (SE), 4.42 h +/- 0.28 and 25.6 h +/- 5.5 for the ordinary and sustained-release forms respectively.",Pharmacokinetics of ordinary and sustained-release lithium carbonate in manic patients after acute dosage. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/365541/),h,25.6,221512,DB01356,Lithium
,25803094,biliary clearance,"The biliary clearance of lithium was calculated to be 0.0779 mL/min/kg, and this was 11.3% of the renal clearance.",Minor contribution of biliary excretion in lithium elimination in rats. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25803094/),[ml] / [kg·min],0.0779,225660,DB01356,Lithium
,2124219,renal clearance,"Lithium renal clearance decreased when it was coadministered with alprazolam (31.2 vs. 22.4 ml/minute, p less than 0.05).",Evaluation of the interaction of lithium and alprazolam. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2124219/),[ml] / [min],31.2,230398,DB01356,Lithium
,2124219,renal clearance,"Lithium renal clearance decreased when it was coadministered with alprazolam (31.2 vs. 22.4 ml/minute, p less than 0.05).",Evaluation of the interaction of lithium and alprazolam. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2124219/),[ml] / [min],22.4,230399,DB01356,Lithium
,2124219,steady-state area under the curve,There was a small but significant increase in the steady-state area under the curve for lithium in the presence of alprazolam (10.3 vs. 11.1 mEq/hour/liter).,Evaluation of the interaction of lithium and alprazolam. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2124219/),[meq] / [h·l],10.3,230400,DB01356,Lithium
,2124219,steady-state area under the curve,There was a small but significant increase in the steady-state area under the curve for lithium in the presence of alprazolam (10.3 vs. 11.1 mEq/hour/liter).,Evaluation of the interaction of lithium and alprazolam. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2124219/),[meq] / [h·l],11.1,230401,DB01356,Lithium
,2124219,urine flow rates,"The small increase in the serum lithium concentrations and decrease in lithium renal clearance was probably the result of lower urine flow rates (1.46 vs. 0.98 ml/minute, p less than 0.05) with the combination of the drugs.",Evaluation of the interaction of lithium and alprazolam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2124219/),[ml] / [min],1.46,230402,DB01356,Lithium
,2124219,urine flow rates,"The small increase in the serum lithium concentrations and decrease in lithium renal clearance was probably the result of lower urine flow rates (1.46 vs. 0.98 ml/minute, p less than 0.05) with the combination of the drugs.",Evaluation of the interaction of lithium and alprazolam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2124219/),[ml] / [min],0.98,230403,DB01356,Lithium
,2520367,CCr,The initial CCr of 65 ml/min (median) was reduced to a nadir of 46 ml/min (p less than 0.01) during the first 2 h after infusion of cimetidine.,"The effects of cimetidine on creatinine excretion, glomerular filtration rate and tubular function in renal transplant recipients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2520367/),[ml] / [min],65,236064,DB01356,Lithium
,2520367,CCr,The initial CCr of 65 ml/min (median) was reduced to a nadir of 46 ml/min (p less than 0.01) during the first 2 h after infusion of cimetidine.,"The effects of cimetidine on creatinine excretion, glomerular filtration rate and tubular function in renal transplant recipients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2520367/),[ml] / [min],46,236065,DB01356,Lithium
,2520367,fractional clearance of c,"GFR remained unchanged, and thus the fractional clearance of creatinine (CCr/CTh) was reduced from 1.43 (median) to 1.03 (p less than 0.01).","The effects of cimetidine on creatinine excretion, glomerular filtration rate and tubular function in renal transplant recipients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2520367/),,1.43,236066,DB01356,Lithium
,2520367,fractional clearance of c,"GFR remained unchanged, and thus the fractional clearance of creatinine (CCr/CTh) was reduced from 1.43 (median) to 1.03 (p less than 0.01).","The effects of cimetidine on creatinine excretion, glomerular filtration rate and tubular function in renal transplant recipients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2520367/),,1.03,236067,DB01356,Lithium
,16197363,plasma half-life,Meloxicam has a plasma half-life of approximately 20 h and is convenient for once daily administration.,"Meloxicam: a reappraisal of pharmacokinetics, efficacy and safety. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16197363/),h,20,236078,DB01356,Lithium
,1489941,tmax,The absorption rate following oral administration of the syrup was greater (tmax 0.8 h) than following administration of regular tablets (tmax 1.4 h).,Bioavailability of lithium from lithium citrate syrup versus conventional lithium carbonate tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1489941/),h,0.8,238685,DB01356,Lithium
,1489941,tmax,The absorption rate following oral administration of the syrup was greater (tmax 0.8 h) than following administration of regular tablets (tmax 1.4 h).,Bioavailability of lithium from lithium citrate syrup versus conventional lithium carbonate tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1489941/),h,1.4,238686,DB01356,Lithium
,1489941,terminal half-life,The terminal half-life of lithium was found to be 22 h after syrup as well as after tablet dosing.,Bioavailability of lithium from lithium citrate syrup versus conventional lithium carbonate tablets. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1489941/),h,22,238687,DB01356,Lithium
,10971303,"Cpre,ss","The geometric mean lithium Cpre,ss was 0.65 mmol l(-1) when coadministered with meloxicam and 0.54 mmol l(-1) for lithium alone.",Steady-state pharmacokinetics of lithium in healthy volunteers receiving concomitant meloxicam. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10971303/),[mM] / [l],0.65,239036,DB01356,Lithium
,10971303,"Cpre,ss","The geometric mean lithium Cpre,ss was 0.65 mmol l(-1) when coadministered with meloxicam and 0.54 mmol l(-1) for lithium alone.",Steady-state pharmacokinetics of lithium in healthy volunteers receiving concomitant meloxicam. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10971303/),[mM] / [l],0.54,239037,DB01356,Lithium
,10971303,"Cmax,ss","Lithium Cmax,ss values were increased by 16% by coadministration of meloxicam, from 0.97 mmol l(-1) to 1.12 mmol l(-1).",Steady-state pharmacokinetics of lithium in healthy volunteers receiving concomitant meloxicam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10971303/),[mM] / [l],0.97,239038,DB01356,Lithium
,10971303,"Cmax,ss","Lithium Cmax,ss values were increased by 16% by coadministration of meloxicam, from 0.97 mmol l(-1) to 1.12 mmol l(-1).",Steady-state pharmacokinetics of lithium in healthy volunteers receiving concomitant meloxicam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10971303/),[mM] / [l],1.12,239039,DB01356,Lithium
,3141484,fast phase half-life,"The fast phase half-life was 6.0 +/- 1.8 hour in the serum, and 5.8 +/- 1.9 hour in the saliva.",Pharmacokinetics of lithium carbonate in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141484/),h,6.0,241282,DB01356,Lithium
,3141484,fast phase half-life,"The fast phase half-life was 6.0 +/- 1.8 hour in the serum, and 5.8 +/- 1.9 hour in the saliva.",Pharmacokinetics of lithium carbonate in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141484/),h,5.8,241283,DB01356,Lithium
,3141484,slow phase half-life,The slow phase half-life was 17.9 +/- 7.4 hour in the serum and 15.6 +/- 8.2 hour in the saliva.,Pharmacokinetics of lithium carbonate in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141484/),h,17.9,241284,DB01356,Lithium
,3141484,slow phase half-life,The slow phase half-life was 17.9 +/- 7.4 hour in the serum and 15.6 +/- 8.2 hour in the saliva.,Pharmacokinetics of lithium carbonate in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141484/),h,15.6,241285,DB01356,Lithium
,9565195,Cmax,"The pharmacokinetic parameters obtained were as follows: Cmax, 0.970 +/- 0.170 (SD) mmol/L; Tmax, 1.59 +/- 0.78 h; AUC31 h = 548.9 +/- 135.4 mmol x m/L; AUC to infinity = 722.6 +/- 262.7 mmol x m/L; beta-half-life = 16.3 +/- 7.18 h; kappa-half-life = 0.613 +/- 0.442 h; Cl(oral) = 1.13 +/- 0.39 mL/min/kg; Vd/F = 1.43 +/- 0.387 L/kg.",Single dose pharmacokinetic study of lithium in Taiwanese/Chinese bipolar patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9565195/),[mM] / [l],0.970,242147,DB01356,Lithium
,9565195,Tmax,"The pharmacokinetic parameters obtained were as follows: Cmax, 0.970 +/- 0.170 (SD) mmol/L; Tmax, 1.59 +/- 0.78 h; AUC31 h = 548.9 +/- 135.4 mmol x m/L; AUC to infinity = 722.6 +/- 262.7 mmol x m/L; beta-half-life = 16.3 +/- 7.18 h; kappa-half-life = 0.613 +/- 0.442 h; Cl(oral) = 1.13 +/- 0.39 mL/min/kg; Vd/F = 1.43 +/- 0.387 L/kg.",Single dose pharmacokinetic study of lithium in Taiwanese/Chinese bipolar patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9565195/),h,1.59,242148,DB01356,Lithium
,9565195,AUC31 h,"The pharmacokinetic parameters obtained were as follows: Cmax, 0.970 +/- 0.170 (SD) mmol/L; Tmax, 1.59 +/- 0.78 h; AUC31 h = 548.9 +/- 135.4 mmol x m/L; AUC to infinity = 722.6 +/- 262.7 mmol x m/L; beta-half-life = 16.3 +/- 7.18 h; kappa-half-life = 0.613 +/- 0.442 h; Cl(oral) = 1.13 +/- 0.39 mL/min/kg; Vd/F = 1.43 +/- 0.387 L/kg.",Single dose pharmacokinetic study of lithium in Taiwanese/Chinese bipolar patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9565195/),[m·mM] / [l],548.9,242149,DB01356,Lithium
,9565195,AUC to infinity,"The pharmacokinetic parameters obtained were as follows: Cmax, 0.970 +/- 0.170 (SD) mmol/L; Tmax, 1.59 +/- 0.78 h; AUC31 h = 548.9 +/- 135.4 mmol x m/L; AUC to infinity = 722.6 +/- 262.7 mmol x m/L; beta-half-life = 16.3 +/- 7.18 h; kappa-half-life = 0.613 +/- 0.442 h; Cl(oral) = 1.13 +/- 0.39 mL/min/kg; Vd/F = 1.43 +/- 0.387 L/kg.",Single dose pharmacokinetic study of lithium in Taiwanese/Chinese bipolar patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9565195/),[m·mM] / [l],722.6,242150,DB01356,Lithium
,9565195,beta-half-life,"The pharmacokinetic parameters obtained were as follows: Cmax, 0.970 +/- 0.170 (SD) mmol/L; Tmax, 1.59 +/- 0.78 h; AUC31 h = 548.9 +/- 135.4 mmol x m/L; AUC to infinity = 722.6 +/- 262.7 mmol x m/L; beta-half-life = 16.3 +/- 7.18 h; kappa-half-life = 0.613 +/- 0.442 h; Cl(oral) = 1.13 +/- 0.39 mL/min/kg; Vd/F = 1.43 +/- 0.387 L/kg.",Single dose pharmacokinetic study of lithium in Taiwanese/Chinese bipolar patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9565195/),h,16.3,242151,DB01356,Lithium
,9565195,kappa-half-life,"The pharmacokinetic parameters obtained were as follows: Cmax, 0.970 +/- 0.170 (SD) mmol/L; Tmax, 1.59 +/- 0.78 h; AUC31 h = 548.9 +/- 135.4 mmol x m/L; AUC to infinity = 722.6 +/- 262.7 mmol x m/L; beta-half-life = 16.3 +/- 7.18 h; kappa-half-life = 0.613 +/- 0.442 h; Cl(oral) = 1.13 +/- 0.39 mL/min/kg; Vd/F = 1.43 +/- 0.387 L/kg.",Single dose pharmacokinetic study of lithium in Taiwanese/Chinese bipolar patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9565195/),h,0.613,242152,DB01356,Lithium
,9565195,Cl(oral),"The pharmacokinetic parameters obtained were as follows: Cmax, 0.970 +/- 0.170 (SD) mmol/L; Tmax, 1.59 +/- 0.78 h; AUC31 h = 548.9 +/- 135.4 mmol x m/L; AUC to infinity = 722.6 +/- 262.7 mmol x m/L; beta-half-life = 16.3 +/- 7.18 h; kappa-half-life = 0.613 +/- 0.442 h; Cl(oral) = 1.13 +/- 0.39 mL/min/kg; Vd/F = 1.43 +/- 0.387 L/kg.",Single dose pharmacokinetic study of lithium in Taiwanese/Chinese bipolar patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9565195/),[ml] / [kg·min],1.13,242153,DB01356,Lithium
,9565195,Vd/F,"The pharmacokinetic parameters obtained were as follows: Cmax, 0.970 +/- 0.170 (SD) mmol/L; Tmax, 1.59 +/- 0.78 h; AUC31 h = 548.9 +/- 135.4 mmol x m/L; AUC to infinity = 722.6 +/- 262.7 mmol x m/L; beta-half-life = 16.3 +/- 7.18 h; kappa-half-life = 0.613 +/- 0.442 h; Cl(oral) = 1.13 +/- 0.39 mL/min/kg; Vd/F = 1.43 +/- 0.387 L/kg.",Single dose pharmacokinetic study of lithium in Taiwanese/Chinese bipolar patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9565195/),[l] / [kg],1.43,242154,DB01356,Lithium
,12242603,elimination phase half-life,"Kinetic analysis showed that the pattern best fit a two-compartment model, with rapid extravascular distribution, an elimination phase half-life of 7.8+/-1.7 h, and clearance of 5.3+/-1.1 l/h.",Lithium carbonate as a potential pharmacological vehicle: intravenous kinetics of single-dose administration in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12242603/),h,7.8,247976,DB01356,Lithium
,12242603,clearance,"Kinetic analysis showed that the pattern best fit a two-compartment model, with rapid extravascular distribution, an elimination phase half-life of 7.8+/-1.7 h, and clearance of 5.3+/-1.1 l/h.",Lithium carbonate as a potential pharmacological vehicle: intravenous kinetics of single-dose administration in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12242603/),[l] / [h],5.3,247977,DB01356,Lithium
,7651910,plasma half-life,"CCK-8 seems to have a plasma half-life of just several minutes, whereas LiCl has a plasma half-life of 6 h in rats.","Multiple, small doses of cholecystokinin octapeptide are more efficacious at inducing taste aversion conditioning than single, large doses. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7651910/),min,several,250397,DB01356,Lithium
,7651910,plasma half-life,"CCK-8 seems to have a plasma half-life of just several minutes, whereas LiCl has a plasma half-life of 6 h in rats.","Multiple, small doses of cholecystokinin octapeptide are more efficacious at inducing taste aversion conditioning than single, large doses. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7651910/),h,6,250398,DB01356,Lithium
,11105800,elimination half-life,"Patients with acute on chronic poisoning that were not hemodialyzed had longer elimination half-life than those for whom hemodialysis was done even before hemodialysis was performed: 50.1 +/- 13.6 h (n = 3) versus 12.9 +/-12.1 (n = 3) (p = 0.007), respectively.",Comparison of patients hemodialyzed for lithium poisoning and those for whom dialysis was recommended by PCC but not done: what lesson can we learn? ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11105800/),h,50.1,251992,DB01356,Lithium
,11105800,elimination half-life,"Patients with acute on chronic poisoning that were not hemodialyzed had longer elimination half-life than those for whom hemodialysis was done even before hemodialysis was performed: 50.1 +/- 13.6 h (n = 3) versus 12.9 +/-12.1 (n = 3) (p = 0.007), respectively.",Comparison of patients hemodialyzed for lithium poisoning and those for whom dialysis was recommended by PCC but not done: what lesson can we learn? ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11105800/),,12.9,251993,DB01356,Lithium
,10749518,apparent volume of distribution,"Celexocib is extensively protein bound, primarily to plasma albumin, and has an apparent volume of distribution of 455+/-166L in humans.",Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10749518/),l,455,252478,DB01356,Lithium
,10749518,elimination half-life,Celecoxib is metabolised primarily by the cytochrome P450 (CYP) 2C9 isoenzyme and has an elimination half-life of about 11 hours in healthy individuals.,Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10749518/),h,11,252479,DB01356,Lithium
,657687,Elimination half-times,Elimination half-times ranged from 19.3 to 41.3 hours (mean +/- SD = 28.9 +/- 7.9h) and were significantly correlated with renal creatinine clearance (p less than 0.01).,"Pharmacokinetics of lithium: elimination half-time, renal clearance and apparent volume of distribution in schizophrenia. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/657687/),h,28.9,254027,DB01356,Lithium
,657687,clearances,Renal lithium clearances ranged from 13.5 to 36.8 ml/min (mean +/- SD = 24.4 +/- 8.0 ml/min) and the apparent volumes of distribution ranged from 0.39 to 1.39 L/kg (mean +/- SD = 0.79 +/- 0.34 L/kg).,"Pharmacokinetics of lithium: elimination half-time, renal clearance and apparent volume of distribution in schizophrenia. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/657687/),[ml] / [min],13.5 to 36.8,254028,DB01356,Lithium
,657687,clearances,Renal lithium clearances ranged from 13.5 to 36.8 ml/min (mean +/- SD = 24.4 +/- 8.0 ml/min) and the apparent volumes of distribution ranged from 0.39 to 1.39 L/kg (mean +/- SD = 0.79 +/- 0.34 L/kg).,"Pharmacokinetics of lithium: elimination half-time, renal clearance and apparent volume of distribution in schizophrenia. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/657687/),[ml] / [min],24.4,254029,DB01356,Lithium
,657687,apparent volumes of distribution,Renal lithium clearances ranged from 13.5 to 36.8 ml/min (mean +/- SD = 24.4 +/- 8.0 ml/min) and the apparent volumes of distribution ranged from 0.39 to 1.39 L/kg (mean +/- SD = 0.79 +/- 0.34 L/kg).,"Pharmacokinetics of lithium: elimination half-time, renal clearance and apparent volume of distribution in schizophrenia. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/657687/),[l] / [kg],0.39 to 1.39,254030,DB01356,Lithium
,657687,apparent volumes of distribution,Renal lithium clearances ranged from 13.5 to 36.8 ml/min (mean +/- SD = 24.4 +/- 8.0 ml/min) and the apparent volumes of distribution ranged from 0.39 to 1.39 L/kg (mean +/- SD = 0.79 +/- 0.34 L/kg).,"Pharmacokinetics of lithium: elimination half-time, renal clearance and apparent volume of distribution in schizophrenia. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/657687/),[l] / [kg],0.79,254031,DB01356,Lithium
,25548209,plasma half-lives,"The calculated plasma half-lives were 40.3 ± 3.8 and 30.9 ± 2.1 h for does and ewes, respectively.",Kinetics of lithium as a lithium chloride dose suitable for conditioned taste aversion in lactating goats and dry sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25548209/),h,40.3,254869,DB01356,Lithium
,25548209,plasma half-lives,"The calculated plasma half-lives were 40.3 ± 3.8 and 30.9 ± 2.1 h for does and ewes, respectively.",Kinetics of lithium as a lithium chloride dose suitable for conditioned taste aversion in lactating goats and dry sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25548209/),h,30.9,254870,DB01356,Lithium
,25548209,clearance time,"In goats, all Li administered was recovered at 96 h (92 ± 4% in urine, 6.5 ± 1.3% in feces, and 2.8 ± 0.4% in milk); however, the estimated clearance time in feces was 11 and 9 d for does and ewes, respectively.",Kinetics of lithium as a lithium chloride dose suitable for conditioned taste aversion in lactating goats and dry sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25548209/),d,11,254871,DB01356,Lithium
,25548209,clearance time,"In goats, all Li administered was recovered at 96 h (92 ± 4% in urine, 6.5 ± 1.3% in feces, and 2.8 ± 0.4% in milk); however, the estimated clearance time in feces was 11 and 9 d for does and ewes, respectively.",Kinetics of lithium as a lithium chloride dose suitable for conditioned taste aversion in lactating goats and dry sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25548209/),d,9,254872,DB01356,Lithium
,25548209,maximum Li excretion,"Additionally, maximum Li excretion in doe milk was 15.6 ± 0.5 mg/L, which was approximately half of the calculated effective dose for a 5-kg BW sucking kid.",Kinetics of lithium as a lithium chloride dose suitable for conditioned taste aversion in lactating goats and dry sheep. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25548209/),[mg] / [l],15.6,254873,DB01356,Lithium
,3447250,Fractional lithium excretion (FE-Li),"Fractional lithium excretion (FE-Li) was 22.6 +/- 2.2% in sodium-replete dogs (fractional sodium excretion, FE-Na greater than 0.4%, n = 11) but only 6.9 +/- 2.3% in sodium-depleted dogs (FE-Na less than 0.4%, n = 25).",Decreased lithium clearance due to distal tubular lithium reabsorption in sodium-depleted dogs. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3447250/),%,22.6,255607,DB01356,Lithium
greater,3447250,"fractional sodium excretion, FE-Na","Fractional lithium excretion (FE-Li) was 22.6 +/- 2.2% in sodium-replete dogs (fractional sodium excretion, FE-Na greater than 0.4%, n = 11) but only 6.9 +/- 2.3% in sodium-depleted dogs (FE-Na less than 0.4%, n = 25).",Decreased lithium clearance due to distal tubular lithium reabsorption in sodium-depleted dogs. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3447250/),%,0.4,255608,DB01356,Lithium
,3447250,"fractional sodium excretion, FE-Na","Fractional lithium excretion (FE-Li) was 22.6 +/- 2.2% in sodium-replete dogs (fractional sodium excretion, FE-Na greater than 0.4%, n = 11) but only 6.9 +/- 2.3% in sodium-depleted dogs (FE-Na less than 0.4%, n = 25).",Decreased lithium clearance due to distal tubular lithium reabsorption in sodium-depleted dogs. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3447250/),%,6.9,255609,DB01356,Lithium
less,3447250,FE-Na,"Fractional lithium excretion (FE-Li) was 22.6 +/- 2.2% in sodium-replete dogs (fractional sodium excretion, FE-Na greater than 0.4%, n = 11) but only 6.9 +/- 2.3% in sodium-depleted dogs (FE-Na less than 0.4%, n = 25).",Decreased lithium clearance due to distal tubular lithium reabsorption in sodium-depleted dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3447250/),%,0.4,255610,DB01356,Lithium
,7914852,urine to plasma concentration ratios (U/P),"In fully hydrated frogs (R. temporaria) a clearance of endogenous lithium (CLi) coincides with the glomerular filtration rate (CCoEDTA) which is on average 32 ml/kg/hr, i.e. fractional lithium excretion (FELi) is close to unity, and urine to plasma concentration ratios (U/P) of Li+ and 57Co-EDTA are about 1.4.",Endogenous lithium clearance as a probable measure of end-proximal fluid delivery in the amphibian kidneys: a study of renal water and Na+ reabsorption in the hydrated and dehydrated frog Rana temporaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7914852/),,1.4,256254,DB01356,Lithium
,7914852,CLi,"On average, in severely dehydrated frogs CCoEDTA decreases to 6.2 ml/kg/hr, CLi to 2.4 ml/kg/hr, and (U/P)CoEDTA and (U/P)Li rise to 8.4 (max = 15.2) and 3.2 (max = 5.5), respectively.",Endogenous lithium clearance as a probable measure of end-proximal fluid delivery in the amphibian kidneys: a study of renal water and Na+ reabsorption in the hydrated and dehydrated frog Rana temporaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7914852/),[ml] / [h·kg],2.4,256255,DB01356,Lithium
,7914852,CLi,"On average, in severely dehydrated frogs CCoEDTA decreases to 6.2 ml/kg/hr, CLi to 2.4 ml/kg/hr, and (U/P)CoEDTA and (U/P)Li rise to 8.4 (max = 15.2) and 3.2 (max = 5.5), respectively.",Endogenous lithium clearance as a probable measure of end-proximal fluid delivery in the amphibian kidneys: a study of renal water and Na+ reabsorption in the hydrated and dehydrated frog Rana temporaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7914852/),,8.4,256256,DB01356,Lithium
,7914852,max,"On average, in severely dehydrated frogs CCoEDTA decreases to 6.2 ml/kg/hr, CLi to 2.4 ml/kg/hr, and (U/P)CoEDTA and (U/P)Li rise to 8.4 (max = 15.2) and 3.2 (max = 5.5), respectively.",Endogenous lithium clearance as a probable measure of end-proximal fluid delivery in the amphibian kidneys: a study of renal water and Na+ reabsorption in the hydrated and dehydrated frog Rana temporaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7914852/),,8.4,256257,DB01356,Lithium
,7914852,max,"On average, in severely dehydrated frogs CCoEDTA decreases to 6.2 ml/kg/hr, CLi to 2.4 ml/kg/hr, and (U/P)CoEDTA and (U/P)Li rise to 8.4 (max = 15.2) and 3.2 (max = 5.5), respectively.",Endogenous lithium clearance as a probable measure of end-proximal fluid delivery in the amphibian kidneys: a study of renal water and Na+ reabsorption in the hydrated and dehydrated frog Rana temporaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7914852/),,15.2,256258,DB01356,Lithium
,7914852,max,"On average, in severely dehydrated frogs CCoEDTA decreases to 6.2 ml/kg/hr, CLi to 2.4 ml/kg/hr, and (U/P)CoEDTA and (U/P)Li rise to 8.4 (max = 15.2) and 3.2 (max = 5.5), respectively.",Endogenous lithium clearance as a probable measure of end-proximal fluid delivery in the amphibian kidneys: a study of renal water and Na+ reabsorption in the hydrated and dehydrated frog Rana temporaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7914852/),,3.2,256259,DB01356,Lithium
,7914852,max,"On average, in severely dehydrated frogs CCoEDTA decreases to 6.2 ml/kg/hr, CLi to 2.4 ml/kg/hr, and (U/P)CoEDTA and (U/P)Li rise to 8.4 (max = 15.2) and 3.2 (max = 5.5), respectively.",Endogenous lithium clearance as a probable measure of end-proximal fluid delivery in the amphibian kidneys: a study of renal water and Na+ reabsorption in the hydrated and dehydrated frog Rana temporaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7914852/),,5.5,256260,DB01356,Lithium
,7914852,FELi,"FELi makes about 0.4, i.e. in these animals, rather than in well hydrated ones, a noticeable lithium reabsorption in the kidney-urinary bladder complex is observed.",Endogenous lithium clearance as a probable measure of end-proximal fluid delivery in the amphibian kidneys: a study of renal water and Na+ reabsorption in the hydrated and dehydrated frog Rana temporaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7914852/),,0.4,256261,DB01356,Lithium
,3586088,maximal plasma concentrations,"Pharmacokinetics of lithium were studied in 4 females acutely intoxicated with lithium with maximal plasma concentrations of 8.7, 4.0, 3.4 and 1.3 mmol/l.",Lithium intoxication: pharmacokinetics during and after terminated hemodialysis in acute intoxications. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3586088/),[mM] / [l],8.7,256913,DB01356,Lithium
,3586088,maximal plasma concentrations,"Pharmacokinetics of lithium were studied in 4 females acutely intoxicated with lithium with maximal plasma concentrations of 8.7, 4.0, 3.4 and 1.3 mmol/l.",Lithium intoxication: pharmacokinetics during and after terminated hemodialysis in acute intoxications. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3586088/),[mM] / [l],4.0,256914,DB01356,Lithium
,3586088,maximal plasma concentrations,"Pharmacokinetics of lithium were studied in 4 females acutely intoxicated with lithium with maximal plasma concentrations of 8.7, 4.0, 3.4 and 1.3 mmol/l.",Lithium intoxication: pharmacokinetics during and after terminated hemodialysis in acute intoxications. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3586088/),[mM] / [l],3.4,256915,DB01356,Lithium
,3586088,maximal plasma concentrations,"Pharmacokinetics of lithium were studied in 4 females acutely intoxicated with lithium with maximal plasma concentrations of 8.7, 4.0, 3.4 and 1.3 mmol/l.",Lithium intoxication: pharmacokinetics during and after terminated hemodialysis in acute intoxications. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3586088/),[mM] / [l],1.3,256916,DB01356,Lithium
,3586088,plasma dialysance,"Mean plasma dialysance values were 103, 105, 102 and 89 ml/min compared to mean renal clearance values of 13, 16, 20 and 30 ml/min, respectively.",Lithium intoxication: pharmacokinetics during and after terminated hemodialysis in acute intoxications. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3586088/),[ml] / [min],103,256917,DB01356,Lithium
,3586088,plasma dialysance,"Mean plasma dialysance values were 103, 105, 102 and 89 ml/min compared to mean renal clearance values of 13, 16, 20 and 30 ml/min, respectively.",Lithium intoxication: pharmacokinetics during and after terminated hemodialysis in acute intoxications. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3586088/),[ml] / [min],105,256918,DB01356,Lithium
,3586088,plasma dialysance,"Mean plasma dialysance values were 103, 105, 102 and 89 ml/min compared to mean renal clearance values of 13, 16, 20 and 30 ml/min, respectively.",Lithium intoxication: pharmacokinetics during and after terminated hemodialysis in acute intoxications. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3586088/),[ml] / [min],102,256919,DB01356,Lithium
,3586088,plasma dialysance,"Mean plasma dialysance values were 103, 105, 102 and 89 ml/min compared to mean renal clearance values of 13, 16, 20 and 30 ml/min, respectively.",Lithium intoxication: pharmacokinetics during and after terminated hemodialysis in acute intoxications. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3586088/),[ml] / [min],89,256920,DB01356,Lithium
,3586088,renal clearance,"Mean plasma dialysance values were 103, 105, 102 and 89 ml/min compared to mean renal clearance values of 13, 16, 20 and 30 ml/min, respectively.",Lithium intoxication: pharmacokinetics during and after terminated hemodialysis in acute intoxications. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3586088/),[ml] / [min],13,256921,DB01356,Lithium
,3586088,renal clearance,"Mean plasma dialysance values were 103, 105, 102 and 89 ml/min compared to mean renal clearance values of 13, 16, 20 and 30 ml/min, respectively.",Lithium intoxication: pharmacokinetics during and after terminated hemodialysis in acute intoxications. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3586088/),[ml] / [min],16,256922,DB01356,Lithium
,3586088,renal clearance,"Mean plasma dialysance values were 103, 105, 102 and 89 ml/min compared to mean renal clearance values of 13, 16, 20 and 30 ml/min, respectively.",Lithium intoxication: pharmacokinetics during and after terminated hemodialysis in acute intoxications. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3586088/),[ml] / [min],20,256923,DB01356,Lithium
,3586088,renal clearance,"Mean plasma dialysance values were 103, 105, 102 and 89 ml/min compared to mean renal clearance values of 13, 16, 20 and 30 ml/min, respectively.",Lithium intoxication: pharmacokinetics during and after terminated hemodialysis in acute intoxications. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3586088/),[ml] / [min],30,256924,DB01356,Lithium
,3586088,half-lives,"During hemodialysis the measured half-lives of the plasma lithium levels in three cases were 4.8, 3.4 and 2.3 hours compared to the corrected values of 12.0, 7.3 and 6.2 hours respectively, when this rebound effect was taken into consideration.",Lithium intoxication: pharmacokinetics during and after terminated hemodialysis in acute intoxications. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3586088/),h,4.8,256925,DB01356,Lithium
,3586088,half-lives,"During hemodialysis the measured half-lives of the plasma lithium levels in three cases were 4.8, 3.4 and 2.3 hours compared to the corrected values of 12.0, 7.3 and 6.2 hours respectively, when this rebound effect was taken into consideration.",Lithium intoxication: pharmacokinetics during and after terminated hemodialysis in acute intoxications. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3586088/),h,3.4,256926,DB01356,Lithium
,3586088,half-lives,"During hemodialysis the measured half-lives of the plasma lithium levels in three cases were 4.8, 3.4 and 2.3 hours compared to the corrected values of 12.0, 7.3 and 6.2 hours respectively, when this rebound effect was taken into consideration.",Lithium intoxication: pharmacokinetics during and after terminated hemodialysis in acute intoxications. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3586088/),h,2.3,256927,DB01356,Lithium
,3586088,half-lives,"During hemodialysis the measured half-lives of the plasma lithium levels in three cases were 4.8, 3.4 and 2.3 hours compared to the corrected values of 12.0, 7.3 and 6.2 hours respectively, when this rebound effect was taken into consideration.",Lithium intoxication: pharmacokinetics during and after terminated hemodialysis in acute intoxications. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3586088/),h,12.0,256928,DB01356,Lithium
,3586088,half-lives,"During hemodialysis the measured half-lives of the plasma lithium levels in three cases were 4.8, 3.4 and 2.3 hours compared to the corrected values of 12.0, 7.3 and 6.2 hours respectively, when this rebound effect was taken into consideration.",Lithium intoxication: pharmacokinetics during and after terminated hemodialysis in acute intoxications. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3586088/),h,7.3,256929,DB01356,Lithium
,3586088,half-lives,"During hemodialysis the measured half-lives of the plasma lithium levels in three cases were 4.8, 3.4 and 2.3 hours compared to the corrected values of 12.0, 7.3 and 6.2 hours respectively, when this rebound effect was taken into consideration.",Lithium intoxication: pharmacokinetics during and after terminated hemodialysis in acute intoxications. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3586088/),h,6.2,256930,DB01356,Lithium
,3061716,clearance (CLi),3. The lithium clearance (CLi) of the remaining kidney rose from 11.6 +/- 3.7 to 20.5 +/- 8.2 ml/min (P less than 0.01) and remained significantly elevated throughout the observation period.,"Changes in glomerular filtration rate, lithium clearance and plasma protein clearances in the early phase after unilateral nephrectomy in living healthy renal transplant donors. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3061716/),[ml] / [min],11.6,260347,DB01356,Lithium
,3061716,clearance (CLi),3. The lithium clearance (CLi) of the remaining kidney rose from 11.6 +/- 3.7 to 20.5 +/- 8.2 ml/min (P less than 0.01) and remained significantly elevated throughout the observation period.,"Changes in glomerular filtration rate, lithium clearance and plasma protein clearances in the early phase after unilateral nephrectomy in living healthy renal transplant donors. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3061716/),[ml] / [min],20.5,260348,DB01356,Lithium
,3061716,Fractional proximal reabsorption (FPR,5. Fractional proximal reabsorption (FPR; APR/GFR) fell from 0.75 +/- 0.06 to 0.66 +/- 0.11 (P less than 0.01) but subsequently rose to levels not significantly decreased from normal.,"Changes in glomerular filtration rate, lithium clearance and plasma protein clearances in the early phase after unilateral nephrectomy in living healthy renal transplant donors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3061716/),,0.75,260349,DB01356,Lithium
,3061716,Fractional proximal reabsorption (FPR,5. Fractional proximal reabsorption (FPR; APR/GFR) fell from 0.75 +/- 0.06 to 0.66 +/- 0.11 (P less than 0.01) but subsequently rose to levels not significantly decreased from normal.,"Changes in glomerular filtration rate, lithium clearance and plasma protein clearances in the early phase after unilateral nephrectomy in living healthy renal transplant donors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3061716/),,0.66,260350,DB01356,Lithium
,2108033,Distal sodium reabsorption,"Distal sodium reabsorption evaluated as a per cent of filtered sodium load was lower in cirrhotics than in controls (19.1 +/- 1.0 vs. 22.4 +/- 1.2%, P less than 0.05) while distal sodium reabsorption evaluated as a per cent of sodium distal delivery was higher in cirrhotics than in controls (96.7 +/- 0.4 vs. 94.4 +/- 0.5%, P less than 0.005).",Tubular site of renal sodium retention in ascitic liver cirrhosis evaluated by lithium clearance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2108033/),%,19.1,260380,DB01356,Lithium
,2108033,Distal sodium reabsorption,"Distal sodium reabsorption evaluated as a per cent of filtered sodium load was lower in cirrhotics than in controls (19.1 +/- 1.0 vs. 22.4 +/- 1.2%, P less than 0.05) while distal sodium reabsorption evaluated as a per cent of sodium distal delivery was higher in cirrhotics than in controls (96.7 +/- 0.4 vs. 94.4 +/- 0.5%, P less than 0.005).",Tubular site of renal sodium retention in ascitic liver cirrhosis evaluated by lithium clearance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2108033/),%,22.4,260381,DB01356,Lithium
,2108033,distal sodium reabsorption,"Distal sodium reabsorption evaluated as a per cent of filtered sodium load was lower in cirrhotics than in controls (19.1 +/- 1.0 vs. 22.4 +/- 1.2%, P less than 0.05) while distal sodium reabsorption evaluated as a per cent of sodium distal delivery was higher in cirrhotics than in controls (96.7 +/- 0.4 vs. 94.4 +/- 0.5%, P less than 0.005).",Tubular site of renal sodium retention in ascitic liver cirrhosis evaluated by lithium clearance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2108033/),%,96.7,260382,DB01356,Lithium
,2108033,distal sodium reabsorption,"Distal sodium reabsorption evaluated as a per cent of filtered sodium load was lower in cirrhotics than in controls (19.1 +/- 1.0 vs. 22.4 +/- 1.2%, P less than 0.05) while distal sodium reabsorption evaluated as a per cent of sodium distal delivery was higher in cirrhotics than in controls (96.7 +/- 0.4 vs. 94.4 +/- 0.5%, P less than 0.005).",Tubular site of renal sodium retention in ascitic liver cirrhosis evaluated by lithium clearance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2108033/),%,94.4,260383,DB01356,Lithium
,9248631,peak serum levels,"A pharmacokinetic study showed that lithium was rapidly absorbed from the peritoneal cavity after the above-stated dose, achieved peak serum levels of 9.8 mmol/l within 1 h, had a half-life in the blood of 5 h and was completely cleared by 16 to 24 h after injection.",The effects of lithium on neurulation stage mouse embryos. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9248631/),[mM] / [l],9.8,267432,DB01356,Lithium
,9248631,half-life in the blood,"A pharmacokinetic study showed that lithium was rapidly absorbed from the peritoneal cavity after the above-stated dose, achieved peak serum levels of 9.8 mmol/l within 1 h, had a half-life in the blood of 5 h and was completely cleared by 16 to 24 h after injection.",The effects of lithium on neurulation stage mouse embryos. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9248631/),h,5,267433,DB01356,Lithium
,8382588,sodium clearance,"2. Baseline sodium clearance with placebo was 0.65 +/- 0.35 ml/min, but with lithium it increased to 1.25 +/- 0.44 (P < 0.001) and 1.17 +/- 0.46 ml/min (P < 0.01) after 450 and 600mg, respectively.","Lithium clearance method and the renal response to low-dose dopamine in man: a randomized, controlled study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8382588/),[ml] / [min],0.65,268518,DB01356,Lithium
,8382588,sodium clearance,"2. Baseline sodium clearance with placebo was 0.65 +/- 0.35 ml/min, but with lithium it increased to 1.25 +/- 0.44 (P < 0.001) and 1.17 +/- 0.46 ml/min (P < 0.01) after 450 and 600mg, respectively.","Lithium clearance method and the renal response to low-dose dopamine in man: a randomized, controlled study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8382588/),[ml] / [min],1.25,268519,DB01356,Lithium
,8382588,sodium clearance,"2. Baseline sodium clearance with placebo was 0.65 +/- 0.35 ml/min, but with lithium it increased to 1.25 +/- 0.44 (P < 0.001) and 1.17 +/- 0.46 ml/min (P < 0.01) after 450 and 600mg, respectively.","Lithium clearance method and the renal response to low-dose dopamine in man: a randomized, controlled study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8382588/),[ml] / [min],1.17,268520,DB01356,Lithium
,6646875,half-life,"The kinetics of plasma chlorpromazine removal were described with a two-compartment model, exhibiting a rapid half-life of 1.46 days and a slow half-life of 3.19 days.",Chlorpromazine excretion by the neonate following chronic in utero exposure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6646875/),d,1.46,268869,DB01356,Lithium
,6646875,half-life,"The kinetics of plasma chlorpromazine removal were described with a two-compartment model, exhibiting a rapid half-life of 1.46 days and a slow half-life of 3.19 days.",Chlorpromazine excretion by the neonate following chronic in utero exposure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6646875/),d,3.19,268870,DB01356,Lithium
,30393876,renal clearance,"In sham-operated rats, the renal clearance of lithium was calculated to be 1.49 ml/min/kg, and its ratio to creatinine clearance (fractional excretion) was 43.4%.",Effect of renal ischemia on urinary excretion of lithium in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30393876/),[ml] / [kg·min],1.49,271163,DB01356,Lithium
,2162278,tubular segmental reabsorption rates,"Using the renal clearance of lithium (CLi) as an index of proximal tubular outflow of sodium and water, together with simultaneous measurements of effective renal plasma flow, glomerular filtration rate (GFR) and sodium clearance (CNa), renal function and the tubular segmental reabsorption rates of sodium and water during dopamine infusion (3 micrograms min-1 kg-1) were estimated in 12 normal volunteers.",Renal tubular reabsorption of sodium and water during infusion of low-dose dopamine in normal man. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2162278/),[μg] / [kg·min],3,271580,DB01356,Lithium
,8162665,clearance of lithium (CLLi),The clearance of lithium (CLLi) for the obese group was significantly greater than that for the control group (33.9 +/- 7.0 ml/min versus 23.0 +/- 6.2 ml/min; p = 0.005).,Lithium pharmacokinetics in the obese. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8162665/),[ml] / [min],33.9,274176,DB01356,Lithium
,8162665,clearance of lithium (CLLi),The clearance of lithium (CLLi) for the obese group was significantly greater than that for the control group (33.9 +/- 7.0 ml/min versus 23.0 +/- 6.2 ml/min; p = 0.005).,Lithium pharmacokinetics in the obese. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8162665/),[ml] / [min],23.0,274177,DB01356,Lithium
,8162665,steady-state volume of distribution (VSS),The steady-state volume of distribution (VSS) for the obese group was significantly less than that for the control group (0.42 +/- 0.09 L/kg versus 0.66 +/- 0.16 L/kg; p = 0.001).,Lithium pharmacokinetics in the obese. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8162665/),[l] / [kg],0.42,274178,DB01356,Lithium
,8162665,steady-state volume of distribution (VSS),The steady-state volume of distribution (VSS) for the obese group was significantly less than that for the control group (0.42 +/- 0.09 L/kg versus 0.66 +/- 0.16 L/kg; p = 0.001).,Lithium pharmacokinetics in the obese. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8162665/),[l] / [kg],0.66,274179,DB01356,Lithium
